In vitro investigation on synergistic anticancer effects between vitamin E isomers, pure compounds and crude alkaloid plant extracts on human cancerous cells by Abubakar, Ibrahim Babangida
Abubakar, Ibrahim Babangida (2017) In vitro 
investigation on synergistic anticancer effects between 
vitamin E isomers, pure compounds and crude alkaloid 
plant extracts on human cancerous cells. PhD thesis, 
University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/35974/1/thesis%20final%20version.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
For more information, please contact eprints@nottingham.ac.uk
1 
 
In vitro investigation on synergistic anticancer effects between vitamin E isomers, 
pure compounds and crude alkaloid plant extracts on human cancerous cells 
 
 
 
 
 
 
 
By Ibrahim Babangida Abubakar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted to the University of Nottingham for the degree of Doctor of 
philosophy (PhD) in Biosciences  
 
 
August 2016 
 
 
 
 
 
 
 
 
 
2 
 
Table of Contents 
ABSTRACT .............................................................................................................. 8 
LIST OF PUBLICATIONS ..................................................................................... 11 
LIST OF TABLES .................................................................................................. 12 
LIST OF FIGURES ................................................................................................. 13 
LIST OF ABBREVIATIONS .................................................................................. 16 
ACKNOWLEDGEMENTS ..................................................................................... 17 
1.0 CHAPTER ONE: INTRODUCTION ................................................................. 18 
1.1 Cancers and treatments ................................................................................... 18 
1.2 Plants serve as natural anticancer agents ......................................................... 18 
1.2.1 Ficus spp and Tabernaemontana corymbosa ................................................ 19 
1.2.2 Tocotrienols ................................................................................................. 21 
1.3 Research problems and rationales of study ...................................................... 22 
1.4 Scope of study ................................................................................................ 24 
1.5 General aim and specific objectives of study ................................................... 25 
1.6 Experimental hypotheses ................................................................................ 26 
1.7 Significance of study ...................................................................................... 27 
2.0 CHAPTER TWO: LITERATURE REVIEW ..................................................... 28 
2.1 Cancer ............................................................................................................... 28 
2.1.1 Pathogenesis of cancer ................................................................................. 29 
2.1.2 Types of cancer ........................................................................................... 30 
2.1.2.1 Lung cancer .............................................................................................. 31 
2.1.2.2 Brain cancer .............................................................................................. 32 
2.1.2.3 Colon cancer ............................................................................................. 33 
2.1.3 Available cancer treatments and limitations ................................................. 34 
3 
 
2.2 Apoptosis as a natural defense mechanism ...................................................... 35 
2.2.1 Difference between apoptosis and necrosis .................................................. 36 
2.2.2 Apoptotic pathways ..................................................................................... 37 
2.2.2.1 Extrinsic pathway ..................................................................................... 37 
2.2.2.2 Intrinsic pathway ...................................................................................... 38 
2.3 Plant derived anticancer agents ....................................................................... 40 
2.3.1 Ficus spp: ethnobothany and ethnomedicinal application ............................. 43 
2.3.1.2 Ficus spp: phytochemistry and pharmacological activities ........................ 44 
2.3.2 Tabernaemontana corymbosa: ethnobotany and ethnomedicinal application 48 
2.3.2.1 Phytochemistry and pharmacological activities ......................................... 51 
2.3.3 Vitamin E: Sources, structure and bioavailability ......................................... 56 
2.3.3.1 Pharmacological activities of tocopherols and tocotrienols ........................ 58 
2.4 Combined treatments using tocotrienols.......................................................... 62 
3.0 CHAPTER THREE ........................................................................................... 64 
In-vitro anti-proliferative effects of individual and combined treatments of 
tocotrienols, jerantinines (A and B) and extracts of Ficus species ............................ 64 
3.1 Introduction ....................................................................................................... 64 
3.2 Materials and Methods ....................................................................................... 67 
3.2.1 Chemical reagent/kits and cell cultureware .................................................. 67 
3.2.2 Plant collection and extraction ..................................................................... 67 
3.2.3 Cell lines and culture conditions .................................................................. 69 
3.2.4 Experimental design .................................................................................... 69 
3.2.5 Cell viability studies .................................................................................... 70 
3.2.6 Determination of synergism and dose reduction ........................................... 71 
3.2.7 Statistical analysis........................................................................................ 71 
4 
 
3.3. Results .............................................................................................................. 73 
3.3.1 Observation of dose dependent growth inhibition on cancer cells by single 
treatments ............................................................................................................. 73 
3.3.2 Induction of synergistic growth inhibition on cancer cells by combined 
treatments ............................................................................................................. 79 
3.4 Discussion ......................................................................................................... 91 
3.5. Conclusion ........................................................................................................ 96 
4.0 CHAPTER FOUR ............................................................................................. 97 
Induction of DNA damage and manifestation of morphological features of apoptosis 
by individual and combined treatments of tocotrienols (delta and gamma) and 
jerantinines (A and B) .............................................................................................. 97 
4.1 Introduction ....................................................................................................... 97 
4.2 Materials and Methods ................................................................................. 101 
4.2.1 Chemical reagent/kits and cell cultureware ................................................ 101 
4.2.2 Haematoxylin and eosin (H&E) staining .................................................... 102 
4.2.3 Acridine orange and propidium iodide (AO/PI) Staining ............................ 103 
4.2.4 Single cell gel electrophoresis (COMET) ................................................... 103 
4.2.5 Statistical analysis...................................................................................... 105 
4.3 Results ............................................................................................................. 106 
4.3.1. Morphological changes on U87MG, A549 and HT-29 cells treated with 
individual and combined low-dose treatments .................................................... 106 
4.3.2. Hematoxylin and eosin staining ................................................................ 106 
4.3.3. Acrindine orange and propidium iodide staining (AO/PI).......................... 110 
4.3.4. DNA damage patterns of U87MG, A549 and HT-29 cells treated with 
individual and combined treatments ................................................................... 119 
5 
 
4.4 Discussion ....................................................................................................... 125 
4.5 Conclusion ....................................................................................................... 131 
5.0 CHAPTER FIVE ............................................................................................. 132 
Induction of cell cycle arrest and disruption of microtubule mediated via caspase 
dependent and independent apoptosis by individual and combined treatments of 
tocotrienols (delta and gamma) and jerantinines (A and B) .................................... 132 
5.1 Introduction ..................................................................................................... 132 
5.1. Materials and Methods .................................................................................... 135 
5.1.1 Chemical reagent/kits and cell cultureware ................................................ 135 
5.1.1 Cell cycle analysis by flow cytometry ........................................................ 135 
5.1.2 Immunofluorescence staining for microtubules .......................................... 136 
5.1.3 Caspase assay ............................................................................................ 137 
5.1.4 Caspase inhibition assay ............................................................................ 138 
5.1.5 Statistical analysis...................................................................................... 138 
5.2 Results ............................................................................................................. 139 
5.2.1. Determination of cell cycle arrest induced by single and combined treatments
 ........................................................................................................................... 139 
5.2.2. Observation of microtubules following single and combined treatments ... 153 
5.2.3. Evaluation of the effects of individual and combined treatments on caspase 
enzyme activity and caspase independent cell death ........................................... 160 
5.3. Discussion ...................................................................................................... 165 
5.4 Conclusion ....................................................................................................... 177 
6.0 CHAPTER SIX ............................................................................................... 178 
Alteration of apoptosis related genes expression in U87MG cells by individual and 
combined treatments of tocotrienols (delta and gamma) and jerantinines (A and B) 178 
6 
 
6.1 Introduction ..................................................................................................... 178 
6.2 Materials and Methods ..................................................................................... 181 
6.2.1 Chemical reagent/kits and cell cultureware ................................................ 181 
6.2.2 Apoptosis array .......................................................................................... 182 
6.2.3 Western blotting analysis ........................................................................... 183 
6.2.4 Enzyme-linked immuno sorbent assay (ELISA) for cytochrome C detection
 ........................................................................................................................... 184 
6.2.5: Statistical analysis .................................................................................... 185 
6.3 Results ............................................................................................................. 186 
6.3.1 Assessment of apoptosis related gene expression levels altered by individual 
and combined treatments on U87MG cells via apoptosis array ........................... 186 
6.3.2 Western detection of Bid and p53 levels altered by individual and combined 
treatment on U87MG cells.................................................................................. 198 
6.3.3 Evaluation of cytochrome C level altered by individual and combined 
treatments on U87MG cells via ELISA............................................................... 200 
6.3. Discussion ...................................................................................................... 201 
6.4 Conclusion ....................................................................................................... 206 
7.0 CHAPTER SEVEN ......................................................................................... 207 
General Discussion and Conclusions ..................................................................... 207 
7.1 Background ..................................................................................................... 207 
7.2 Combined low-dose treatments exert synergistic anticancer effects on cancer cells 
and minimize toxicity towards non-cancerous cells ................................................ 209 
7.3 Tocotrienols induce apoptosis via death receptor and mitochondria pathway.... 212 
7.4 Jerantinines target Fas and p53 linked apoptosis with anti-microtubule effects . 215 
7 
 
7.5 Combined treatment confers multi-targeted mechanisms for enhanced therapeutic 
application ............................................................................................................. 218 
7.6 Conclusions ..................................................................................................... 222 
7.7 Limitations of current study and recommendations for future investigations .... 223 
References ............................................................................................................. 226 
APPENDIX ........................................................................................................... 257 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
ABSTRACT 
Anticancer chemotherapeutic treatment using single dose has been limited due to drug 
resistance and potential metabolic degradation. For instance, high-dose tocotrienols 
undergo metabolic degradation that limits the availability of therapeutic dose thereby 
limiting the potency in vivo. Combined treatment of tocotrienols at low dosage has 
been suggested as alternative to circumventing this limitation. This study was 
designed to investigate the cytotoxic effects and subsequently the apoptotic 
mechanisms of individual doses and combined treatments at lower dosages of 
tocotrienols (delta and gamma), jerantinines (A and B) and extracts (ethanol and 
alkaloid crude) from leaves and bark of Ficus hispida, Ficus fistulosa and Ficus 
schwarzii on lung (A549), brain (U87MG) and colon (HT-29) cancer cell lines. 
Neutral red uptake assay was conducted to evaluate the antiproliferative effect of 
individual and combined treatments. Staining techniques (histochemical and 
fluorescence), COMET assay flow cytometric analysis and immunofluorescence were 
conducted to evaluate cell morphology, DNA damage, cell cycle arrest pattern and 
antimicrotubule effects. Finally cell and molecular based assays were conducted to 
investigate the pathways for induction of apoptosis.  
 
Cell viability study revealed that alkaloid crude extracts of leaves and bark of F. 
fistulosa demonstrated the highest potency with IC50 range of 0.96 – 46.81 µg/ml 
compared to F. schwarzii (8.79 – 107.9 µg/ml) and F. hispida (15.14 – 49.58 µg/ml) 
on A549, U87MG and HT-29 cells. Both delta- and gamma-tocotrienols induced 
antiproliferative effects on A549, U87MG and HT-29 cells with IC50 values of 3.12 - 
12.40 µg/ml and 3.17 – 16.36 µg/ml, respectively. Potent antiproliferative effects 
were also evident for jerantinine A (IC50 0.62 – 1.74 µg/ml), jerantinine B (IC50 0.58 – 
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1.48 µg/ml) and vinblastine (IC50 0.03 – 0.71 µg/ml). However, similar toxic effects 
on these three compounds were also evident on non-cancerous lung fibroblast 
(MRC5) cells. The leaf and bark alkaloid crude extracts of F. fistulosa and F. 
schwarzii were selected for combined treatments. The combined treatment of IC20 
doses of F. fistulosa with both delta- and gamma-tocotrienols induced synergistic 
antiproliferative effects (combination index (CI) < 1) on U87MG and HT-29 with up 
to 34.7-fold and 4-fold dose reductions for tocotrienols and F. fistulosa extracts, 
respectively. In contrast, additive (CI = 0.98) or antagonistic effects (CI > 1) were 
observed for IC20 doses of F. schwarzii extracts combined with delta- and gamma-
tocotrienols on HT-29 cells. On the other hand, combined treatments of tocotrienols 
(delta and gamma) with IC20 doses of jerantinines (A and B) induced synergistic 
effects (CI < 1) on A549, U87MG and HT-29 cells causing up to 4.48-fold dose 
reduction of tocotrienols thus reducing toxicity towards MRC5 cells compared to 
cancer cells.  
 
Further morphological and DNA damage assessment focusing on tocotrienols (delta 
and gamma), jerantinines (A and B) and combined low-dose treatments revealed 
anticancer features including cell shrinkage, nuclear chromatin condensation and 
fragmentation, membrane blebbing, apoptotic bodies and induction of predominantly 
double stranded DNA breaks. Cell cycle analysis demonstrated the induction of 
G0/G1 and G2/M cell cycle arrests by tocotrienols (delta and gamma) and jerantinines 
(A and B), respectively on U87MG, A549 and HT-29 cells. Meanwhile, G2/M (A549) 
and G0/G1 (U87MG and HT-29) cell cycle arrests were evident for combined low-
dose treatments of tocotrienols (delta and gamma) with IC20 doses of jerantinines (A 
and B). Jerantinines A and B and combined low-dose treatments with tocotrienols 
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(delta and gamma) caused disruption of microtubule networks and induction of 
caspase 8-, 9- and 3-mediated apoptosis with caspase-independent growth inhibition 
evidenced in the presence of caspase inhibitors on U87MG, A549 and HT-29 cells. In 
contrast, although treatments of tocotrienols (delta and gamma) alone caused similar 
apoptotic features as those of combined, disruption of microtubule networks were not 
characterized on these three cancer cell lines. Further mechanistic study on U87MG 
cells revealed that the apoptosis triggered by individual doses of tocotrienols (delta 
and gamma) involved the activation of TRAIL and Bid as well as the release of 
cytochrome C, thus confirming the recruitment of the death receptor and 
mitochondria-mediated pathways. On the other hand, individual doses of jerantinines 
(A and B) and combined low-dose treatments with tocotrienols resulted in the 
activation of TRAIL, FAS, p53 and Bid, as well as the release of cytochrome C. The 
activation of both death receptors, p53 and microtubule disruption by combined low-
dose treatments demonstrates an improved mechanism of action comparing to 
individual doses of tocotrienols and jerantinines. In addition, the combined low-dose 
treatments also caused a reduction of required potent doses thereby minimizing the 
toxicity of jerantinines (A and B) towards the non-cancerous MRC5 cells. In 
conclusion, this research has presented valuable combined treatment candidates which 
are warranted for further investigations as future chemotherapeutic agents against 
cancers.  
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1.0 CHAPTER ONE: INTRODUCTION 
1.1 Cancers and treatments 
Cancer is still one of the leading causes of death around the world. The incidence of 
cancer and cancer related deaths are increasing worldwide surpassed only by heart 
related diseases.  An estimated figure of over 1.6 million people diagnosed with 
cancer was expected in 2015 with over 589,430 cancer related deaths in the US thus 
accounting for 1 in every 4 deaths (Siegel et al., 2015). Lung, breast, colorectal, 
stomach and liver cancers remain the leading causes of death largely due to smoking, 
alcohol consumption, fat rich diet and less exercise (Cancer Research UK, 2014). 
Furthermore, epidemiological studies have demonstrated that types of cancer are 
largely influenced by culture (Kolonel et al., 2004). For instance, there is a higher 
prevalence of lung, colon, prostate and breast cancers in Western countries compared 
to Eastern countries. Cancers of the head, neck and cervix are more prevalent in India, 
whereas, stomach cancer is the most common in Japan (Aggarwal and Shishodia, 
2006). The advents of modern treatments that include chemotherapy, radiotherapy and 
surgery have definitely improved the care of cancer patients. However, high cost of 
treatment, advanced cancer metastasis, non-selective toxicity, resistance to synthetic 
drugs and undesirable side effects highlight the limitations of these treatments. 
Therefore, it is urgently needed for a more efficient and cost-effective cure.  
 
1.2 Plants serve as natural anticancer agents  
Over the years, a consensus amongst the scientific community began to emerge on the 
possible role of diet in the prevention of cancer. This perception has received great 
attention even amongst consumers on the high prospect of consumptions of vitamins, 
vegetables, fruits and other natural plant compounds which could potentially provide 
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an alternative towards the prevention and treatment of diseases (Cai et al., 2004). 
Indeed, several epidemiological studies have indicated a lower incidence of cancer in 
populations that consume fruits and vegetables rich food. An extensive review of 22 
animal and 206 human epidemiological studies had shown an inverse relationship 
between consumption of fruits and vegetables and risk for various types of cancer 
(stomach, oesophagus, lung, oral cavity, endometrium, pancreas and colon) 
(Steinmetz and Potter, 1996). Medicinal plants have also played a vital role in cancer 
treatment, especially in the developing and underdeveloped parts of the world and 
most phytochemicals discovered over the past half century have been used towards 
treatment of cancer (Balunas and Kinghorn, 2005). In 1950, the U.S. National Cancer 
Institute (NCI) recognised the potential use of natural products as anticancer agents 
and since then, there has been a surge of interest in natural product research leading to 
discovery of new anticancer agents (Cragg and Newman, 2005). About 40% of 
available anticancer drugs between 1940 and 2002 are natural products while an 
additional 8% are termed as natural product mimics (Balunas and Kinghorn, 2005). 
Several natural products isolated from plants have been successfully used as 
anticancer agents and the prominent examples are the vinca alkaloids, vincristine and 
vinblastine isolated from Catharanthus roseus used against lung, breast, leukemia, 
germ-cell and renal cancers (Rocha et al., 2001).  
 
1.2.1 Ficus spp and Tabernaemontana corymbosa 
Ficus spp exemplifies an excellent source of phytochemicals that have widespread 
distribution across Asia and Africa with applications in traditional medicine and 
serves as food. Historically, the use of Ficus spp in health improvement could be 
traced back to ten thousand years (Shi et al., 2011). Traditionally, parts of the fig tree 
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which include the root, stem, bark, fruit and latex have been used in treatment of 
different types of ailment including antitumor  (Hashemi et al., 2011; Khodarahmi et 
al., 2011; Lansky et al., 2008; Shi et al., 2011). Pharmacological studies have shown 
that the fruit, stem, leaf and latex of Ficus spp contain the active ingredient 
triterpenoids which have cytotoxic activity (Khodarahmi et al., 2011; Lansky et al., 
2008). In fact, recent studies have also demonstrated that Ficus spp are applicable as 
adjunct cytotoxic regimens (Nugroho et al., 2013, 2012). Three Ficus spp namely F. 
hispida, F. fistulosa and F. schwarzii were selected for this study. The selection of F. 
hispida and F. fistulosa was based on data gathered from previous pharmacological 
studies indicating good cytotoxic potencies of these plants on a broad range of cancer 
cells in vitro (Pratumvinit et al., 2009; Subramaniam et al., 2009; Yap et al., 2015; 
Zhang et al., 2002). In contrast, there are no pharmacological studies on F. schwarzii. 
Nonetheless, F. schwarzii was selected because studies on phytochemistry have 
demonstrated that Ficus spp are repository to potential cytotoxic phytochemicals. 
Therefore, the present study would provide insightful information on bioactivity of F. 
schwarzii.  
 
Similarly, Tabernaemontana corymbosa is another plant with long history of 
medicinal uses across Asia for treatment of various diseases including syphilis, 
fractures and tumors amongst others (Hasan et al., 2012; Van Beek et al., 1984; Wiart, 
2006). Phytochemical studies on different parts of the plant revealed a pool of novel 
indole and bisindole alkaloids and some possess interesting anticancer activity. Initial 
cytotoxic screenings showed that derivatives of jerantinine (A-G) exhibited the most 
potent cytotoxic effect in reversing vincristine resistance in human oral KB cancer 
cells (Lim et al., 2008). Recently, limited mechanistic studies had revealed the 
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potential mechanism mediating the cytotoxic effects of jerantinine derivatives (A and 
E), however, similar toxic effect was also evidenced on normal cells (Frei et al., 2013; 
Raja et al., 2014).  
 
1.2.2 Tocotrienols  
Vitamin E, a typical example of nutritious phytochemical derived from non-medicinal 
plants, is often affected by the need for high-dose delivery and toxicity. Vitamin E 
represents a group of isomers comprising of tocopherols and tocotrienols that possess 
potent therapeutic potentials against diseases including cancer. Since the discovery of 
vitamin E in 1922, several in vitro, in vivo and human supplementation studies have 
focused on its therapeutic potentials. However, despite the abundance of literature of 
vitamin E, only 1% research was conducted on tocotrienols comparing to tocopherols. 
This represents a  major void in the research that necessitates further studies 
considering that the biological function of vitamin E analogues are not the same 
(Wong and Radhakrishnan, 2012). There have been well documented in vitro studies 
with certain degree of success about the effects of vitamin E isomers on cancers. 
However, the same success has not been recorded in intervention studies of vitamin E 
supplementation in humans. This lack of success has been further complicated with 
adverse side effects of high dosage such as an increased risk of heart failure and 
hemorrhagic stroke observed in the HOPE-TOO (Heart outcomes prevention 
evaluation-the ongoing outcome) trial (Bennett et al., 2012). In addition, low 
therapeutic dose has limited the potential of oral tocotrienols and this has been 
attributed to the high-dose delivery that overloads the transport protein subsequently 
resulting in metabolic degradation (Sylvester et al., 2010). Thus far, combinatorial 
treatments with adjuvant originated from nutritional and medicinal sources that would 
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minimize the dose and improve potency of tocotrienols have been recommended as a 
possible alternative (Constantinou et al., 2008; Sylvester et al., 2010).  
 
1.3 Research problems and rationales of study  
Cancer incidence increases dramatically and current treatments are associated with 
undesirable side effects. Cancer treatment using plant-derived natural products or 
mimics of natural products such as vinca alkaloids have shown promise. However, as 
with most drugs, administration of high dosage is often required for potent activity. 
This results in acquired drug resistance, non-selective toxicity to non-cancerous cells 
and possible metabolic degradation thereby limiting the availability of therapeutic 
dose. Indeed, as shown in previous studies, alkaloids derived from Ficus spp such as 
hispiloscine and jerantinines A and B (isolated from Tabernaemontana corymbosa) 
demonstrated similar non-selective toxicity to both cancer and non-cancerous cells in 
vitro (Raja et al., 2014; Yap et al., 2015). Similarly, tocotrienols represent the most 
potent cytotoxic vitamin E isomers that have demonstrated promising anticancer 
properties. However, the potential successful application of tocotrienols as cancer 
therapeutic agents has been limited by problems that include the following; 
a) The need for delivery of high dosage especially via oral route of 
administration. 
b) Low bioavailability of therapeutic dose due to the overloading of the transport 
protein by high doses and subsequent metabolic degradation of tocotrienols.  
c) Potential side effects such as increased risk of heart failure and hemorrhagic 
stroke as evident in the HOPE-TOO trial (Bennett et al., 2012) . 
Combinatorial treatment approaches resulting in either synergistic or additive 
pharmacological interactions are continuously been explored to develop cytotoxic 
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regimens with improved potency to overcome drug resistance and also minimize non-
selective toxicity to non-cancerous cells (Boik, 2001; Lim et al., 2013). The concept 
of drug combinations is to maximize potency of chemotherapeutic agents especially 
against drug resistance. The drug combinations can be between direct and indirect 
acting drugs that can result in sequential, concurrent or concerted synergistic 
pharmacological interactions (Boik, 2001). Indeed recent studies have suggested drug 
combinations at lower dosages as potential alternative to circumvent limitations 
associated with single high-dose tocotrienols(Shirode and Sylvester, 2010). Drug 
combinations at lower dosages can minimize toxicity of single high doses whilst 
improving potency via multi-target pathways that results from two or more drug 
combinations. Although several studies have investigated the synergistic potency of 
tocotrienols previously, most combinations were conducted at high dosage and the 
potential toxicity to non-cancerous cells was not properly addressed (Wali and 
Sylvester, 2007; Yang et al., 2010).  
 
Therefore, in a continual contribution towards developing value-added tocotrienols 
with an improved anticancer potency and elucidating the mechanisms of action for 
jerantinines (A and B), the present study was undertaken to investigate the in vitro 
anticancer activities of these tocotrienols, the indole alkaloids jerantinines A and B 
(isolated from Malaysian Tabenaemontana corymbosa), ethanol extracts and alkaloid 
crude extracts from the leaves and bark of Ficus sp (Ficus hispida, Ficus fistulosa, 
and Ficus schwarzii) collected from various locations in Malaysia. 
 
Three different cancer cell lines including brain, lung and colon cancer were selected 
for this study. The brain (U87MG) cancer cells was selected because only a few 
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cytotoxic studies have been conducted to date despite the poor survival rate in patients 
(Lim et al., 2014b; Siegel et al., 2016). In addition, recent studies have shown that 
tocotrienols can penetrate the blood brain barrier (Kaneai et al., 2016). Likewise, to 
date there are no reported studies on the potential mechanism jerantinines induced 
apoptosis on U87MG brain cancer cells. On the other hand, both lung (A549) and 
colon (HT-29) cells were selected due to the higher incidences. In fact, lung and colon 
cancers are currently ranked as 1
st
 and 3
rd
 leading causes of cancer related deaths 
(Siegel et al., 2016). In addition, these cancers offer a potential oral route of 
administration for chemotherapeutic agents. This would allow for future testing on the 
potency of successful low-dose combinations via the oral route considering that oral 
route of administration limits the anticancer potency of high-dose tocotrienols. 
 
1.4 Scope of study  
The study enlisted tocotrienols (delta and gamma), extracts from Ficus spp and 
jerantinines (A and B) for the individual and combined treatments to act on three 
cancer cell lines, namely human lung adenocarcinoma (A549), brain glioblastoma 
(U87MG) and colorectal adenocarcinoma (HT-29) cells and one normal (non-
cancerous) cell line, namely human lung fibroblast (MRC5) cells for a parallel 
comparison. In this thesis, Chapter Two describes the background knowledge and 
literature review detailing information on cancers, bioactive compounds and plant 
extracts selected for this study as well as the apoptotic mechanisms. Chapter Three 
focuses on the screening for antiproliferative activities of individual and combined 
treatments as well as quantitative measurement of pharmacological interactions 
between combined treatments on brain (U87MG), lung (A549) and colon (HT-29) 
cancers. Following the determination of synergistic growth inhibition, the effects of 
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potent individual and combined treatments on cellular morphological features and 
DNA damage patterns were subsequently determined as reported in Chapter Four. 
Furthermore, investigations on cell cycles, microtubules and the role of caspase 
enzymes were conducted to learn about the apoptosis phenomenon and presented in 
Chapter Five. Chapter Six signifies the mechanisms mediating apoptosis induction by 
individual and combined treatments on brain (U87MG) cancer cells which were 
elucidated via apoptosis array, enzyme linked immunosorbent assay (ELISA) and 
Western blotting techniques. Finally, Chapter Seven exemplifies the general 
discussion of the whole study leading to generation of final research conclusions with 
limitations of study well-appreciated and future prospects recommended. 
 
1.5 General aim and specific objectives of study 
The general aim of this research is to seek for a value added anticancer 
chemotherapeutic regimen from plant sources via combined treatments which could 
improve anticancer potency and reduce non-selective toxicity towards normal cells. In 
order to achieve this general aim, several investigations had been carried out and 
described in details at separate chapters, i.e. from Chapter Three to Six. 
The specific objectives of the study were: 
1) To determine the in vitro antiproliferative effects of individual and combined 
treatments of tocotrienols, extracts from Ficus spp and jerantinines as well as 
their pharmacological interactions (Chapter Three). 
2) To assess the DNA damage patterns and changes in cellular morphology 
associated with apoptosis induced by individual and combined treatments of 
tocotrienols and jerantinines on three cancer cell lines (Chapter Four).  
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3) To deduce the cell cycle arrest, microtubule integrity and involvement of 
caspase enzymes in the execution of apoptosis by individual and combined 
treatments of tocotrienols and jerantinines on three cancer cell lines (Chapter 
Five). 
4) To elucidate the molecular apoptotic mechanisms involving apoptosis related 
gene expressions triggered by individual and combined treatments of 
tocotrienols and jerantinines on brain cancer cell line (Chapter Six). 
1.6 Experimental hypotheses  
Previous ethno-medicinal and pharmacological studies have demonstrated the 
cytotoxic potentials of Ficus species, Tabernaemontana corymbosa and palm oil 
derived tocotrienols(Lansky et al., 2008; Lim et al., 2014b; Qazzaz et al., 2016; Raja 
et al., 2014). Therefore, it is hypothesized that the individual treatments of 
tocotrienols, jerantinines (A and B) and extracts (ethanol and alkaloid crude) of Ficus 
spp (Ficus hispida, Ficus fistulosa, and Ficus schwarzii) shall induce potent 
antiproliferative effects on lung (A549), brain (U87MG) and colon (HT-29) cancer 
cells. The ideal combinations at lower dosages of two cytotoxic candidates exhibiting 
a synergism shall reduce the required potent doses. This would subsequently 
minimize toxicity to non-cancerous cells and improve the selectivity window between 
cancer and non-cancerous cells. The combined treatments shall also result in an 
improved efficacy of apoptosis induction through the activation of multiple pathways 
as compared to individual treatments.  
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1.7 Significance of study 
The current research activities advance the search for anticancer drug candidates from 
the nature. This study is impactful as the cancer incident is constantly increasing 
which necessitates utmost attention of researchers. The qualities of life of the cancer 
patients have also been jeopardized with the undesirable side effects associated with 
the current available treatments. The combined treatments may be advantageous in 
increasing efficacy and effectiveness of chemotherapy. The combined treatments 
might provide maximum cancer cell cytotoxicity within the range that is tolerable by 
the patients. This could potentially also minimize the duration of cancer 
chemotherapy thereby reducing the suffering of patients and the side effects which are 
often encountered during the chemotherapy process. The use of combined low-dose 
treatments could also prolong the use of these chemotherapeutic regimens which 
could potentially reduce the risks of cancer recurrence and drug resistance.  
 
On the other hand, Tabernaemontana corymbosa has been placed on the red list under 
the lower risk category of endangered species by the International Union for 
Conservation of Nature (World Conservation Monitoring Centre, 1998). Therefore, 
this study would be significant as it would provide valuable additional knowledge on 
the pharmacological activities and mechanistic action of jerantinines (A and B) 
(isolated from Tabernaemontana corymbosa) on top of the very limited studies 
(Qazzaz et al., 2016; Raja et al., 2014). Furthermore, the combinations of delta and 
gamma tocotrienols at lower doses with jerantinines (A and B) and extracts (ethanol 
and alkaloid crude) of Ficus hispida, Ficus fistulosa, and Ficus schwarzii as described 
in this study were the first of its kind and hence are highly valuable.  
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2.0 CHAPTER TWO: LITERATURE REVIEW 
2.1 Cancer 
Cancer is a collection of diseases of more than 100 characterized by uncontrolled 
proliferation that can lead to undesirable fatal consequences. The incidence of cancer 
can vary depending on gender, ethnicity and geographical location. Globally, there 
were over 8.2 million cancer related deaths and over 14 million new cases of cancer in 
2012 which are projected to rise by exceeding 70% over the next two decades 
(American Cancer Society, 2012). Lung (13%), breast (11.9%) and large bowel 
(9.7%) were the most commonly diagnosed cancers. Whereas, lung (19.4%), liver 
(9.1%) and stomach cancers (8.8%) were recorded as the most common causes for 
cancer deaths. Africa, Asia and South America account for 60% of global new cases 
and  70% of cancer deaths (Stewart and Wild, 2014). In 2016, over 16 million new 
cases and over five hundred thousand cancer related deaths are expected in the United 
States (Siegel et al., 2016). Prostate (21%) and breast (29%) cancers are the leading 
estimated new cases of cancer types in males and females, respectively. Whereas, 
lung and bronchus are the leading types for estimated cancer related deaths in both 
males (27%) and females (27%) (American Cancer Society, 2016). Key risk factors 
related to health and environmental conditions that are avoidable, account for more 
than 30% of cancer deaths. For instance, tobacco use alone accounts for 20% of 
cancer death globally. Whereas, HBV (hepatitis B virus) and HPV (human 
papillomavirus) infections account for 20% cancer deaths especially in low income 
countries (Stewart and Wild, 2014).  
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2.1.1 Pathogenesis of cancer  
The etiological causes of cancer are classified into three groups that include chemical 
carcinogens, biological carcinogens and physical carcinogens. These eventually cause 
damage in genetic materials that is considered as the primary trigger of cancer 
pathogenesis from normal to tumor cells. Cancers cells cause a range of pathological 
processes that include inflammation, immune system disruption and invasion, 
metastasis, angiogenesis and oxidative nitrosative stress (Bukhtoyarov and Samarin, 
2015). 
 
Uncontrolled proliferation is one of the pathophysiological mechanisms of cancer. 
Temporary suspension of anti-tumor activity is a natural physiological condition that 
allows for repairing tissues that have been damaged due to chemical, physical or 
biological carcinogens (Martinez and Gordon, 2014; Mosser and Edwards, 2008). 
However, a myriad of factors that include multiple microdamage often cause 
prolonged uncontrolled proliferation of tumor cells  (Bukhtoyarov and Samarin, 
2015). Furthermore, unlike healthy cells, tumor cells are not dependent on exogenous 
growth factors due to adoption of an autocrine signaling through production of 
receptor tyrosine kinases that are secreted into extracellular matrix. In addition, 
tumors alternatively divide by mutating and activating the quiescent Ras oncoprotein 
which permanently conveys growth signal. Indeed, the Ras oncogene is mutated in 
about 20% of cancer cells (Whellan et al., 2009).  Tumor cells progress by evading 
apoptotic machinery through mutation of death receptors, gene silencing and 
increased production of anti-apoptotic factors (Igney and Krammer, 2005). 
Eventually, tumor cells produce small capillaries (tumor vascularization) through a 
process termed as neo-angiogenesis.  Hypoxia occurs in the event of insufficient 
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vascularization in tumor cells which triggers the production of pro-angiogenic factors 
such as fibroblast growth factor (FGF), platelet derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF) and angiostatin amongst others that 
promote angiogenesis (Auguste et al., 2005). Invasiveness and metastasis are other 
important features that distinguish between benign and malignant tumors. Malignant 
tumors leave primary tumor sites via circulation to invade adjacent tissues to form 
secondary tumor through a series of steps termed as the metastatic cascade. The 
secondary tumors proliferate and induce angiogenesis to ensure sufficient 
vascularization of cancer cells (Leber and Efferth, 2009). 
 
2.1.2 Types of cancer  
Globally, cancer is a major public health problem. Although there are over 100 
different types of cancers, cancers of the lung, liver, colorectal, stomach, breast, and 
oesophageal account for the most number of cancer deaths globally. Herein, lung, 
colon and brain cancers were selected for this study. Both lung and colon cancers 
have high incidence rate and are the leading causes of cancer related death ranked 
globally at 1
st
 and 3
rd
, respectively. On the other hand, brain cancer is the leading 
cause of cancer death in children and adolescents. In addition few studies have been 
conducted on the cytotoxic potency of tocotrienols on brain cancer even though 
studies have shown that tocotrienols can penetrate the blood brain barrier. Similarly, 
to date there are no reported studies on the cytotoxic potency of jerantinines on brain 
cancer cells. Finally, the potential oral route of drug administration for these cancers 
offers an opportunity to determine in the future the potency as well as the 
susceptibility of combined low-dose treatments to metabolic degradation. This 
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necessitates investigations on potential future chemotherapeutic regimens against 
lung, colon and brain cancers. 
 
2.1.2.1 Lung cancer 
Lung cancer is one of the most common avoidable cancer diseases worldwide. A rare 
disease before the 20
th
 century, its incidence has since expanded significantly over the 
past 10-20 years accounting for the highest mortalities resulting from oncological 
problems in the 21
st
 century (van Zandwijk, 2001). Non-small cell lung cancers 
account for about 85% of lung cancers and is characterised by subtypes that include 
adenocarcinoma, squamous cell carcinoma, large cell carcinoma and small cell 
carcinoma. In the United States, squamous cell carcinoma and adenocarcinoma are 
the most prevalent types of non-small cell lung cancers in men and women, 
respectively. According to estimates from the American Cancer Society, in 2015, 
221,200 new cases and 158,040 deaths from lung cancer were reported in America 
(Siegel et al., 2015). There is higher incidence in men and women above 40 years 
especially in the former thus correlating with the differences in the pattern of tobacco 
smoking (van Breda et al., 2008). However, there has been an increase in lung cancer 
deaths in women in developed countries in contrast to observed decrease in fatalities 
amongst men. This emerging trend has been linked to the increasing prevalence of 
females smoking cigarette in the United States, Europe and Asia (American Cancer 
Society, 2012). Furthermore, there are indications of other risk factors such as genetic 
susceptibility, biologic and hormonal factors by some studies indicating the possible 
partly or wholly contribution in the regards of tobacco effect in women (Pauk et al., 
2005). Family and smoking history have been accepted to play a possible role in lung 
cancer. In addition, genetically susceptible genes such as CYP1A1 (a cytochrome 
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P450 family1 member A1 gene), which is common to both lung and breast cancers 
have also been identified. In addition, the expression of gastrin-releasing peptide 
receptor (GRPR) as well as the G to T transversion in p53 have been found to be 
higher in woman lung cancer cases compared to those of males indicating these 
possible roles towards lung cancer susceptibility in women (Shriver et al., 2000). 
 
2.1.2.2 Brain cancer 
Brain tumour is leading cause of cancer related deaths in children, places at the 
second only to leukaemia, although it only accounts for 50% of frequency of 
leukaemia (Pfister et al., 2009). In fact, recent data showed that brain cancer has 
surpassed leukaemia as the leading cause of cancer death among children and 
adolescents aged 19 years (Siegel et al., 2016).  In Britain, around 400 children below 
the age of 15 years are diagnosed with brain, central nervous system (CNS) and 
intracranial tumours annually representing 27% and ranked the second most 
diagnosed childhood cancer (Cancer Research UK, 2014). Epidemiological data in 
2008 showed the global age standardised incidence of 3.7 and 2.6 per 100,000 men 
and women, respectively for primary brain tumour (PBT). Reported approximations 
of 21,800 individuals in the United States were diagnosed with malignant primary 
brain tumour in 2008 with Caucasians recording the highest rate (Bondy et al., 2008). 
In 2011, around 9,400 people were diagnosed with brain and / or CNS, intracranial 
tumours in the United Kingdom with 57% of the aforementioned diagnosis occurring 
in people under 65 years.  Furthermore, brain cancer is the 15
th
 and 13
th
 leading cause 
of cancer deaths amongst Taiwanese males and females, respectively with a 1.5 times 
greater incidence of glioma in the former when compared to the latter (Chiu et al., 
2012).  
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Possible protective roles of female hormones against brain cancer development have 
been suggested as a probable reason for lower incidence in females. Studies have 
shown that the higher incidence in females only reaches its maximum around the age 
of female menopause and subsequently diminishes thereafter  (McKinley et al., 2000). 
Histologically, a population study showed that gliomas accounted for approximately 
57% of paediatric brain tumors whereas craniopharyngiomas (4%), pineal tumors 
(1%), meningiomas (1%), medulloblastomas and other embryonal tumors (26 %) and 
others (11%) constituted for the remaining 43% (Kaatsch et al., 2001).  
 
2.1.2.3 Colon cancer 
Globally, colorectal cancer is ranked the third leading cause of cancer related deaths 
(Purim et al., 2013). An estimated 136,830 and 50,310 people were reported to be 
diagnosed or die from colorectal cancer in 2014 (American cancer society, 2014). 
There are several risk factors to colon cancer that have been classified into modifiable 
and non-modifiable. Hereditary or family history exemplifies the latter as individuals 
with family history of colorectal cancer are 2 to 3 times the risk of developing colon 
cancer. In fact, about 20% of colorectal cancer patients have relatives that were 
previously diagnosed (Lynch and Chapelle, 2003). On the other hand, behavioural 
risk activities that include physical activities, diet, smoking, alcohol, overweight and 
obesity constitute the modifiable risk factors. The survival rate for colorectal cancers 
varies globally. For instance, 65% of five-year survival rate has been reported in 
Israel and South Korea in contrast to 20% to 55% recorded in other parts of Asia. 
Similarly, there is five-year survival rate of 60% to 65% in North America, New 
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Zealand, Australia and majority of European countries (American Cancer Society, 
2015). 
 
2.1.3 Available cancer treatments and limitations  
There are different types of cancer treatments that have continuously changed over the 
past four decades. The most prominent age long treatments include surgery, 
radiotherapy, and chemotherapy. Surgery is a very effective treatment that has been 
used prior to the advent of radiotherapy and chemotherapy. As an individual 
treatment, it is more effective compared to radiotherapy and chemotherapy as it is 
based on zero-order kinetics thereby kill 100% of excised cells. In addition, surgery is 
pivotal for improving five-year survival rate of colorectal liver metastases by 30-40% 
although this therapeutic approach is applicable to only confined metastases that 
represent 10-15% of cases (Urruticoechea et al., 2010). However, surgery is temporal 
palliative and accessibility to some parts by surgery is difficult. In addition, surgery is 
not applicable to sub-clinical metastases and cannot completely eliminate cancer cells.  
 
On the other hand, radiotherapy is an alternative palliative that is used to slow down 
cancer growth or shrink massive tumors to enable removal by surgery. In fact, over 
45% of new cases are expected to receive radiation therapy (Delaney et al., 2005). 
Unlike surgery, radiotherapy is a curative to early stage cancers of head and neck, 
pancreas and Hodgkin’s disease. In addition, radiotherapy is used in combination with 
surgery or chemotherapy as a preoperative or intraoperative palliative. However, 
major limitations include potential damage to organs close to tumor sites, 
inconvenience of regular hospital visits and inability to completely eradicate cancer 
cells amongst others (Urruticoechea et al., 2010).  
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Chemotherapy is the use of drugs at different stages of cancer as a cure, a preventive 
against cancer spread or palliative. Unlike radiotherapy and surgery, chemotherapy 
can spread quickly throughout the whole body to kill local cancer, metastasize cancer 
and restrain tumor growth. A typical example of chemotherapeutic drugs is tamoxifen 
that has been used as an adjuvant for breast cancer treatment which has resulted in 
11% improvement of ten-year survival rate (Shiau et al., 1998). The vast majority of 
chemotherapeutic drugs currently in clinical use or development are derived from 
natural products or mimics of natural products  (Cragg and Newman, 2005). 
However, the potential of non-specific killing of cells,  acquired drug resistance over 
time and difficulty of overcoming blood-brain barrier highlight some of the 
limitations of cancer chemotherapy (Alfarouk et al., 2015). Nonetheless, 
chemotherapeutic drugs from natural products are continuously being developed. 
Strategies such as combination therapy between multiple chemotherapeutic agents 
and targeted delivery using nano-materials are suggested to overcome some of the 
limitations (Boik, 2001; Sylvester et al., 2010). 
  
2.2 Apoptosis as a natural defense mechanism  
Apoptosis or programmed cell death is a highly preserved and regulated mechanism 
that occurs at developmental stages and aging, playing key roles in regulating 
physiological growth and tissue homeostasis. The discovery of apoptosis as a mode of 
cell death was the highlight of cancer research considering its critical role in 
regulating tumor growth and determining therapeutic response (Fulda and Debatin, 
2006a). In addition to apoptosis, there are other forms of cell deaths such as necrosis, 
autophagy and mitotic catastrophe amongst others (Edinger and Thompson, 2004). 
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Apoptosis is characterized by morphological features and energy dependent 
biochemical mechanism. The morphological features of apoptosis are visible under 
the light microscope. At early stage, apoptosis is characterized by cell shrinkage and 
nuclear chromatin is condensed into masses that become marginated from the 
membrane (Saraste and Pulkki, 2000). Thereafter, extensive plasma membrane 
blebbing occurs and the subsequent separation of cellular fragment into apoptotic 
bodies. The apoptotic bodies are subsequently phagocytosed by neighboring cells 
including parenchymal cells and macrophages. Apoptotic cells appear as oval or 
circular shaped single or small clusters of cells with dark eosinophilic cytoplasm and 
dense purple nuclear chromatin when examined using histological dyes, namely 
hematoxylin and eosin (Elmore, 2007). The degradation of DNA by endogenous 
DNases into double stranded fragments of 180-200 base pair highlights the 
biochemical hallmark of apoptosis. DNA fragments appear as ladder in 
electrophoresis whereas cells with fragmented DNA become visible under light 
microscope when tested with terminal transferase mediated DNA nick end labelling. 
In addition, the activation of cysteine proteases (caspase) enzymes and the subsequent 
cleavage of their substrates are a biochemical process that is essential for apoptotic 
cell death (Hengartner, 2000). 
 
2.2.1 Difference between apoptosis and necrosis 
Necrosis represents an undesirable form of cell death in cancer research. Unlike 
apoptosis, necrosis is an energy independent process that is accompanied by rapid loss 
of homeostasis resulting in accidental cell death. It is characterized by morphological 
features that include swelling, formation of distended endoplasmic reticulum, 
cytoplasmic vacuole and blebs, disrupted membrane organelle and rupture of 
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mitochondria and ribosomes. Furthermore, unlike apoptosis, necrosis is absence of 
apoptotic bodies formation and consists of inflammation attributed by subsequent 
leakage of intracellular contents (Denecker et al., 2001). Nevertheless, there are 
similarities between apoptosis and necrosis. For instance, mitochondrial membrane 
permeability present in apoptotic cell death has also been characterized in necrotic 
cell death. There are similarities on the potential roles of anti-apoptotic proteins such 
as B-cell lymphoma protein 2 (Bcl2) family proteins and pro-apoptotic proteins 
including Bax towards inhibition or activation of apoptotic and non-apoptotic cell 
death. The activation of caspase enzymes ultimately determines phenotypically if cell 
death is apoptotic or necrotic (Elmore, 2007). 
 
2.2.2 Apoptotic pathways  
In anticancer therapy, apoptotic death often involves activation of caspase enzymes 
that act as mediator of cell death although there is also evidence of caspase 
independent apoptosis.  These processes are mediated via intricate signaling 
mechanism categorized into extrinsic (death receptor) and intrinsic (mitochondria) 
pathways. 
 
2.2.2.1 Extrinsic pathway 
The extrinsic signaling pathway also known as the death receptor pathway involves 
transmembrane death receptors belonging to the tumor necrosis factor (TNF) receptor 
gene superfamily. The TNF has an 80 amino acid rich death domain that plays critical 
role in transmitting death signal from cell surface to intracellular signaling  (Edinger 
and Thompson, 2004). The best characterized death receptors and their ligands 
involve in apoptosis include tumor necrosis factor alpha/tumor necrosis factor 
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receptor 1 (TNF-α/TNFR1), fatty acid synthetase ligand/fatty acid synthetase receptor 
(FASL/FASR), Apo3 ligand/death receptor 3(Apo3L/DR3), Apo2 ligand/death 
receptor 3 (Apo2L/DR3), Apo2 ligand/death receptor 5 (Apo2L/DR5) (Rubio-
Moscardo et al., 2005). Upon induction of death signal, two of the best understood 
ligands, TNF-α and FasL bind to the respective receptor thereby recruiting death 
domains including TNF receptor associated death domain (TRADD) and Fas 
associated death domain (FADD), respectively. The death domains form death 
inducing signaling complex (DISC) and subsequently activate caspase 8 via 
autocatalytic activation. Subsequently, caspase 8 activates executioner caspase 3 to 
trigger apoptotic cell death. However, this can be inhibited by FLICE inhibitory 
protein (c-FLIP) that renders the death receptor mediated pathway becoming effective 
(Fig. 2.1). Alternatively, caspase 8 induces truncation and activation of BH3 
interacting death domain agonist (BID) protein that subsequently triggers the 
mitochondria mediated pathway of apoptosis (Wajant, 2002). 
 
2.2.2.2 Intrinsic pathway  
As shown in Fig. 2.1, the intrinsic or mitochondria mediated pathway, caspase 
activation is accompanied with permeabilization of the mitochondrial membrane. 
Upon induction of death stimuli and disruption of mitochondrial membrane, 
intramembrane proteins including cytochrome c, second mitochondrial activator of 
caspases/direct inhibitor IAP binding protein with low PI (SMAC/DIABLO) and 
endonuclease G are released into the cytosol to induce apoptosis. Cytochrome c binds 
to apoptotic protease activating factor (APAF-1) and caspase 9 to form the active 
apoptosome complex. Eventually, the executioner caspase 3 is recruited by the 
apoptosome and activated by caspase 9 to trigger key cellular and biochemical events 
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of apoptosis (Blagosklonny, 2003). Furthermore, additional mitochondrial proteins 
such as SMAC/DIABLO and high temperature requirement HtrA2/Omi promote 
mitochondria mediated apoptosis by stopping inhibitors of apoptosis (IAP). A second 
group of proteins including the apoptosis inducing factor (AIF) and endonuclease G 
are released by mitochondria and translocated to the nucleus at the later stages of 
apoptosis (Candé et al., 2002). Both proteins promote apoptosis by causing DNA 
fragmentation as well as caspase independent apoptosis. The Bcl-2 family proteins are 
comprised of about 26 pro- and anti-apoptotic proteins that control the mitochondria 
membrane and the balance between these groups of proteins ultimately determine 
apoptosis. The pro-apoptotic proteins include Bid, Bad, Bax, Bim, Bik, Bcl-10, Bak 
and Blk. In addition, the tumor suppressor protein p53 associates with Phorbol-12-
myristate-13-acetate-induced protein 1 (Noxa) and Bcl2 binding component 3 (Puma) 
to induce mitochondria mediated apoptosis (Chipuk, 2004). Puma causes 
conformational change and expression of Bax, cytochrome c release and reduction of 
mitochondrial membrane potential. Noxa localizes to the mitochondria to interact 
with anti-apoptotic Bcl2 proteins and induce activation of caspase 9 (Chipuk, 2004). 
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Fig. 2.1: Extrinsic (death receptor) and intrinsic (mitochondria) apoptotic pathways 
(Hengartner, 2000). 
 
2.3 Plant derived anticancer agents 
Mortality and new diagnosed cases of cancer are continuously rising. Some cases can 
in fact be minimized as shown in the cases of the aforementioned cancers (lung and 
colon), however, the ineffectiveness of chemoprevention approaches have limited the 
potent treatment of cancers. Therefore, potential new drugs are continuously under 
development and many of which are sourced from natural products such as plants. 
The historical application of plants as remedies for various diseases could be traced 
back to several decades before the synthetic era with majority of medicines are 
obtained from barks, roots and leaves (McChesney et al., 2007). A review by Hartwell 
41 
 
in 1982 listed over 3000 plant species which have been used for anticancer treatment 
although in several instances, the type of cancer is undefined (Cragg and Newman, 
2005). An estimate by the World Health Organisation (WHO) showed over 80% of 
the populace in developing countries rely on traditional medicine for various health 
needs (Madhuri and Pandey, 2009). In fact, a survey showed that over 60% of cancer 
patients depended on herbs and vitamins (Unnati et al., 2013). Plants defend 
themselves from predators and also compete for space against other species through a 
mechanism that produces toxic metabolites such as tannin, tritepenoids, and alkaloids 
etc (Rocha et al., 2001) thus making plants interesting sources of novel bioactive 
compounds for drug development. Bioactive compounds of natural origin constitute 
over 50% of modern drugs, many of which possess anticancer activity (Unnati et al., 
2013). The discovery of the vinca alkaloid family as anticancer agents in the 1950s 
and subsequent collection and isolation of compounds from plants in temperate 
regions by the National Cancer Institute (NCI) had led to the discovery of several 
natural compounds with anticancer activity. Vincristine and vinblastine (vinca 
alkaloids) isolated from Madagascar periwinkle. Catharanthus roseus was the first 
plant derived anticancer agents to be successfully used in clinical practice to treat 
different types of cancers such as leukemias, lymphomas, Hodgkins disease, lung and 
liver cancers (Noble, 1990). Etoposide a semisynthetic compound of 
epipodophyllotoxin isolated from Podophyllum species inhibits topoisomerase II 
resulting in DNA breaks and has been used in treating lymphomas with even more 
effective cure rate against testicular cancer when combined with bleomycin (Canel et 
al., 2000). Furthermore, the discovery of taxanes, paclitaxel and docetaxel with 
anticancer activity against breast, ovarian, small and non-small lung cancers 
exemplifies another success in natural product drug discovery. Paclitaxel exerts its 
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antitumor effect by stabilizing microtubules, resulting in mitotic arrest. 
Notwithstanding its impressive antitumor activity, taxanes could be associated with 
severe irreversible toxicity; although these effects are rarely life threatening (Newman 
et al., 2003).  
 
In addition, there are also plant derived natural compounds undergoing clinical 
development. Flavopiridol is another interesting plant based anticancer agent 
currently entering clinical phase. Although a synthetic flavonone, flavopiridol was 
derived from an alkaloid rohitukine isolated from stems and leaves of Amoora 
rohituka and Dysoxylum binectariferum. It blocks the phosphorylation of cyclin 
dependent kinases (CDK) leading to cell cycle arrest at G1 or G2  and growth 
inhibition against breast and lung carcinoma cell lines (Kelland, 2000). A 
collaborative effort by the NCI and botanical research institute of South Africa lead to 
the collection of the plant, Combretum caffrum (Combretaceae) and subsequent 
isolation of ccombretastatins. Combretastatins is considered to be the most cytotoxic 
phytomolecule isolated thus far (Cirla and Mann, 2003). Combretastatins act as 
antiangiogenic agent by causing vascular short down and tumor necrosis.  
 
Although these drugs have shown a great potential, however, toxicity and in most 
cases drug resistance due to the multidrug resistance gene (MDR) especially with 
regards to microtubule targeting drugs have limited the potency of such 
chemotherapeutic drugs. In fact, considering the significance in combating cancer, 
new crops of anti-microtubule drugs are under development and these are mostly 
synthetic derivatives of natural products such as the vinca alkaloids (Perez, 2009). 
Multiple drugs combination approach has been attracting interest amongst the 
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scientific community as an alternative to combat drug resistance and minimize the 
non-selective toxicity of single high-dose treatments. Indeed as shown by previous 
studies, natural products or even extracts from plants such as Ficus spp can be 
effectively combined to induce synergistic anticancer effects (Nugroho et al., 2013). 
 
2.3.1 Ficus spp: ethnobothany and ethnomedicinal application 
Moraceae also commonly known as the mulberry family with flowering plants 
comprising of forty (40) genus with over a thousand (1000) species, spans across 
tropical and subtropical regions and to a lesser extent in temperate climates. The 
genus contains great secondary metabolites thus exhibiting potential biological 
activities like anticancer, anti-inflammatory, antibacterial and respiratory disorders 
amongst others. Ficus spp possess genus of over 800 species of woody trees, shrubs 
and vines in the family of Moraceae, which are mostly found in the tropics. The 
height of the Ficus ranges from 30-40 m tall with a stout trunk up to 2 m in diameter. 
It has a broad oval leaves of 10-35 cm long and 5-15 cm broad and the flowers are 
pollinated by particular species of fig wasp in a co-evolved relationship. As a 
moderate sized tree with a height of almost 3m, Ficus hispida is native to Asia 
spanning across India, Sri Lanka, Myanmar, Southern region of China (Howlader and 
Dey, 2012). Its habitat mostly includes secondary forest river banks with an altitude 
of 1200m and open lands (Kunwar and Bussmann, 2006). Ficus schwarzii Koord is a 
small dioecious tree of approximately 8-10 m height. The plant often grows as 
clusters along streams found predominantly in Sarawak, Malaysia with a widespread 
distribution across Southeast Asia (Harrison, 2014). Ficus spp also commonly called 
figs, are found in Egypt at parks, streets, gardens with fruits from F. carcia and F. 
sycomorus have been favourably consumed (Abdel-Hameed, 2009). 
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Traditionally, the ethnomedicinal application of several members of Ficus spp as 
agents for treatment of various ailments and their consumption as food probably 
predates cereals, dating back to ten thousand years (Lansky et al., 2008; Shi et al., 
2011). A historical perspective of potential activity and application of figs against 
cancer and related diseases showed that Ficus carcia and Ficus sycomorus were of 
most concern as parts including the tree barks, leaf twigs, young shoots, latex and 
fruits from different stages of ripening (dried or fresh) were used for treatment of 
tumor and inflammation related diseases (Lansky et al., 2008). Furthermore, fruit and 
latex of figs were used in combination with other ingredients such as blue flag, barley 
and fenugreek and administered orally against cancer ailments. Whereas, other parts 
of fig used for treatment of cancer, tumor and swelling were administered topically 
regardless of whether the ailment was internal or external. Additionally, three species 
(F. benghalensis, F. racemosa and F. religiosa) have been used in ayurvedic 
medicine for external treatment of diseases such as eczema, leprosy ulcers and pain 
(Khan and Balick, 2001).  In contrast, there has been little medicinal application of 
figs in traditional Chinese medicine (TCM) as its fruits are often consumed as food 
and considered for improving appetite, whereas, its leaves are considered to be 
slightly poisonous (Lansky et al., 2008).  
 
2.3.1.2 Ficus spp: phytochemistry and pharmacological activities  
Phytochemical investigations have been conducted on various parts of Ficus spp and 
several studies have shown phenolics as the major phytochemical constituent of many 
Ficus spp (Li et al., 2006; Sandabe et al., 2006; Tuyen et al., 1998). Biological 
activity has been reported in roots, leaves and fruits of Ficus hispidia. These include 
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antidiarrhoeal (Mandal and Ashok, 2002), antidiabetic, cardioprotective 
(Shanmugarajan et al., 2008) and antinociceptive and neuropharmacological activities 
of ethanolic extracts (Fig. 2.2) (Howlader and Dey, 2012). Phytochemical studies 
have resulted in identification of over 100 compounds; most of which are 
triterpenoids, phenanthroindolizidine alkaloids, sitosterols amongst others. Ficus 
hispida and Ficus septica had substantial amount of phenanthroindolizidine alkaloids 
(Chiang et al., 2005; Damu et al., 2005; Peraza-Sánchez et al., 2002; Rubnov et al., 
2001). Furthermore, cumarins and multiple flavonoids and triterpenoids were 
identified from roots, stems, leaves and latex of different Ficus spp (Chiang and Kuo, 
2000, 2002; Li et al., 2006). Studies on biological activities have shown that both 
crude extracts and pure compounds of Ficus spp possess antioxidant and free radical 
scavenging activities (Abdel-Hameed, 2009; Rawat et al., 2012; Shi et al., 2011; 
Singh et al., 2011). A review on ethnomedicinal and pharmacognostic properties of 
Ficus hispida showed it possess cardiporotective, antidiarrheal, neuroprotective, 
hepatoprotective, anti-inflammatory and antineoplastic activities (Safwan et al., 
2011). Similarly, species such as F. fistulosa has been shown to possess cytotoxic and 
antimalaria activities (Subramaniam et al., 2009; Zhang et al., 2002). However, to 
date there are no studies on the bioactivity of F. schwarzii.  
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Fig. 2.2: Pharmacological activities of Ficus species. 
 
Discovery of the anticancer properties of Ficus spp dates back to the 19
th
 century 
when preliminary investigations by Ullman and colleagues in 1940 showed that latex 
extracts of Ficus carcia inhibited growth of sarcoma with subsequent tumor 
disappearance in albino rats (Lansky et al., 2008). Over the years, several Ficus spp 
have been extensively investigated on potential anticancer activity leading to isolation 
and subsequent structural elucidation of a series of compounds. A study investigating 
the potential anticancer activity of Ficus hispida showed that chloroform extract of its 
twigs and leaves had significant cytotoxicity against human lung (Lu1) and colon 
(Col2) cancers (Peraza-Sánchez et al., 2002). Furthermore, the fig fruit latex from 
Ficus carcia showed a potent cytotoxicity by inducing apoptosis, blocking DNA 
synthesis and cell cycle arrest in a range of human cancer cells but only also displayed 
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a mild effect on normal cells (Wang et al., 2008; Hashemi et al., 2011). Similarly, a 
mixture of 6-O-acyl-β-D-glucosyl-β-sitosterols isolated from Ficus carcia latex and 
soybeans showed potent cytotoxicity and in vitro growth inhibitory effects against 
burkitt B cell lymphoma, T-cell leukemia, prostate and mammary cancer cells 
(Rubnov et al., 2001). 
 
In addition to single treatments, extracts and compounds from Ficus spp have also 
been shown to effectively combine with other chemotherapeutic drugs. For instance, a 
fraction of dichloromethane extract of Ficus critifolia combined effectively with 
vinblastine and daunomycin by enhancing the cytotoxicity of the former and 
increasing the intracellular concentration of the latter in human sarcoma 
(MESSA/Dx5) and human chronic myelogenous leukaemia (K562/R7) cells, 
respectively. These are models of cells that overexpress p-glycoprotein, a major cause 
of multidrug resistance, thus suggesting the therapeutic potential of Ficus criticola in 
cancer chemotherapy (Simon et al., 2001). In another combinational study, hexane 
insoluble fraction (HIF) of Ficus septica combined with doxorubicin exhibited higher 
growth inhibitory effect, cell cycle arrest and up regulation of cleaved PARP 
compared to single treatment in T74D breast cancer cells indicating possible future 
development of HIF as a co-chemotherapeutic drug (Nugroho et al., 2013). 
 
Pharmacological studies have demonstrated the cytotoxic potency of Ficus hispida as 
demonstrated in the previous literature; however, there are no studies on Ficus 
schwarzii and a few studies on Vietnamese and Singaporean Ficus fistulosa yielded 
non-cytotoxic alkaloids with antifungal and antimalarial properties (Subramaniam et 
al., 2009; Zhang et al., 2002). More importantly, there is a potential of Ficus spp to 
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act as adjuvant for combined treatments thus further justifies the need to investigate 
the cytotoxic potency of the aforementioned species (fistulosa, hispida and schwarzii) 
individually and in combination with other pytochemical agents as potential future 
therapeutic agents.  
 
2.3.2 Tabernaemontana corymbosa: ethnobotany and ethnomedicinal application 
The genus Tabernaemontana also has vast medicinal application, exemplifying an 
excellent source of bioactive phytochemicals and thus has been of research interest for 
phytochemists especially from Asia. There are about 110 species of the genus 
Tabernaemontana of the Apocynaceae plant family native to tropical, subtropical 
regions and West African forest, with a widespread distribution across Asia, Africa 
and South America (Kuete et al., 2010; Lim et al., 2008; Low et al., 2010; 
Pratchayasakul et al., 2008). Tabernaemontana constitutes amongst the sixteen 
species of the sub family Plumerioideae which is known to be rich in structurally 
novel indole and bisindole alkaloids (Kam et al., 1999; Kam and Sim, 2003; Lim et 
al., 2008). Medicinal application of genus Tabernaemontana in Thai, Ayurvedic and 
Chinese traditional medicine includes treatment of ailments such as fever, pain 
dysentery etc (Van Beek et al., 1984). According to ethnobotanical data on the uses of 
75 Tabernaemontana species, up to 78% was for medicinal purpose, whereas, 22% 
was for non-medicinal purpose. The species were mostly used to treat diseases, 
classified as antimicrobial, antiparasitic and analgesic in Africa, whereas, 
antimicrobial, central nervous system (CNS), febrifuge, antitumor, and analgesic were 
mostly treated in Americas, Asia/Australia and Pacific regions (Fig. 2.3). 
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Fig. 2.3: Disease conditions treated by Tabernomantana species in traditional medicine at 
different regions (Van Beek et al., 1984). 
 
One of the interesting species is the Malayan Tabernaemontana corymbosa. Its roots 
and bark are used in making arrow poison in Thailand while the latex is used by 
Malaysians to treat syphilitic ulceration (Table 2.1). Sap from the leaves is used to 
treat sores while pounded roots are used against orchitis (Van Beek et al., 1984).The 
leaves and bark are also used to treat fracture in Southern region of China (Wiart, 
2006). In Bangladesh, the leaves are used to treat tumors, whereas, the roots are 
crushed and the extracted juice used to treat jaundice (Hasan et al., 2012; Rahmatullah 
et al., 2010). 
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Table 2.1: Summarized bioactivities, medicinal and non-medicinal uses of different parts of Tabernaemontana corymbosa. 
Bioactivities Medicinal Uses Non-medicinal Uses 
Parts of Plant Phytochemical 
Constituents 
Pharmacological 
Activities 
Parts of Plant Preparation 
Methods 
Disease Conditions Parts of Plant Uses 
Leaf, stem bark, 
twigs and whole 
plant 
Alkaloids   Anticancer 
 Vasorelaxation 
Leaf Sap and 
poultice 
 Tumor  
 Sore 
 Fractures  
 Postnatal 
recovery 
 
Root   Arrow Poison 
Stem bark Alkaloid crude 
extract 
 Antimicrobial 
 Antifungal 
 Anticancer  
 
Bark Decoction, boiled 
juice and infusions  
 Syphilis 
 Ulceration, 
fractures 
Leaf, seed, stem, 
flower and root 
Methanol extract  Antiviral 
 Antinematodal 
Antihelmintic 
 Analgesic 
Root  Pounded, decoction 
and crushed root 
juice 
 Syphilis 
 Fever 
 Jaundice 
 Postnatal 
recovery 
 
Latex   Birdlime 
Unspecified Boiled juice and 
paste  
 Fever 
 Orchitis 
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2.3.2.1 Phytochemistry and pharmacological activities 
As shown in Table 2.1, the medicinal history of T. corymbosa prompted 
pharmacological studies that reveal several bioactivities including antioxidant, 
antimalarial, vasorelaxant, antiviral, antinematodal, antihelmentic and cytotoxicity 
amongst others (Alen et al., 2000; Das and Chowdhury, 2015; Nge et al., 2014; 
Rizwana et al., 2010; Taher et al., 2011; Zulkefli et al., 2013). Over the past 20 years 
studies, phytochemistry of T.corymbosa has led to isolation and structural elucidation 
of novel structured compounds comprising mostly of indoles and bisindole alkaloids. 
Studies have also shown that the types of alkaloids produced by T. corymbosa 
depended on the time of collection and location of plants. For instance, T. corymbosa 
collected from two different locations in Malaysia produced several different 
alkaloids (Lim et al., 2015). As shown in Table 2.2, these alkaloids demonstrated 
interesting bioactivities most notably is cytotoxicity and the reversal of vincristine 
resistance in human drug resistant carcinoma (KB) cells. As demonstrated by previous 
studies, the aspidosperma type alkaloids jerantinine derivatives (Fig 2.4) are the most 
potent cytotoxic alkaloids isolated from T. corymbosa with growth inhibitory 
concentrations (IC50 <1 µg/ml) against drug sensitive and vincristine resistant KB 
cells (Lim et al., 2008). Although jerantinine derivatives exhibited the highest 
potency, thus far fewer studies have been conducted on the potential mechanism of 
action on jerantinine A and E derivatives only. Indeed, preliminary study on synthetic 
jerantinine E showed disruption of microtubule networks as possible mechanism of 
action (Frei et al., 2013). Further mechanistic study on jerantinine A revealed 
inhibition of tubulin polymerization, microtubule disruption and mitotic arrest as 
mechanism of action. However, similar toxic effects were also evidenced against non-
cancerous cells treated with jerantinine A (Raja et al., 2014). Recent mechanistic 
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study further confirmed jerantinine B as a microtubule targeting agent (MTA) and 
unlike the an established MTA, vincristine, jerantinine B induced potent cytotoxic 
effects against variant vincristine resistant (VR-HCT 116) cells  that express p-
glycoprotein with over 300-fold resistance to vincristine (Qazzaz et al., 2016). This 
suggests an alternative mechanism of action to circumvent the efflux effects of the p-
glycoprotein. To date, MTAs are under different stages of clinical trials although 
toxicity to non-cancerous cells and susceptibility to p-glycoprotein induced multidrug 
resistance limit the efficacy of these drugs. This has prompted the development of 
new crop of MTAs with improved potency, some of which are synthetic derivatives of 
the vinca alkaloids (Perez, 2009). The non-susceptibility of jerantinine to p-
glycoprotein further justifies the need to understand the mechanism of action against 
broad range of cancer cells. Furthermore, the toxicity to non-cancerous cells as 
demonstrated in previous studies could be minimized via combinational treatments at 
low dosage and more efficient targeted-delivery systems.   
 
Fig. 2.4: Structure of jerantinines (A-G) (Lim et al., 2008) 
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Table 2.2: Cytotoxic alkaloids isolated from whole plant, leaf, stem bark and twig parts of Tabernaemontana corymbosa. 
No. Parts of 
Plant 
Location of 
Collection 
Types Alkaloids IC50 (µM) on Cell Types  Ref. 
KB/S KB/VJ300 KB/VJ300
ab
 Lung Liver Breast Colon 
1 Leaf Tekam Forest, 
Pahang Malaysia 
Aspidosperma 
indole 
Jerantinine A 1.99 1.73 - - - - 0.43 
(VR-HCT-
116) 
(Lim 
et al., 
2008) 
 
Jerantinine B 1.11 0.95 - - - - 0.49 
(VR-HCT-
116) 
(Lim 
et al., 
2008) 
 Jerantinine C 0.81 1.54 - - - - - 
Jerantinine D 0.68 0.95 - - - - - 
Jerantinine E 2.55 2.03 - - - - - 
Jerantinine F 12.80 12.30      
Jerantinine A-
acetate 
1.04 0.83 - - - - - 
Jerantinine B-acetate  0.70 0.75 - - - - - 
10-O-methyl 
jerantinine A 
12.0 13.6 - - - - - 
10-O-methyl 
jerantinine B 
7.36 10.70 - - - - - 
2 Stem 
bark 
Tekam Forest, 
Pahang, Malaysia 
Hexacyclic 
indole 
Conolutinine  NA NA 51.25a - - - - (Lim 
et al., 
2009) 
3 Stem 
bark 
Malaysia Indole Lirofolines A NA NA 10.45a - - - - (Low 
et al., 
2010) Lirofolines B NA NA 21.11
a - - - - 
4 Whole 
plant 
Yunnan province, 
China 
Indole Ervachinine E - - - 
 
11.22 
(A549) 
13.61 
(SMMC-
7721) 
14.44  
(MCF-
7) 
14.70 
(SW480) 
 Guo 
et al., 
2012) 
5 Bark Johor, Malaysia Pentacyclic 
indole 
Voatinggine  >80.00 - - - - - - (Nge 
et al., 
2013) 
Tabertinggine >58.00 - 30.94a - - - -  
6 Leaf Yunnan province, 
China 
Indole  
 
Tabercarpamine A - - - - 3.31 
(HepG2) 
8.54  
(MCF-
- (Ma et 
al., 
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6.76 
(SMMC-
7721) 
7) 2014a) 
7 Leaf Yunnan province, 
China 
Monoterpene 
indole 
Bistabercarpamine 
A 
- - - - 38.14 
(HepG2) 
- - (Ma et 
al., 
2014b) 
8 Stem 
bark 
Johor, Malaysia Indole  Criofolinine  >60.00 >60.00 - >60.00 
(A549) 
- - >60.00 
(HCT-116) 
(Nge 
et al., 
2014) 
Vernavosine >60.00 - - >60.00 
(A549) 
  >60.00 
(HCT-116) 
9 Stem 
bark 
Tekam Forest, 
Pahang, Malaysia 
Indole Vincamajicine  >70.00 >70.00 2.62a - - - - (K.-H. 
Lim et 
al., 
2015) 
Cononusine >70.00 >70.00 >70.00a - - - - 
Ervaluteine >70.00 >70.00 53.20a - - - - 
Tacamonidine >70.00 >70.00 >70.00a - - - - 
10 Leaf Malaysia Vobasine-iboga 
bisindoles 
Conodiparine A 25.59 17.99 1.93b - - - - (Kam 
et al., 
1998) 
Conodiparine B 27.69 19.98 3.26b - - - - 
Conodiparine C 28.58 22.69 7.48b - - - - 
Conodiparine D 24.84 18.16 6.14b - - - - 
11 Whole 
plant 
Yunnan province, 
China 
Vobasinyl–
ibogan bisindole 
Ervachinine A - - - 2.86 
(A549) 
3.35 
(SMMC-
7721) 
3.20  
(MCF-
7) 
2.39 
(SW480) 
 Guo 
et al., 
2012) 
Ervachinine B - - - 15.98 
(A549) 
11.40 
(SMMC-
7721) 
15.17 
(MCF-
7) 
15.33 
(SW480) 
Ervachinine C - - - 0.84 
(A549) 
3.46 
(SMMC-
7721) 
3.25 
(MCF-
7) 
3.66 
(SW480) 
Ervachinine –D - - - 3.10 
(A549) 
4.63 
(SMMC-
7721) 
11.76 
(MCF-
7) 
3.63 
(SW480) 
12 Stem 
bark 
Taiping, Perak, 
Malaysia 
Indole 
Bisindole 
Vobasidine A 15.48 >70.00 >70.00a - - - - (Sim 
et al., 
2014) 
Vobasidine B 53.67 >70.00 >70.00a - - - - 
Vobasidine C 15.53 >70.00 26.54a - - - - 
16-epivobasine 15.90 62.47 38.33a - - - - 
Taipinisine  44.22 >70.00 18.57a - - - - 
Tabernaemontanine >70.00 >70.00 >70.00a - - - - 
Dreagamine  >70.00 >70.00 >70.00a - - - - 
Vobasine >70.00 >70.00 >70.00a - - - - 
Vobasenal >70.00 >70.00 >70.00a - - - - 
16-epivobasenal 14.48 >70.00 >70.00a      - - - - 
13 Stem 
bark 
Tekam Forest, 
Pahang, Malaysia 
Vobasinyl-iboga 
isindole 
Ervatensine A  1.39 1.21 0.98a - - - - (K.-H. 
Lim et Ervatensine B 0.95 1.11 1.20a - - - - 
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al., 
2015) 
14 Leaf 
and twig 
Xishuangbanna, 
Yunnan, China 
Vobasinyl-
ibogan 
binsindole 
Tabercorine A - - - 4.14 
(A549) 
3.53  
(SMMC-
7721) 
8.10 
(MCF-
7) 
9.24 
(SW480) 
(Zhang 
et al., 
2015) 
Tabercorine B - - - 10.34 
(A549) 
13.31 
(SMMC-
7721) 
4.70 
(MCF-
7) 
16.93 
(SW480) 
Tabercorine C - - - 33.16 
(A549) 
31.52  
(SMMC-
7721) 
>40.00  
(MCF-
7) 
>40.00  
(SW480) 
Cell lines: KB/S = vincristine-sensitive human oral epidermoid; KB/VJ300 = vincristine-resistant human oral epidermoid; SMMC-7721 = human hepatocellular 
carcinoma; HepG2 = human hepatocellular liver carcinoma; HL-60 = human myeloid leukemia; A549 = human lung adenocarcinoma; MCF-7 = human breast 
adenocarcinoma; SW480 = human colon adenocarcinoma; HCT-116 = human colorectal carcinoma; VR-HCT-116 = vincristine-resistant human colorectal 
carcinoma. KB/VJ300: a = with addition of vincristine (0.12µM) as adjunct treatment; b = with addition of vincristine (0.30µM) as adjunct treatment. NA = no 
activity. (-) = not reported. 
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2.3.3 Vitamin E: Sources, structure and bioavailability 
Vitamin E was first discovered in 1922 by Evans and Bishop as a necessary dietary 
factor for reproduction in rats. It is an essential fat soluble vitamin which contains 
natural sources of tocopherol and tocotrienol with an antioxidant property that has 
made it an ideal and popular supplement. Natural vitamin E has eight isomers known 
as alpha (α)-, beta (β)-, gamma (γ)- and delta (δ)-tocopherols and alpha-, beta-, 
gamma-, and delta-tocotrienols. Since the discovery of vitamin E, major research has 
focused on tocopherols representing an almost 99% research. However, there has 
been a dramatic change on the direction of vitamin E research, where research on 
bioactivity of tocotrienols has gained substantial recognition since the year 2000 
representing a two third of available PubMed literature (Sen et al., 2007). 
 
Both tocotrienols and tocopherols are synthesized as natural sources in plants. 
Tocopherols occur exclusively in plant leaves and seeds of most monocot plants. On 
the other hand, tocotrienols are present in seed endosperm of most monocots and few 
dicots such as tobacco. Cereals such as barley, wheat, and rice also contain a decent 
amount of tocotrienols. Palm oil represents an excellent source of tocotrienols with a 
significant vitamin E distribution of 70% tocotrienols compared to 30% for 
tocopherols (Sundram et al., 1989). Structurally, tocopherols and tocotrienols are 
similar yet only differentiated by the presence of double bond in the side chain 
(Bardhan et al., 2011). Tocopherols have a trimethyltridecyl tail with three chiral 
centres at carbons 2', 4' and 8' occurring naturally in the RRR configuration whereas 
tocotrienols have one chiral centre and three unsaturated bonds in the carbon side 
chain at positions 3', 7', 11'  (Schneider, 2005). The unique structure of tocotrienols 
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with the presence of three double bonds (Table 2.3) gives it a better mobility and 
penetration through lipid membrane of various target organs (Wong and 
Radhakrishnan, 2012). The level of electron unsaturation in tocotrienols gives it a 
superior antioxidant activity and reversal of lipid peroxidation compared to 
tocopherols (Tan and Houston, 2005). 
 
Table 2.3: Structure of tocotrienols. 
Types R1 R2 R3 STRUCTURE 
Alpha-Tocotrienol Me Me Me  
Beta-Tocotrienol Me H Me  
Gamma-Tocotrienol H Me Me  
Delta-Tocotrienol H H Me  
Tocotrienols are characterised by unsaturated side chain: Sourced from (Zingg, 2007). 
Tocopherols are absorbed by the intestinal mucosa and incorporated into chylomicron 
particles where they are transported to the liver tissue via the lymphatic system. 
Alpha-tocopherol transport protein (alpha-TTP) mediates the transfer of alpha-
tocopherol in the liver to a very low density lipoprotein (VLDL) where it is 
subsequently secreted into circulation into peripheral tissues. The preferential 
transportation of alpha-tocopherol is due to its high affinity for alpha-TTP. However, 
other isoforms of vitamin E,  beta-, gamma- and delta-tocopherols have low affinity 
for alpha-TTP resulting in rapid metabolism in the liver, hence, only small portions 
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are found in blood and tissues and most of them are excreted in the faeces (Ju et al., 
2010). In addition, due to its low affinity to transport protein, excess tocotrienols 
undergo β-oxidation and subsequent conversion to α,γ,δ-
carboxyethylhydroxychroman metabolites which are excreted through the urine 
(Schneider, 2005). High concentration of tocotrienols would interfere with cellular 
reactions as studies have shown that the four tocotrienols exert biological activities at 
nanomolar concentration (Zingg, 2007). Although studies on transportation of vitamin 
E over the last two decades had focused on α-TTP which has an 8.5-fold lower 
binding affinity for alpha-tocotrienol compared to alpha-tocopherol, the extent of its 
effect on delivery of orally supplemented tocotrienol is yet to be determined. More 
recent animal and human studies have shown an increase delivery of oral tocotrienols 
independent of alpha-TTP indicating the possibility of other transport mechanisms 
(Khanna et al., 2005; Sylvester et al., 2010). For instance, animal studies showed that 
TTP-knockout mice suffered from alpha-tocopherol deficiency even in the presence 
of supplemented alpha-tocopherol (Brigelius-flohé, 2009). In contrast, oral 
supplementation of alpha-tocotrienol in TTP-knockout mouse restored fertility 
indicating possible alternative mechanisms of its delivery to tissues (Khanna et al., 
2005).  
 
2.3.3.1 Pharmacological activities of tocopherols and tocotrienols  
Several vitamin E isomers have been shown to poses anticancer activities and initial 
studies showed that alpha-tocopherol was potent in suppressing carcinogen induced 
cancer in mice and especially when the dietary supplement was given in combination 
with selenium.  However, inconsistent results were observed in epidemiological and 
subsequent in vivo and in vitro studies further confirmed that alpha-tocopherol has 
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little or no anticancer effect (Gould et al., 1991; Sylvester et al., 2005). The anticancer 
effects of vitamin E are mediated via induction of apoptosis which often involves 
activation of defective intracellular signal pathways and enzymes present in cancer 
cells. Despite having the strongest antioxidant activity, available literatures  have 
shown that alpha-tocopherol is a weak pro-apoptotic inducer compared to other 
vitamin E isomers such as gamma-tocopherols and tocotrienols thus suggesting that 
apoptotic properties are not related to antioxidant properties (Constantinou et al., 2008 
; Sylvester et al., 2001). Alpha-tocopherol failed to induce any form of cell death in a 
range of colon cancer cell lines, whereas, a significant induction of apoptosis was 
observed when cells were treated with gamma-tocopherols (Campbell et al., 2006). In 
contrast, alpha-tocopherol blocked cell cycle at late G1 phase in smooth muscle at a 
concentration of 10-50µM (Constantinou et al., 2008). 
 
On the other hand, gamma-tocopherol which is the most abundant form of vitamin E 
in American diet with low plasma and tissue concentration and a mean serum 
concentration of 5.74 μM (Ford et al., 2006) has more potent and effective pro-
apoptotic activity than alpha-tocopherol (Campbell et al., 2003). A combination of 
alpha-tocopherol and gamma-tocopherol induced apoptosis only in androgen-sensitive 
LNCaP prostate cancer cells via the mitochondria pathway (Jiang et al., 2004). In 
addition, gamma tocopherol also inhibits cell cycle progression which was associated 
with down regulation of cyclin D1 and cyclin E (Gysin et al., 2002). 
 
In contrast to tocopherols, studies have demonstrated that tocotrienols exhibit more 
effective and potent anticancer effects even at lower concentrations (Kline et al., 
2004). Anticancer potential of tocotrienols was first discovered when studies 
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investigated the role of high dietary fat intake on the development of carcinogen 
induced mammary cancer in rats. Although all fat diets regardless of the formulation, 
stimulated tumor development, it was observed that palm oil diet suppressed tumor 
development indicating the anti-tumor potential of palm oil rich diet (Sundram et al., 
1989).  The potential role of tocotrienol diet against cancer was further confirmed 
when palm oil diet devoid of tocotrienol promoted mammary tumor in rats 
(Nesaretnam, 2008; Sylvester et al., 2010). In vitro studies have shown that 
tocotrienol rich fraction (TRF) obtained from palm oil (80% tocotrienols and 20% 
tocopherols) exhibited antiproliferative potencies and induced cell death in a dose 
dependent  mammary tumor cells (Srivastava and Gupta, 2006). Further studies 
conducted to determine the most potent vitamin E isomers present in TRF by 
comparing the two subclasses of vitamin E showed that tocotrienols had significantly 
more antiproliferation and induced cell death at micro molar concentrations with 
minimal toxicity to normal cells compared to tocopherols (Constantinou et al., 2008). 
 
The pathway and intracellular mechanisms for mediation of apoptosis by tocotrienol 
isomers differ depending on the types of cancer. For instance, gamma-tocotrienol 
induced apoptosis in neoplastic mammary epithelial cells by activating caspase 8 and 
3 which was subsequently blocked when combined with specific caspase inhibitors 
strongly suggesting that apoptosis was associated with the death receptor signalling 
pathway (Shah et al., 2003). Further studies by Shah and Sylvester, (2005) confirmed 
the above suggestion by showing that treatment with cytotoxic doses of gamma-
tocotrienol did not disrupt mitochondrial membrane potential or release of 
cytochrome c to the cytoplasm. In addition, there was an observed increase in the ratio 
of anti-apoptotic proteins compared to pro-apoptotic proteins; an indication of 
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enhanced mitochondrial membrane stability (Shah and Sylvester, 2005). In contrast, 
gamma-tocotrienols caused disruption of mitochondrial membrane in human breast 
cancer with concomitant release of cytochrome c to the cytoplasm in a mechanism 
independent of caspase 9 activation or altered BcL2 levels (Takahashi and Loo, 
2004). Similarly, Agarwal et al., (2004) showed that increase in Bax/BcL2 ratio, 
release of cytochrome c and caspase 9 activation were associated with tocotrienol 
mitochondria stress mediated apoptosis in human colon carcinoma cells. 
 
Unlike drugs that regulate or act on single target, tocotrienols induce apoptosis 
regulating signalling molecules which are vital to cancer progression. The 
transcriptional factor, nuclear factor-kappa B (NF-kB) and signal transducer and 
activator of transcription 3 (STAT3) also plays vital role in cancer progression as 
chemoresistance and radioresistance have been related to activated STAT3 in 
collaboration with other factors such as NF-kB, hypoxia inducible Factor (HIF)-1 and 
peroxisome proliferator-activated receptor. In vitro studies demonstrated that gamma-
tocotrienol blocked STAT3 activation in multiple myeloma cells by inhibiting the 
activation of Src kinase, Janus Kinase (JAK)-1 and JAK-2 (Kannappan et al., 2010a). 
Similarly, combined gamma-tocotrienol and tyrosine inhibitors (erlotinib and 
gefitinib) inhibited growth of anchorage-independent cells with a reduction in the 
levels of phosphorylated PDK-1, AKT, STAT3 and STAT5 in murine mammary 
tumor cells (Bachawal et al., 2010). Furthermore, studies showed that gamma-
tocotrienol induced apoptosis in neuroplasmic +SA mammary epithelial cells by 
suppression of receptor tyrosine kinase (ErbB3) tyrosine phosphorylation and down 
regulation of PI3K/PDK-1/AKT mitogenic signalling (Samant and Sylvester, 2006). 
Whilst studies have demonstrated the potency of tocotrienols, fewer studies have been 
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conducted to understand the mechanism of action of delta-, alpha- and beta-
tocotrienol isomers compared to gamma-tocotrienols. Furthermore, even least studies 
have been conducted on lung and brain cancers (Lim et al., 2014a; Lim et al., 2014b). 
Despite the remarkable therapeutic potency, the potential clinical application of 
tocotrienols as anticancer agents has been limited by the need to use high dosage. 
High doses of tocotrienols overload the TPP resulting in metabolic degradation and 
subsequent reduction in available therapeutic doses (Shirode and Sylvester, 2010). 
Enhanced delivery mechanism using nano-particles and synergistic drug combinations 
with other chemotherapeutic agents are under investigation as alternative way to 
reduce dosage and improved potency of tocotrienols (Constantinou et al., 2008; 
Shirode and Sylvester, 2010) 
 
2.4 Combined treatments using tocotrienols 
Synergism is another area of anticancer research that has recently attracted more 
interest. The prospect of combining more than one compound with anticancer effects 
seems promising with the possibilities of anticancer activities at sub-effective doses, 
thus reducing the risk and adverse side effects commonly posed by other 
chemotherapeutic agents (Boik, 2001). Drug synergism has continuously been 
explored as potential alternative to circumventing limitations of tocotrienols and in 
the last 20 years, studies have been conducted investigating the synergistic effect of 
tocotrienols combined with other natural compounds against cancer cells. Indeed, 
some combined treatments demonstrated lower toxicity towards non-cancerous cells 
as well as dose reduction. For instance, combined treatment of sesamin with gamma-
tocotrienol at sub-effective doses caused reduction of required potent doses and 
induced synergistic antiproliferative effects on neuroplastic mouse and human 
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mammary cancer cells. The combined treatments had little or no effects on normal 
cells. However, subsequent studies revealed the effects were rather cytostatic and 
sesamin did not prevent metabolic degradation of gamma-tocotrienol (Akl et al., 
2013; Akl et al., 2012). In addition, the combined treatment of statin and gamma-
tocotrienol caused reduction of required potent doses and induced potent cytotoxic 
effects on +SA mammary tumor cells. Toxicity has limited the clinical use of statin. 
Therefore, dose reduction of statin following combined treatments with gamma-
tocotrienol  suggested a potential future use of statin while avoiding the undesirable 
myotoxicity associated with statin chemotherapy (Wali and Sylvester, 2007; Wali et 
al., 2009). However, it is noteworthy to mention that the studies did not investigate 
the potential toxicity of the combined treatments towards non-cancerous cells. 
 
On the other hand, in some studies although the combined treatment with tocotrienol 
induced potent cytotoxicity, the combinations were at high dosage and the potential 
toxicity towards non-cancerous cells was not determined. For instance, combined 
treatment of gamma-tocotrienol with atorvastatin and celecoxib synergistically 
inhibited growth of HT29 and HCT116 human colon cancer cells with induction of 
G0/G1 cell cycle arrest and apoptosis (Yang et al., 2010). Similarly, combined 
treatment of gamma-tocotrienol with statin (Tuerdi et al., 2013) and 6-gingerol (Yusof 
et al., 2015) induced potent cytotoxic effects on human malignant mesothelioma and 
human colorectal cancer cells, respectively. However, the combinations in these 
studies were conducted at high doses and hence did not address the problems of 
metabolic degradation associated with high-dose tocotrienols. Again, the potential 
toxicity of these high-dose combinations towards non-cancerous cells was not 
reported.  
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3.0 CHAPTER THREE 
In-vitro anti-proliferative effects of individual and combined treatments of 
tocotrienols, jerantinines (A and B) and extracts of Ficus species 
 
3.1 Introduction  
Tocotrienols are a group of vitamin E isomers that have demonstrated potent 
cytotoxic effects against cancer cells in vitro. However as reviewed in literatures from 
Chapter Two, such potency has been limited especially in orally delivered tocotrienols 
due to high dosage associated toxicity and metabolic degradation which results in low 
availability of therapeutic dose. Thus, combined treatments have been suggested as a 
potential alternative to circumvent such limitations. Similarly, indole alkaloids 
jerantinines (A-G) isolated from Tabernaemontana corymbosa have been shown to 
possess potent cytotoxic effects with a potential of reversing vincristine drug 
resistance in cancer cells (Lim et al., 2008). However despite this remarkable potency, 
not many mechanistic studies have been conducted on jerantinines (A, B and E) (Frei 
et al., 2013; Qazzaz et al., 2016; Raja et al., 2014). In addition, the studies have also 
demonstrated that jerantinine derivatives induce toxicity to non-cancerous cells. As 
such it was imperative to further study the cytotoxic effects of jerantinines to 
elucidate the mechanism of action and also adopt a combinatory treatment approach 
that would reduce the dosage and potentially minimize toxicity to non-cancerous 
cells. 
 
On the other hand, Ficus species have a well-documented history of use for anticancer 
treatment in traditional medicine (Lansky et al., 2008). The ethno-medicinal uses have 
been supported by pharmacological data that demonstrated the cytotoxic potency of 
Ficus species. In fact recent literatures have suggested that Ficus species can be used 
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as an adjunct treatment (Nugroho et al., 2013, 2012) thus, making suitable for 
combined treatments with tocotrienols that could potentially improve potency and 
minimize required dosage and toxicity to non-cancerous cell lines.  Three different 
plant species were employed in the study, namely as F. fistulosa, F. schwarzii and F.  
hispida collected from different locations in Malaysia. F. fistulosa and F. hispida 
were selected based the respective medicinal and pharmacological history as indicated 
in different literatures. Whereas, F. schwarzii was chosen because thus far no 
pharmacological activity of this plant was conducted, hence the present study would 
provide new and valuable information. The leaf and bark of plants were extracted by 
ethanol to obtain the crude ethanol extract that was subsequently subjected to acid-
base extraction for collection of alkaloid crude extract. The comparison between 
ethanol and alkaloid crude extracts would allow determining if the observed 
antiproliferative effects are attributed by the presence of alkaloids or non-alkaloids in 
the extracts.  Three different cancer cell lines representing brain, lung and colon 
cancer were chosen. The brain (U87MG) cancer cells was selected because only a few 
cytotoxic studies have been conducted to date despite the poor survival rate in patients 
(Lim et al., 2014b; Siegel et al., 2016) whereas, both lung (A549) and colon (HT-29) 
cells were selected due to the higher incidences and  the potential oral route of 
administration for chemotherapeutic agents, respectively. On the other hand, as a 
control measure normal lung fibroblast (MRC5) cells and commercial 
chemotherapeutic agent vinblastine were selected as negative and positive controls, 
respectively for comparison purpose.   
 
The distinct characteristics in cancer cells are uncontrolled proliferation. Therefore, 
cell proliferation assay was employed as the first line investigation for cancer drug 
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discovery. For the determination of antiproliferative potency the neutral red uptake 
assay was adopted. The assay is based on the lysosomal capacity of viable cells to 
take up the neutral red dye hence it offers greater sensitivity with less interference 
compared to unstable reagents used in other tests such as 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT). In addition, a recent study demonstrated 
that vitamin E isomers reduced MTT in the absence of cells (Lim et al., 2015).  For 
the combined treatments, a fixed sub-effective (IC20) dose of plant extracts or 
jerantinines (A and B) with a dose range of tocotrienols was adopted to allow 
determination for possible reduction in the potent doses and subsequent synergistic 
effects via combination index and dose reduction index methods. 
The specific objectives of this chapter are: 
i) To determine the antiproliferative potency (IC50) of tocotrienols (delta and 
gamma), jerantinines (A and B) and extracts of leaf and bark of F. hispida, 
F. fistulosa and F. schwarzii on U87MG, A549 and HT-29 cancer cells.  
ii) To determine the required potent doses in combined treatments of the potent 
extracts of Ficus species, jerantinines (A and B) with the low-dose delta 
and gamma tocotrienols. 
iii)  To determine the type of pharmacological interaction (combination index) 
between the combined treatments as well as the fold reduction (dose 
reduction index) in the required potent doses.   
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3.2 Materials and Methods 
3.2.1 Chemical reagent/kits and cell cultureware 
The following reagents and kits listed in Table 3.1 were used to conduct the 
experiments.  
 
Table 3.1: List of chemical reagents, kits and glassware used and the respective 
manufacturers. 
S/no Chemical reagents/kits/lab wares Manufacturer  
1 RPMI 1640, trypsin/EDTA, 0.5%-trypan blue 
stain solution, minimum essential medium 
(MEM) with Earle's salts, L‐Glutamine and 
non‐essential amino acids, phosphate buffer 
saline (D-PBS) (-) without Ca
2+
 and Mg
2+
 
Nacalai Tesque, Japan 
2 Penicillin/streptomycin  GIBCO, USA 
3 Fetal bovine serum JR Scientific, USA 
4 Neutral red dye, dimethyl sulfoxide  (DMSO) Sigma Aldrich, USA 
5 Acetic Acid  Amresco, USA 
6 Ethanol  Merck, USA 
8 28% ammonia solution  Reindmann Schmide, 
Switzerland 
9 Tataric acid, chloroform  Fisher Scientific, USA 
10 Vitamin E isomers  Davos Life Science Ltd 
Pte, Singapore 
11 96-well plates  SPL Life Sciences, Korea 
 
Jerantinines (A and B) were isolated from leaf alkaloid crude extract of 
Tabernaemontana corymbosa as previously described  (Lim et al., 2008) and supplied 
in kind by Prof. Toh-Seok Kam of University of Malaya.  
3.2.2 Plant collection and extraction 
The plants, namely Ficus fistulosa Reinw ex. Blume, Ficus hispida and Ficus 
schwarzii Koord used for anticancer studies were collected from various locations in 
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Malaysia and identified by Dr Yong Kien Thai (Institute of Biological Sciences, 
University of Malaya). The bark and leaves of F. fistulosa, F. hispida, F. schwarzii 
were collected, tagged and assigned specimen vouchers as UNMC 68 (KLU 47988), 
UNMC 77 (KLU 48172) and UNMC87 (KLU 48174), respectively (Table 3.2). The 
tagged plants were subsequently deposited at the herbarium of University of Malaya. 
Table 3.2: Summary on scientific names, specimen, collection and extraction details 
of the collected plant species under this study. 
Plant code Plant name Date of 
collection 
Place of 
collection 
Plant Part 
Used 
Type of 
extract 
used 
UNMC 68  
(KLU 47988) 
Ficus fistulosa 
Reinw ex. 
Blume 
08/06/11 Near Semenyih 
Dam, Selangor 
  
Bark, 
leaves 
Ethanol, 
alkaloid 
crude 
UNMC 77 
(KLU 48172) 
Ficus hispida 24/07/13 Jalan Broga, 
Semenyih, 
Selangor 
Bark, 
leaves 
Ethanol, 
alkaloid 
crude 
UNMC 87 
(KLU 48174) 
Ficus schwarzii 
Koord 
24/07/13 Jalan Gombak, 
Selangor 
Bark, 
leaves  
Ethanol, 
alkaloid 
crude 
The leaves and bark of the plants under investigation were cut into smaller pieces and 
air dried. The crude ethanol extract of the plants was prepared by soaking in distilled 
ethanol for three days with continuous collection until all extracts were collected. The 
crude ethanol extract was subjected to evaporation until dryness using a rotary 
evaporator. To further obtain the alkaloid crude extracts, the ethanol extracts were 
acidified with 3% tartaric acid (in dH20), filtered and basified to pH 10 with 28% 
ammonia solution and chloroform was subsequently added to obtain an aqueous layer 
which was collected using a separating funnel. Distilled water was used to wash three 
times to remove excess ammonia and sodium anhydrase was added to dry up any 
water, and subsequently filtered. Thereafter, the mixtures were evaporated to dryness 
to obtain the alkaloid crude extracts and were stored at -20
o
C until use.  
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3.2.3 Cell lines and culture conditions  
All cell lines were purchased from American Type culture collection (ATCC, USA). 
Human lung adenocarcinoma (A549), normal human lung fibroblast (MRC5) and 
human colorectal adenocarcinoma (HT-29) cells were cultured in RPMI 1640 with L-
glutamine and non-essential amino acids supplemented with 10% (v/v) fetal bovine 
serum (FBS) and 1% penicillin/streptomycin mix solution. Human brain glioblastoma 
(U87MG) cells were cultured in minimum essential medium (MEM) with Earle’s salt, 
sodium pyruvate and supplemented with 1% penicillin/streptomycin mix solution and 
10% FBS. Cells were grown in an incubator (Binder, Germany) with a humidified 
condition of 5% CO2 at 37
o
C. Medium was changed at least 3 times a week and only 
viable cells with at least 95% confluency were seeded for neutral red up take assay for 
single and combined low dose treatments. 
 
3.2.4 Experimental design 
One gram of delta or gamma tocotrienol was dissolved in 40 ml DMSO to give a final 
stock of 25 mg/ml. A working concentration of 1mg/ml was prepared and thereafter 
subsequent dilutions in a range of 0.01 μg/ml to 24 μg/ml were prepared. Similarly, 1 
mg of jerantinines (A and B) or vinblastine (control drug) was dissolved in 40 µl 
DMSO and 960 µl dH2O for a stock concentration of 1 mg/ml. For Ficus species, 10 
mg was dissolved in 1ml DMSO and a working concentration of 1 mg/ml was 
subsequently prepared. For single treatments of plant extracts, a dose range of 0.1 
µg/ml – 120 µg/ml was prepared against cancer cell lines. On the other hand, a dose 
range of 0.1 µg/ml – 300 µg/ml and 0.1 µg/ml – 40 µg/ml for Ficus species and pure 
compounds (jerantinines A and B), respectively were tested against normal MRC5 
cells. 
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For combined treatments, a sub-effective dose (IC20) of jerantinines (A and B) and 
alkaloid crude extracts of leaf and bark F. fistulosa and F. schwarzii was combined 
with a dose range of 0.01 μg/ml to 24 μg/ml for tocotrienols (delta and gamma) to 
screen against normal and cancer cells. The potent concentration that resulted in 50% 
growth inhibition (IC50) was subsequently determined. 
 
3.2.5 Cell viability studies  
For assessment of cell viability and subsequent determination of IC50, the neutral red 
uptake cell viability assay was adopted and all reagents were prepared as previously 
described (Repetto et al., 2008). A total of 5 x 10
3 
cells were seeded in a 96-well plate 
and incubated under cell culture conditions for 24 h to facilitate attachment. 
Thereafter, the cells were placed into different groups (treated and untreated) and the 
medium was replaced with 200 μl treatment medium without FBS for 72 h under cell 
culture conditions (treatment group). Whereas, plain medium containing an equivalent 
amount of DMSO was added to the untreated group (negative control). The neutral 
red medium was prepared 24 h prior to the the assay and incubated in cell culture 
condition. The neutral red medium was centrifuged at 1,800 rpm for 10 min to 
separate un-dissolved crystals prior to use.  The treatment and plain media were 
discarded after 72 h and each well was rinsed with 150 μl PBS after which 100 μl of 
the neutral red medium was added and incubated for 2 h under cell culture conditions.  
Finally, after removal of the neural red medium the plates were washed with 150 μl 
PBS. De-stain solution in a volume of 150 μl was added to extract the absorbed 
neutral red dye and the absorbance was measured at 540nm after shaking for 10 min 
using the Varioskan multiplate reader (Thermo Scientific, USA) 
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3.2.6 Determination of synergism and dose reduction  
For combined treatments, sub effective doses of IC20 of potent plant extracts and pure 
compounds (Jerantinines A and B) were combined with doses of gamma and delta 
tocotrienols and the combined low-dose treatments that induced 50% growth 
inhibition (IC50) were subsequently determined using the GraphPad prism 5 software. 
The combination index (CI) and dose reduction index (DRI) were determined as 
described by Wali and Sylvester, (2007). Combination index (CI) was used to 
quantitatively measure the pharmacological interaction between combined treatments 
of tocotrienols with plant extracts or jerantinine (A and B). A CI value <1 indicates 
synergistic effect whereas values >1 or =1 represent antagonistic or additive 
pharmacological interaction, respectively between combined treatments. The 
combination index (CI) was quantified using the following formula: 
CI = (Xc/X + Tc/T) 
X represents the concentrations of plant extracts or jerantinines (A and B), whereas, T 
represents the concentration of delta or gamma tocotrienol that inhibited 50% cell 
growth. Similarly, Xc represents the IC20 doses of plant extracts or jerantinines (A and 
B), whilst, Tc represents the low doses of delta or gamma tocotrienol that induced 
50% growth inhibition following combined treatments. Dose reduction Index (DRI) is 
a representation of fold decrease of combined treatments that resulted in 50% growth 
inhibition. It was calculated as DRI= (X/Xc or T/Tc) for plant extracts or jerantinines 
(A and B) and tocotrienols, respectively. 
 
3.2.7 Statistical analysis 
The IC50 for the tested compounds was determined by the non-linear regression curve 
fit using the GraphPad prism 5 software (GraphPad software Inc, USA). Each sample 
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was done in triplicates at three independent experiments and results were expressed as 
Mean ± SEM. One way ANOVA using the Dunnet T-test was used to compare the 
treated and untreated groups. P values <0.001 (***), P <0.01 (**) and P <0.5 (*) were 
considered statistically significant. 
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3.3. Results  
 
3.3.1 Observation of dose dependent growth inhibition on cancer cells by single 
treatments  
Results from acid-base extraction showed that Ficus hispida (leaf) had the highest 
crude alkaloid content compared to F. fistulosa and F. schwarzii (Table 3.3). 
Alkaloids were found with tending to accumulate more in leaves compared to bark 
although the bark of F. fistulosa had higher crude alkaloid content than the leaves.  
Following extraction, A549, U87MG, HT-29 and MRC5 cells were subjected to 72 h 
treatment with ethanol and alkaloid crude extracts of leaves and bark from F. hispida, 
F. fistuosa and F. schwarzii, the antiproliferative potencies and respective IC50 values 
were evaluated and are summarized in Table 3.4.  Of all the plant extracts, only 4 
extracts, 5 extracts, and 1 extract had potent antiproliferative effects with IC50 values 
below 20 µg/ml (bolded in Table 3.4) on U87MG, HT-29 and A549 cells, 
respectively. The strongest antiproliferative activity observed was for the alkaloid 
crude extracts of F. fistulosa leaf and bark (IC50= 0.96 - 2.10 µg/ml) on HT-29 and 
U87MG cells (Table 3.4). Ethanol and alkaloid extracts of leaves from F. hispida 
(FHL ET and FHL ALK) inhibited proliferation of U87MG cells whereas only 
alkaloid extracts of the bark (FHB ALK) was toxic to HT-29 cells although a similar 
effect was observed on non-cancerous MRC5 cells (Table 3.4) (For histogram, see 
appendix 1a,b). Ethanol extracts of F. schwarzii bark (FSB ET) had growth inhibitory 
effects against A549 with IC50 < 30 µg/ml. Similar growth inhibitory effects were 
evident on HT29 cells treated with alkaloid extracts from bark and leaves of F. 
schwarzii (FSB ALK and FSL ALK) with IC50 values below 20 µg/ml. The 
antiproliferative potency of the plant extracts are ranked in a descending order as 
Ficus fistulosa > Ficus schwarzii > Ficus hispida.  
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Table 3.3: Yield of crude alkaloid extracts of Ficus spp. 
s/no Plant species Plant part Yield of alkaloid extract 
(g/kg) 
1 Ficus fistulosa (FF) Leaf (L) 0.28 
  Bark (B) 0.37 
2 Ficus hispida (FH) Leaf (L) 0.56 
  Bark (B) 022 
3 Ficus schwarzii (FS) Leaf (L) 0.22 
  Bark (B) 0.07 
 
 
 
Table 3.4: Antiproliferative effects (IC50) of plant extracts of Ficus species tested on 
U87MG, A549, HT-29 and MRC5 cells (Mean ± SEM). 
s/no Plant Part 
of 
plant 
Type 
of 
extract 
U87MG 
(μg/ml) 
A549 
(μg/ml) 
HT-29 
(μg/ml) 
MRC 5 
(μg/ml) 
1 FF B ET 21.62±1.15 49.61±1.18 32.08±1.19 30.95±1.12 
   ALK 2.10±1.34 44.35±1.18 2.00±1.23 18.90±1.36 
2 FF L ET 66.02±1.21 46.95±1.08 27.73±1.11 29.32±1.14 
   ALK 0.96±1.12 46.81±1.25 1.92±1.30 12.47±2.79 
3 FH B ET 88.01±1.14 61.41±1.07 57.09±1.18 72.20±1.14 
   ALK 31.24±1.26 52.98±1.08 15.14±1.21 19.94±1.16 
4 FH L ET 11.98±2.28 40.82±1.22 43.90±1.21 18.39±1.31 
   ALK 17.49±1.25 49.58±1.12 20.71±1.31 11.27±1.78 
5 FS B ET 84.38±1.17 19.21±1.16 >120±1.24 61.60±1.17 
   ALK 107.90±1.16 44.83±1.13 14.49±1.20 >120±1.14 
6 FS L ET 35.31 ± 1.31 73.71±1.09 29.00±1.19 >120±2.29 
   ALK 29.39 ± 1.25 >120±1.15 8.79±1.20 63.54±1.23 
ET = ethanol extract, ALK = alkaloid crude extract, FF = Ficus fistulosa, FH = Ficus hispida, FS = 
Ficus scharzii, B = bark, L= leaf. Potent extracts with IC50 < 20 µg/ml are bolded. 
 
In addition to the crude extracts, vitamin E isomers (delta and gamma tocotrienols) 
and jerantinines (A and B) were screened for antiproliferative activity. Following 72 h 
treatment, a dose dependent growth inhibition was evident and the IC50 values of 
jerantinines A and B against U87MG, HT-29 and A549 cells tested were below the 4 
μg/ml (Fig. 3.1 c d, 3.2 c d, 3.3 c, d). However, similar toxicity of jerantinines (A and 
B) was evidenced on non-cancerous MRC5 cells too (Table 3.5). In contrast, although 
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tocotrienols demonstrated dose dependent growth inhibition (Fig. 3.1 a b, 3.2 a b, 3.3 
a b), only gamma and delta tocotrienols had IC50  < 4 μg/ml against U87MG cells 
compared to the higher IC50 values of gamma and delta tocotrienols against A549 and 
HT-29 cells (Table 3.5). Furthermore, delta and gamma tocotrienols demonstrated 
good selectivity window in exhibiting lower toxicity towards normal lung fibroblast 
cells (MRC5) compared to U87MG and HT-29 cells. However, delta and gamma 
tocotrienols induced similar toxic effects on A549 and MRC5 cells demonstrating 
poor selectivity window.  Control drug vinblastine demonstrated the highest toxicity 
towards both normal and cancer cells. In term of antiproliferative potency based on 
this study delta tocotrienol was better than gamma tocotrienol.      
Table 3.5: Antiproliferative effects (IC50) of delta and gamma tocotrienols, jerantinine 
(A and B) and vinblastine (Mean ± SEM) on U87MG, A549, HT-29 and MRC5 cells. 
s/no Compound U87MG 
 
A549 
 
HT-29 
 
MRC 5 
 
  IC50 (μg/ml) 
(Mean ± SEM ) 
1 Delta Tocotrienol 
(δ-T3) 
3.12 ± 1.26 12.40 ± 1.09 5.71 ±1.23 15.71 ± 1.19 
2 Gamma 
Tocotrienol 
(γ-T3) 
3.17 ± 1.29 16.36 ± 1.07 6.14 ± 1.15 14.20 ± 0.08 
3 Jerantinine A 
(JA) 
0.62 ± 1.19 1.42 ± 1.31 1.74 ± 1.24 0.97 ± 0.11 
4 Jerantinine B 
(JB) 
0.74 ± 0.04 1.48 ± 1.14 0.58 ± 0.18 2.83 ± 0.38 
5 Vinblastine 0.04 ± 0.14 0.03 ± 0.16 0.71 ± 0.12 0.26 ± 0.47 
IC50 values of tocotrienols (delta and gamma), Jerantinines (A and B) and vinblastine below 4 µg/ml on 
cancer cells are bolded. 
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Fig 3.1: Antiproliferative profiles of selected individual treatments with potent dose < 20 
µg/ml on U87MG brain cancer cells. a) Delta tocotrienol, b) gamma tocotrienol, c) jerantinine 
A, d) jerantinine B, e) F. fistulosa Leaf (ALK) and f) F. fistulosa Bark (ALK). U87MG cells 
were exposed to treatments for 72 h and the cell viability was determined using the neutral 
red uptake assay as described in methods. Results are expressed in Mean ± SEM. N=9 
*P<0.001. 
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Fig 3.2:  Antiproliferative profiles of selected individual treatments with potent dose < 20 
µg/ml on A549 lung cancer cells a) Delta tocotrienol, b) gamma tocotrienol, c) jerantinine A, 
d) jerantinine B, e) F. schwarzii bark (ET). A549 cells were exposed to treatments for 72 h 
and the cell viability was determined using the neutral red uptake assay as described in 
methods. Results are expressed in Mean ± SEM. N=9 *P<0.001. 
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Fig 3.3: Antiproliferative profiles of selected individual treatments with potent dose < 20 
µg/ml on HT-29 colon cancer cells.  a) Delta tocotrienols, b) gamma tocotrienols, c) 
jerantinine A, d) jerantinine B,  e) F. fistulosa leaf (ALK),  f) F. fistulosa bark (ALK),  g) F. 
schwarzii leaf (ALK), h) F. schwarzii bark (ALK). HT-29 cells were exposed to treatments 
for 72 h and the cell viability was determined using the neutral red uptake assay as described 
in methods. Results are expressed in Mean ± SEM. N=9 *P<0.001. 
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3.3.2 Induction of synergistic growth inhibition on cancer cells by combined 
treatments   
Guided by antiproliferative results, the sub-effective dose (IC20) of potent Ficus 
extracts and jerantinines A and B (1C50 < 20 μg/ml and < 4 μg/ml, respectively) were 
combined with a dose range of delta and gamma tocotrienols. This was aimed at 
improving the potency and efficacy of gamma and delta tocotrienols and on the other 
hand minimizes the toxicity to normal cells. The combined treatments of delta and 
gamma tocotrienols with alkaloid crude extracts of F. fistulosa leaf (FFL ALK) and 
bark (FFB ALK) induced strong synergistic antiproliferative effect on U87MG cells 
(CI = 0.28 - 0.29) (Fig. 3.4 c, g and  3.5 c, g). The combinatory approach caused up to 
4-fold and 34.7-fold reduction in required potent doses for extracts and tocotrienols, 
respectively thereby minimizing toxicity to MRC5 cells (Table 3.6) (appendix 1b). 
Furthermore, a moderate synergistic antiproliferative effect was evident for combined 
treatment of delta or gamma tocotrienol with alkaloid extracts of leaf (FFL ALK) and 
bark (FFB ALK) of F. fistulosa against HT-29 cells (Table 3.8). However, a poor 
selectivity window with toxicity imposed towards MRC5 cells was also evident.  In 
contrast, a weak synergistic effect and antagonistic effect were observed when 
alkaloid crude extracts of bark (FSB ALK) and leaf (FSL ALK) of F. schwarzii were 
combined with gamma tocotrienol against HT-29 cells, respectively (Fig. 3.8 k, i and  
3.9 k, i). Similarly, as shown in Table 3.8 and isobologram (Fig. 3.9 e, f), the 
combined treatment delta tocotrienol with alkaloid crude extracts from leaf (FSL 
ALK) and bark (FSB ALK) of F. schwarzii induced an antagonistic effect on HT-29 
cells. 
Isobologram analysis revealed that the combined treatment of delta tocotrienol with 
IC20 dose of jerantinine A induced an antagonistic effect on U87MG cells (Fig 3.5). In 
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contrast, a dose dependent synergistic antiproliferative effect was evident on U87MG 
cells receiving combined treatment of delta tocotrienol with IC20 dose of jerantinine B 
and the combined treatment of gamma tocotrienol with IC20 dose of jerantinines A 
and B (Fig 3.4, 3.5). This caused up to 2.5-fold and 4-fold reductions in potent doses 
of tocotrienols (delta and gamma) and jerantinines (A and B), respectively (Table 
3.6). On the other hand, the combination of jerantinine A or B with delta or gamma 
tocotrienol induced synergistic antiproliferative effect against A549 cells that resulted 
to almost 5-fold decrease in tocotrienol doses (Fig. 3.6, 3.7). However, a poor 
selectivity window between A549 and MRC5 cells was also evident in addition to 
combined IC50 values above 4 µg/ml (Table 3.7). Nonetheless, on a more positive 
note combined treatment of Jerantinine A with delta tocotrienol against A549 cells 
demonstrated an improved selectivity window compared to single delta tocotrienol 
dose with IC50 below 4 µg/ml (Table 3.7). Similarly, as shown in Table 3.8, the 
combined treatments of low-dose tocotrienols (delta and gamma) with jerantinines (A 
and B) induced dose dependent synergistic antiproliferative effect on HT-29 cells 
(Fig. 3.8, 3.9). This caused up to 2.7- fold and 4-fold reductions for jerantinines (A 
and B) and tocotrienols (delta and gamma), respectively (Table 3.8). 
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Table 3.6 Combinational index (CI) and dose reduction index (DRI) values for 
combined treatments of tocotrienols (delta and gamma) with F. fistulosa extracts and 
jerantinines (A and B) on U87MG and MRC5 cells. 
s/no Treatments  Combined Low-Dose 
Treatments 
(µg/ml) 
Combination 
Index (CI) 
 
Dose Reduction 
Index (DRI) 
 
Low-Dose  
Tocotrienol 
on MRC5 
Cells 
 U87MG  
  Low-dose 
T3 
 
IC20 Dose 
of J/Ficus 
extract 
 T3 J/Ficus 
extract 
 
 δ-T3 
1 JA 2.52±1.19 0.16±0.29 1.10 1.24 3.88 13.71±1.12 
2 JB 1.83±1.11 0.19±0.27 0.85 1.70 3.89 6.77±1.67 
3 FFL ALK 0.11±0.22 0.24±0.28 0.29 28.36 4.00 2.23±1.44 
4 FFB ALK 0.09±0.24 0.53±0.34 0.28 34.67 3.96 4.68±1.17 
 γ-T3 
5 JA 1.29±1.26 0.16±0.29 0.67 2.46 3.88 6.55±1.13 
6 JB 1.61±1.38 0.19±0.27 0.77 1.99 3.89 7.70±1.13 
7 FFL ALK 0.11±0.19 0.24±0.28 0.29 28.82 4.00 1.44±1.48 
8 FFB ALK 0.12±0.20 0.53±0.34 0.29 26.42 3.96 3.07±1.12 
J = Jerantinine, JA = Jerantinine A, JB = Jerantinine B, δ-T3 = delta tocotrienol, γ-T3 = gamma 
tocotrienol, T3 = Tocotrienol, FFL = Ficus fistulosa leaf, FFB = Ficus fistulosa bark, ALK = alkaloid 
extract.CI values show < 1 (synergism), > 1 (antagonism) and = 1 (additive) pharmacological 
interactions between combined treatments. Whereas, DRI represents the fold decrease in potent dose 
required to induce 50% growth inhibition following the combined treatments.  
 
 
 
Table 3.7 Combinational index (CI) and dose reduction index (DRI) values for 
combined treatments of tocotrienols (delta and gamma) with jerantinines (A and B) on 
A549 and MRC5 cells. 
s/no Treatments  Combined Low-Dose 
Treatments 
(µg/ml) 
Combination 
Index (CI) 
 
Dose Reduction 
Index (DRI) 
 
Low-Dose  
Tocotrienol 
on MRC5 
Cells 
 A549  
  Low-dose T3 
 
IC20 Dose of 
J/Ficus 
extract 
 T3 J  
 δ-T3 
1 JA 2.77±1.09 0.35±0.32 0.47 4.48 4.06 5.57±1.22 
2 JB 3.89±1.11 0.37±0.29 0.56 3.19 4.00 4.14±1.19 
 γ-T3 
5 JA 4.95±1.07 0.35±0.32 0.55 3.31 4.06 5.90±1.11 
6 JB 5.27±1.13 0.37±0.29 0.57 3.10 4.00 5.80±1.18 
J = Jerantinine, JA = Jerantinine A, JB = Jerantinine B, δ-T3 = delta tocotrienol, γ-T3 = gamma 
tocotrienol, T3 = Tocotrienol. CI values show < 1 (synergism), > 1 (antagonism) and = 1 (additive) 
pharmacological interactions between combined treatments. Whereas, DRI represents the fold decrease 
in potent dose required to induce 50% growth inhibition following the combined treatments.  
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Table 3.8 Combinational index (CI) and dose reduction index (DRI) values for 
combined treatments of tocotrienols (delta and gamma) with F. fistulosa, F. schwarzii 
extracts and jerantinines (A and B) on HT-29 and MRC5 cells.  
s/no Treatments  Combined Low-Dose 
Treatments 
(µg/ml) 
Combination 
Index (CI) 
 
Dose Reduction 
Index (DRI) 
 
Low-Dose  
Tocotrienol 
on MRC5 
cells 
 HT-29  
  Low-dose T3 
 
IC20 Dose of 
J/Ficus 
extract 
 T3 J/Ficus 
extract 
 
 δ-T3 
1 JA 2.12±1.49 0.44±0.28 0.62 2.69 3.95 4.68±1.29 
2 JB 2.99±1.18 0.15±0.05 0.77 1.91 3.87 9.99±1.53 
3 FFL ALK 2.10±0.16 0.50±0.33 0.63 2.72 3.84 0.92±0.22 
4 FFB ALK 2.62±0.12 0.50±0.31 0.71 2.17 4.00 4.40±1.41 
5 FSL ALK 5.43±1.29 2.20±0.31 1.20 1.05 4.00 4.32±1.17 
6 FSB ALK 4.42±1.26 3.60±0.30 1.02 1.29 4.02 5.66±1.14 
 γ-T3 
7 JA 3.70±1.59 0.44±0.28 0.60 1.66 3.95 4.50±1.15 
8 JB 4.37±1.66 0.15±0.05 0.96 1.41 3.87 8.50±1.15 
9 FFL ALK 2.45±0.18 0.50±0.33 0.66 2.51 3.84 0.72±0.26 
10 FFB ALK 2.67±0.19 0.50±0.31 0.68 2.30 4.00 4.82±1.32 
11 FSL ALK 8.29±1.20 2.20±0.31 1.60 - 4.00 4.67±1.26 
12 FSB ALK 4.48±1.31 3.60±0.30 0.98 1.37 4.02 4.31±1.28 
J = Jerantinine, JA = Jerantinine A, JB = Jerantinine B, δ-T3 = delta tocotrienol, γ-T3 = gamma 
tocotrienol, T3 = Tocotrienol, FFL = Ficus fistulosa leaf, FFB = Ficus fistulosa bark, FSL = Ficus 
schwarzii leaf, FSB = Ficus schwarzii bark, ALK = alkaloid extract. CI values show < 1 (synergism), > 
1 (antagonism) and = 1 (additive) pharmacological interactions between combined treatments. 
Whereas, DRI represents the fold decrease in potent dose required to induce 50% growth inhibition 
following the combined treatments.  
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Fig 3.4:  Antiproliferative profiles of combined low-dose treatments of tocotrienols (delta and 
gamma) with IC20 doses of F. fistulosa extracts and jerantinines A and B on U87MG cells.  
U87MG cells were exposed to treatments for 72 h and the cell viability was determined using 
the neutral red uptake assay as described in methods. Results are presented as Mean ± SEM. 
N=9 *P<0.001. NB: JA= jerantinine A, JB= jerantinine B, FF (B), (L) = F. fistulosa (bark), 
(Leaf), ALK= alkaloid crude extract. 
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Fig 3.5:  Isobologram profiles of U87MG cells receiving combined low-dose of tocotrienols 
(delta and gamma) with IC20 doses of jerantinines (A and B) or alkaloid extracts form leaves 
and bark of F. fistulosa. Data point below, above and on top of the diagonal line indicated 
synergism, antagonism and additive pharmacological interactions between combined 
treatments, respectively. All combined treatments except for combined treatment of low-dose 
delta tocotrienol with IC20 dose of jerantinine A induced synergistic effect on U87MG cells. 
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Fig 3.6: Antiproliferative profiles of combined low-dose treatments of tocotrienols (delta and 
gamma) with IC20 doses of jerantinines (A and B) on A549 cells.  A549 cells were exposed to 
treatments for 72 h and the cell viability was determined using the neutral red uptake assay as 
described in methods. Results are presented as Mean ± SEM. N=9 *P<0.001. NB: JA= 
jerantinine A, JB= jerantinine B. Individual and combined low-dose treatments induced dose 
dependent growth inhibition. 
 
 
 
 
 
86 
 
 
Fig 3.7: Isobologram profiles of A549 cells receiving combined low-dose of tocotrienols 
(delta and gamma) with IC20 doses of jerantinines (A and B). Data point below, above and on 
top of the diagonal line indicate synergism, antagonism and additive pharmacological 
interactions between combined treatments, respectively. Combined treatment of low-dose 
tocotrienol (delta and gamma) with IC20 dose of jerantinines A and B induced synergistic 
effect on A549 cells. 
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Fig 3.8: Antiproliferative profiles of combined low-dose treatments of tocotrienols (delta and 
gamma) with IC20 doses of F. fistulosa, F. schwarzii and jerantinines (A and B) on HT-29 
cells. HT-29 cells were exposed to treatments for 72 h and the cell viability was determined 
using the neutral red uptake assay as described in methods. Results are presented as Mean ± 
SEM. N=9 *P<0.001. NB: JA= jerantinine A, JB= jerantinine B, FF (B), (L) = F. fistulosa 
(bark), (Leaf), FSB (B), (L) = F. schwarzii (bark), (leaf), ALK= alkaloid crude extracts. Both 
individual IC50 doses of tocotrienols (delta and gamma tocotrienols) and combined treatment 
of low-dose tocotrienols (delta and gamma) with IC20 dose of jerantinines (A and B) and 
extracts of F. fistulosa and F. schwarzii induced dose dependent growth inhibition. 
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Fig 3.9:  Isobologram profiles of HT-29 cells receiving combined low-dose of tocotrienols 
(delta and gamma) with IC20 doses of jerantinines (A and B) or alkaloid extracts form leaves 
and bark of F. fistulosa and F. schwarzii. Data point below, above and on top of the diagonal 
line indicated synergism, antagonism and additive pharmacological interaction between 
combined treatments, respectively. Combined treatment of tocotrienols with IC20 dose of 
jerantinines induced synergistic effect. Combined treatment of low-dose tocotrienol (delta and 
gamma) with IC20 dose of F.schwarzii leaf induced antagonistic effect on HT-29 cells.
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3.4 Discussion  
The flora across Asia and specifically Malaysia is hugely endowed with plants possessing 
potential bioactivities. The Moreacea plant family constitutes decent proportion and in 
fact over 40 different species are found in Malaysia. Thus, in search for new plant 
alkaloids with antiproliferative activity, three different Ficus species collected from 
various locations in Malaysia were selected based on published literatures that indicated 
the presence of bioactive compounds amongst Ficus species. Indeed, previous 
pharmacological study on constituents of chloroform extracts of a mixture of twigs and 
leaves of F. hispida collected from Chiang Rai in Thailand showed a cytotoxic activity 
against human Lu1 lung cancer (IC50 = 0.5 μg/ml) and Col2 colon cancer (IC50 = 0.1 
μgml) (Peraza-Sánchez et al., 2002). In contrast,  results obtained in this study showed 
that alkaloid extract of Ficus hispida leaves did not induce potent growth inhibition on 
A549 lung cancer cells with IC50 > 40 μg/ml although improved antiproliferative activity 
was observed on U87MG brain cancer cells and HT-29 colon cancer cells (IC50 > 20 
µg/ml). The combination of twigs and leaves as reported in the previous study may have 
resulted in synergistic effect of constituents of the chloroform extracts compared to that 
of leaves only in the present study. Hence, this probably accounted for the observed 
difference on the level of cytotoxicity to different types of lung cancer cells.  
 
In addition, F. fistulosa demonstrated a potent antiproliferative effect on U87MG and 
HT-29 cells with IC50 < 20 µg/ml and causing mild toxicity towards non-cancerous 
MRC5 cells thus conforming to the potency standard for crude extracts as established by 
the national cancer institute (NCI) (Suffness and Pezzuto, 1990). However, this is 
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contrary to previous studies that demonstrated non cytotoxic potency of crude and 
purified alkaloids of F. fistulosa species from Vietnam and Singapore (Zhang et al., 2002; 
Subramaniam et al., 2009). Location of plant as well as time of collection may affect the 
availability of metabolites as these secondary metabolites are produced by plants in 
response to environmental conditions such as stress, competition for space and protection 
etc. (Rocha et al., 2001). This accounts for the different potencies exhibited by Ficus 
species investigated in the present study which could be ranked in descending order as F. 
fistulosa > F. schwarzii > F. hispida. Furthermore, the greater potency demonstrated by 
the crude alkaloid extracts compared to ethanol extracts especially with F. fistulosa and 
F. schwarzii indicates that such antiproliferative effects are due to alkaloids present in the 
crude mixture rather than other phytochemicals contained in the ethanol extracts. In 
addition, the observed antiproliferative effects of F. schwarzii on A549 and HT-29 cells 
which to date there are no reported studies on its bioactivity provides new information for 
potential future uses as source of new cytotoxic alkaloids. 
 
Similarly, treatment of cells with jerantinine A and B demonstrated dose-dependent 
antiproliferative effects against A549, HT-29, and U87MG cells in agreement with 
previously published study on the potency of jerantinine derivatives (Frei et al., 2013). 
However, toxicity to normal cells was evident which is in agreement to previously 
published study on jerantinines (Qazzaz et al., 2016; Raja et al., 2014). On the other 
hand, a dose dependent growth inhibition was evident on U87MG, A549 and HT-29 cells 
treated with tocotrienols. In fact, preferential toxicity towards cancer cells was only 
evident on U87MG and HT-29 cells receiving delta and gamma tocotrienols. Based on 
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this study, the potency of delta tocotrienol is higher than that of gamma corroborating to 
previous studies (Bardhan et al., 2011). Furthermore the study provides additional 
information on the antiproliferative potency of tocotrienols especially delta isomer on 
brain and lung cancers which were scarcely reported compared to gamma tocotrienol 
(Lim et al., 2014a, 2014b; Yano et al., 2005).  
 
Undoubtedly, tocotrienols possess remarkable anticancer properties as demonstrated by 
previous studies (Aggarwal and Nesaretnam, 2012; Wada, 2012). However, metabolic 
degradation resulting from high dose delivery and subsequent over load of transport 
protein for tocotrienol has continuously limited the level of therapeutic doses. Thus far, 
studies and reviews have suggested synergism that would minimize dosage, toxicity and 
improve potency in addition to nano-deliveries as a potential alternative (Constantinou et 
al., 2008; Sylvester et al., 2010). Indeed studies have been conducted demonstrating the 
synergistic potency of tocotrienols (Akl et al., 2012; Tuerdi et al., 2013), however in 
some instances, the potential toxicity of such combinations to non-cancerous cells were 
not determined (Wali and Sylvester, 2007). Similarly, a study by Hafid et al., (2010) 
showed that tocotrienols are also good adjuvants for development of cancer vaccines.  
 
Herein, the combined studies demonstrated the synergistic potency of delta and gamma 
tocotrienols. Interestingly, combined treatments with alkaloids extracts of bark and leaf 
of Ficus fistulosa demonstrated the strongest synergistic effects against U87MG cells 
with reduction of up to 35 and 29 folds for delta and gamma tocotrienols, respectively 
(Table 3.6). Such remarkable reduction clearly resulted in the nontoxic effects evidenced 
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on non-cancerous MRC5 cells in comparison to U87MG cancer cells. However, though 
synergistic effects were also evident against HT-29 cells, there was poor selectivity 
window between cancerous and non-cancerous cells treated with combined doses of F. 
fistulosa and delta or gamma tocotrienol. This indicated that the observed synergistic 
effect preceded by mild toxicity to normal cells was cell specific.  Besides, this might 
also be attributed by the combined synergistic effects of several alkaloids present in the 
crude alkaloid extracts. In contrast, combined treatments with F. schwarzii caused an 
additive or antagonistic effect against HT-29 cells with toxic effects to normal cancer 
cells. Nevertheless, this demonstrates the antiproliferative and synergistic potencies of 
alkaloid extracts from Ficus species which may vary depending on species as 
demonstrated by previous studies. For instance, a combined treatment of hexane 
insoluble fraction of Ficus septica with doxorubicin increased the incidence of apoptosis 
and also caused a shift from G2/M to G1 phase cell cycle arrest. Although the study 
demonstrated the potential application of F. septica as adjunct treatment however, the 
potential toxicity of such high dose combinations to non-cancerous cells as well as the 
type of pharmacological interaction between F. septica and doxorubucin was not reported 
(Nugroho et al., 2013). In contrast a synergistic pharmacological interaction was reported 
for combined sub-effective doses of doxorubicin and ethyl acetate extract of F. septica 
against T47D human breast cancer cells (Nugroho et al., 2012). However, unlike the 
present study, the potential toxicity of such combinations to non-cancerous cells was also 
not investigated.  
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Recent studies have demonstrated that the cytotoxic potency of Jerantinine derivatives is 
mediated via inhibition of microtubules (Frei et al., 2013; Raja et al., 2014). Microtubule 
inhibiting drugs such as the vinca alkaloids are currently under clinical use as anticancer 
chemotherapeutic agents. However, susceptibility to p-glyprotein multidrug resistance 
and toxicity to the peripheral nervous system has limited the potency of these classes of 
drugs. This has prompted the development of more efficient synthetic analogues (Canta 
et al., 2009). Indeed, control drug vinblastine in the present study exhibited the highest 
toxicity to non-cancerous MRC5 cells compared to jerantinines A and B which conforms 
to the aforementioned suggestion on the undesirable toxicity of tubulin inhibiting drugs. 
The potential of combination of two drugs as hybrid drugs with at least one a tubulin 
inhibiting drug has been suggested as an alternative to enhancing activity and improving 
clinical outcome of tubulin targeting drugs (Breen and Walsh, 2010). In the present study, 
the combined low dose treatment of delta or gamma tocotrienol with IC20 dose jerantinine 
showed up to 5-fold selective toxicity towards U87MG cells compared to MRC5 cells 
(Table 3.6). Similarly, up to 2-fold selectivity was also evident for combined treatments 
except for gamma tocotrienol with jerantinine A towards HT-29 cells compared to MRC5 
cells. In contrast, only combined treatments of delta tocotrienol with jerantinine A 
showed at least 2-fold selective toxicity towards A549 cells compared to MRC5 cells 
(Table 3.7). This demonstrates the synergistic potency of jerantinines A and B in 
combination with delta or gamma tocotrienol did occur and more importantly toxicity 
towards non-cancerous MRC5 cells had been minimized. The induction of such 
antiproliferative effects by tocotrienol and jerantinines (A and B) is potentiated via 
different mechanisms further justifies the present study. Certainly, these potentially 
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varied mechanisms would provide an alternative for more potent multi-targeted cancer 
killing and probably account for the observed potent effects herein at low dosage of 
tocotrienol and jerantinines (A and B).   
 
3.5. Conclusion  
The study demonstrated the antiprofilrative potencies of Ficus species on A549, HT-29 
and U87MG cancer cells which can  be ranked in a descending order as Ficus fistulosa > 
Ficus schwarzii > Ficus hispida in terms of superior potency. Similarly, tocotrienols 
(delta and gamma) and jerantinines (A and B) induced dose dependent growth inhibition 
on A549, HT-29 and U87MG cells although similar toxicity was evidenced for 
jerantinines (A and B) towards MRC5 cells.  The combined low-dose treatments of 
tocotrienols with jerantinines (A and B) or alkaloid extracts of F. fistulosa caused 
reduction in required potent dosage and subsequently minimizing toxicity to non-
cancerous cells. Combination treatments have been reported as alternatives to circumvent 
limitation of high dose tocotrienols and minimize the undesirable toxicity of tubulin 
targeting drugs. Thus, it is interesting to further investigate and elucidate the mechanism 
mediating the antiproliferative effects of combined low-dose treatment of tocotrienols 
with jerantinines (A and B) or alkaloid extracts of F. fistulosa. 
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4.0 CHAPTER FOUR 
Induction of DNA damage and manifestation of morphological features of apoptosis 
by individual and combined treatments of tocotrienols (delta and gamma) and 
jerantinines (A and B) 
 
4.1 Introduction 
Cell viability study from Chapter Three confirmed the antiprofilerative potency of 
individual and combined low-dose treatments of tocotrienols (delta and gamma), 
jerantinines (A and B) and alkaloid crude extracts of leaves and bark of F. fistulosa and 
F. schwarzii thus necessitating further investigations on programmed cell death (PCD) or 
apoptosis. Apoptosis is one of the many models of programmed cell death in addition to 
other proposed alternative models such as autophagy, paraptosis and mitotic catastrophe. 
Apoptosis is a key regulator of physiologic growth and homeostasis and hence cell death 
by apoptosis has been recognised as crucial to antitumor growth which determines the 
response to chemotherapeutic agents (Fulda and Debatin, 2006b). Morphologically, 
apoptosis is characterised by features including nuclear chromatin condensation and 
fragmentation, shrinkage and disassembly into apoptotic bodies that are eventually 
phargocytosed. In addition to morphological features, apoptosis is also characterised by 
biochemical hallmarks that include internucleosomal DNA fragmentation and caspase 
enzymes activity. This is contrary to undesirable necrotic cell death characterised by 
swelling of organelles and early plasma membrane rupture thereby inducing 
inflammatory response (Saraste and Pulkki, 2000). Therefore it is imperative to 
determine the type of cell death induced by individual and combined low-dose 
treatments.  
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For evaluation of possible changes in cell morphology, histochemical (haematoxylin and 
eosin) and fluorescence (acridine orange and propidium iodide) staining techniques were 
adopted. Haematoxylin and eosin (H&E) stains would allow for extensive evaluation of 
morphological features of apoptotic cell death to distinguish from necrosis. Cells 
undergoing apoptosis upon H&E staining appear as single or cluster of cells with dark 
eosinphillic cytoplasm, dense nuclear chromatin fragments, extensive membrane 
blebbing and apoptotic body formation. Similarly, acridine and propidium (AO/PI) 
staining was adopted to further corroborate the data from H&E and potentially determine 
the different stages of apoptosis. Cells stained green indicate early stage of apoptosis 
whereas cells stained yellow or orange indicate late stage of apoptosis. Cells undergoing 
early stage apoptosis are AO positive and stain green. Whereas, cells at the late stage of 
apoptosis are permeable to both AO and PI and therefore appear as yellow or orange 
stained cells. 
 
On the other hand, oxidative DNA damage is a biochemical hallmark of apoptosis that 
results from degradation of DNA at internucleosomal regions by DNases characterised by 
double stranded DNA fragments of 180 – 200 base pairs (Saraste and Pulkki, 2000). 
Therefore, the single gel electrophoresis assay (COMET) was adopted for investigation 
on DNA damage pattern as an additional diagnostic tool for apoptosis. The COMET 
assay is based on the ability of negatively charged DNA fragments in single cells to 
migrate through low melting agarose in response to and electric field (Kumaravel et al., 
2009). Alkali COMET assays detects single stranded breaks whereas, COMET assay 
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done under neural conditions allows for detection of double stranded breaks independent 
of single stranded breaks (Olive and Banáth, 2006). This technique was chosen because 
unlike the DNA laddering technique that detects only DNA fragments, the COMET assay 
is able to obtain more details and allows for the detection of both single and double 
stranded DNA breaks. The comparison on the changes in cell morphology and DNA 
damage pattern induced by vinblastine (positive control) and treatments (individual and 
combined low-dose) would allow the possibility to predict a hypothetical clue of 
apoptotic mechanism in U87MG, A549 and HT-29 cells. This study signified the 
absolute determination of potential apoptosis in comparison to uncontrolled necrosis 
based on morphological and DNA damage assessments.  
 
Guided by data gathered from cell viability studies in Chapter Three, the following 
treatments listed in Table 4.2 were selected for further assessment of morphological 
features of apoptosis and DNA damage patterns. For single treatments studies only 
purified alkaloids, jerantinines A and B and tocotrienol isomers (delta and gamma) were 
selected for further mechanistic studies. Although alkaloid crude extracts of Ficus 
fistulosa demonstrated strong synergistic antiproliferative effects however such effects 
could be as a result of multiple bioactive compounds present in the crude extracts. 
Furthermore, unlike pure compounds, crude extracts can trigger both single stranded and 
double stranded DNA breaks as demonstrated by previous studies on extracts of 
Acalypha wilkesiana (Lim et al., 2013, 2011). Hence, this would not allow for an 
absolute determination of the type of cell death induced by alkaloid crude extract of Ficus 
fistulosa based on morphology and DNA assessments. On the other hand, combined low-
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dose of jerantinines (A and B) and tocotrienols (delta and gamma) that induced 
synergistic effects with IC50 values below 4 µg/ml and demonstrated at least 2-fold 
selective toxicity towards cancer cells compared to normal cells were also selected for 
further mechanistic studies.  
The specific objectives of this chapter are: 
i) To assess changes in cell morphology for features indicative of apoptotic cell 
death on U87MG, A549 and HT-29 cells induced by individual and combined 
low-dose treatments.  
ii) To determine the pattern of DNA damage induced by individual and combined 
low-dose treatments. 
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4.2 Materials and Methods 
4.2.1 Chemical reagent/kits and cell cultureware 
The following reagents and kits listed in Table 4.1 were used to conduct the experiments.  
 
Table 4.1: List of chemical reagents, kits and glassware used and the respective 
manufacturers. 
S/no Chemical reagents/kits/lab wares Manufacturer  
1 Haematoxylin, eosin Y powder, per-mount  Sigma, USA 
2 Methanol, absolute ethanol  Systems, USA 
3 Ethylene glycol, sodium iodate and ammonium 
aluminium sulphate, xyelene, acridine orange, 
propidium iodide  
Nacalai Tesque, Japan 
4 Glacial acetic acid  Amresco, USA 
5 Fluorogel mounting medium  Genetex, USA 
6 Oxiselect STA 351 Comet assay kit  Cell Biolabs, USA 
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Table 4.2: Compounds and their concentrations selected in individual and combined low-
dose treatments for morphological and DNA damage evaluation studies. 
s/no Compounds  Cancer cells 
Single treatments (µg/ml) 
  U87MG  A549  HT29  
1 Delta tocotrienol 
(δ-T3) 
3.17 12.40 5.71 
2 Gamma tocotrienol 
(γ-T3) 
3.12 - - 
3 Jerantinine A 
(JA) 
0.62 1.42 1.74 
4 Jerantinine B 
(JB) 
0.74 1.48 0.58 
5 Vinblastine 0.04 0.03 0.71 
Combined treatments (µg/ml) 
6 Delta tocotrienol + jerantinine A  
(δ-T3+ JA) 
- 2.77 + 0.35 2.12 + 0.44 
7 Delta tocotrienol + jerantinine B  
(δ-T3+ JB) 
1.83 + 0.19 - 2.99 + 0.15 
8 Gamma tocotrienol + jerantinine 
A (γ-T3 + JA) 
1.29 + 0.16 - - 
9 Gamma tocotrienol + jerantinine 
A (γ-T3 + JB) 
1.61 + 0.19 - - 
 
4.2.2 Haematoxylin and eosin (H&E) staining  
A total of 1 x 10
4 
U87MG, A549 and HT-29 cells were seeded in 2-well chamber slides 
and incubated overnight to facilitate attachment. Thereafter, the medium was replaced 
with treatment medium containing individual IC50 doses or combined low-dose 
tocotrienols (delta and gamma) with IC20 dose of jerantinines (A and B) for respective 
cell lines as shown in Table 4.2. Whereas, vinblastine treated and untreated cells 
containing plain medium with equivalent amount of DMSO served as positive and 
negative controls, respectively. The treated cells were incubated in cell culture conditions 
for 24 h prior to staining. For H&E staining (For recipe see appendix 6a, b), cells were 
fixed and rehydrated in decreasing ethanol concentrations (100% (3x), 95% (3x), and 
70% (1x)) for 3min each, after the final step, the slides were rinsed in distilled water for 3 
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min. Rehydrated slides were stained in gills (I) haematoxylin for 3min and subsequently 
washed in 95% ethanol for 1 min. The slides were stained with alcoholic eosin for 2 min 
and then dehydrated in decreasing ethanol concentrations (95% (2x) and 100% (2x)) for 1 
min each. The slides were finally cleared with two changes of xylene for 1min, mounted 
with per-mount and viewed under the Nikon 80i eclipse microscope (Nikon, Japan) at 
40x magnification. 
 
4.2.3 Acridine orange and propidium iodide (AO/PI) Staining  
A total of 5 x 10
3 
U87MG, A549 and HT-29 cells were seeded in 2-well chamber slides 
and incubated for 24 h to facilitate attachment. Thereafter, cells were treated with 
individual IC50 doses or combined low-dose tocotrienols (delta and gamma) with IC20 
dose of jerantinines (A and B) as shown in Table 4.2. Similarly, vinblastine treated and 
untreated cells containing plain media with equivalent amount of DMSO served as 
positive and negative controls, respectively. Following 24 h treatment, the cells were 
fixed with -20
o
C methanol for 10 min, rinsed three times with PBS and stained with a 
mixture of acridine orange (10 µg/ml) and propidium iodide (10 µg/ml) in ratio 1:1. 
Slides were mounted with fluorogel mounting medium and morphological images were 
captured using the Nikon Ti eclipse confocal microscope (Nikon, Japan) at 40x 
magnification. 
 
4.2.4 Single cell gel electrophoresis (COMET) 
COMET assay was conducted according to previously described protocol (Lim et al., 
2011). A total of 5 x 10
3
 U87MG, A549 and HT-29 cells were treated with individual 
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IC50 doses or combined low-dose tocotrienols (delta and gamma) with IC20 dose of 
jerantinines (A and B) as shown in Table 4.2. Cells treated with vinblastine or plain 
media with DMSO served as positive and negative controls, respectively. After 72 h 
treatment, the cells were detached and centrifuged at 2000rpm for 5min. Subsequently, 
200 µl of low melting agarose was mixed with 20 µl of cell pellets in PBS and 75 µl of 
the mixture was spread gently on the COMET slides. The slides were laid horizontally in 
the dark at 4
o
C for 30 min to solidify. The slides were then lysed in pre-chilled 1x lysis 
buffer for 60 min at 4
o
C and further incubated horizontally in a container containing cold 
alkaline solution for 30 min at 4
o
C in the dark. Thereafter, neutral and alkaline COMET 
assays were conducted to investigate for double strand breaks (DSBs) and single strand 
breaks (SSBs), respectively. For neutral COMET assay, the slides were placed in 
horizontal electrophoresis chamber containing cold 1 x TBE buffer and voltage of 20V 
was applied for 45 min. For alkaline COMET assay, the horizontal chamber was filled 
with cold alkaline electrophoresis solution (300 mM NaOH, pH >13, 1 mM EDTA) and 
voltage of 20V was applied for 30 min. After electrophoresis, the slides were rinsed in 
three changes of cold distilled water for 2 min and then placed horizontally in ice cold 
70% ethanol for 5 min. Finally, the slides were air-dried and stained with 100 µl of vista 
green dye for 15 min. Images were captured using Nikon AZ100 fluorescence 
microscope (Nikon, Japan) at 20x magnification. For quantification of DNA damage, the 
DNA COMET profiles were analysed using the OpenComet software according to 
previously described protocol (Gyori et al., 2014). A total of 200 cells were analysed 
from two independent experiments and results were presented as Mean ± SD fold change 
of percent DNA in the tail compared to untreated controls.  
105 
 
4.2.5 Statistical analysis  
Statistical analysis was conducted using one way ANOVA to compare between treated 
and untreated groups. P values <0.001 (***), P <0.01 (**) and P <0.5 (*) were 
considered statistically significant. 
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4.3 Results  
4.3.1. Morphological changes on U87MG, A549 and HT-29 cells treated with 
individual and combined low-dose treatments 
 
4.3.2. Hematoxylin and eosin staining  
Following 24 h treatment of U87MG cells with IC50 doses of jerantinines A and B, 
morphological features of apoptosis including nuclear chromatin condensation and 
fragmentation, cytoplasmic extension and formation of multinucleated bodies were 
evident (Fig. 4.1 d, e). In addition, U87MG cells treated with IC50 doses of delta and 
gamma tocotrienols showed evidence of condensed nuclear chromatin and cell shrinkage 
(Fig. 4.1 b, c), whereas,  apoptotic bodies were observed  in cells treated with control 
drug vinblastine (Fig. 4.1 f). Similarly, A549 cells subjected to 24 h treatments with 
individual IC50 doses of  jerantinines A and B or vinblastine showed clear evidence of 
membrane blebbing, nuclear chromatin condensation and cell shrinkage (Fig. 4.2 c, d, e) 
compared to untreated cells (Fig. 4.2a).  Apoptotic cells appeared as dense bodies with a 
circular or oval structure. HT-29 cells treated with jerantinine A or B showed massive 
membrane blebbing, nuclear chromatin condensation and apoptotic bodies (Fig. 4.3 c, d) 
compared to untreated cells (Fig. 4.3 a). Circular shaped shrinking cells with condensed 
nuclear chromatin morphologies were also observed in HT-29 cells treated with delta 
tocotrienol and vinblastine (Fig. 4.3 b, e). 
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Fig 4.1: Representative H&E images of U87MG cells treated for 24 h. a) Untreated, b) delta 
tocotrienol, c) gamma tocotrienol, d) jerantinine A, e) jerantinine B,   f) vinblastine, g) gamma 
tocotrienol + jerantinine A, h) delta tocotrienol + jerantinine B, i) gamma tocotrienol + jerantinine 
B.  Morphological features of apoptosis including nuclear chromatin condensation (black arrows), 
multinucleated bodies (red arrows), cytoplasmic extension (green arrows) apoptotic bodies 
(yellow arrow) and cell shrinkage were evident. Scale bar represents 50 µm.  
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Fig 4.2: Representative H&E images of A549 cells treated for 24 h. a) Untreated, b) delta 
tocotrienol, c) jerantinine A, d) jerantinine B, e) vinblastine, f) jerantinine A + delta tocotrienol. 
Morphological features of apoptosis including membrane blebbing (blue arrows), nuclear 
chromatin condensation and cell shrinkage (black arrows) were evident. Scale bar represents 50 
µm.  
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Fig 4.3: Representative H&E images of HT-29 cells treated for 24 h. a) Untreated, b) delta 
tocotrienol, c) jerantinine A, d) jerantinine B, e) vinblastine, f) delta tocotrienol + jerantinine A, 
g) delta tocotrienol + jerantinine B. Morphological features of apoptosis including membrane 
blebbing (blue arrows), nuclear chromatin condensation and cell shrinkage (black arrows), 
nuclear chromatin fragmentation (red arrow) and apoptotic bodies (yellow arrows) were evident. 
Scale bar represents 50 µm. 
 
For combined studies, U87MG cells were treated with combined low-dose tocotrienols 
(delta and  gamma) with IC20 doses of jerantinines (A and B) for 24 h and subsequent  
evaluation of morphological changes revealed features of apoptosis including 
multinucleated bodies, nuclear chromatin condensation and cytoplasmic extension (Fig. 
4.1 g, h, i). These features were similar to those observed in single treatments of 
tocotrienols (Fig. 4.1b, c) thus indicating potential synergism of the combined drugs at 
lower dose with an effect of the same multitude as that of single high dose. Similarly, 
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A549 and HT-29 cells treated with combined low-dose delta tocotrienol with IC20 doses 
of jerantinines (A and B)  showed morphologies similar to single high-dose tocotrienol 
including circular or oval shaped cells with condensed nuclear chromatin and minimal 
membrane blebs  as observed in (Fig. 4.2 f) and (Fig. 4.3 f, g), respectively.  
 
4.3.3. Acrindine orange and propidium iodide staining (AO/PI) 
Guided by H&E staining, further fluorescence staining was conducted to further 
corroborate evidence of morphological features of apoptosis. The massive multinucleated 
bodies observed in H&E stained U87MG cells treated with jerantinines A and B were 
also evident in fluorescence stained cells (Fig. 4.4), including minor nuclear chromatin 
fragmentation and condensation. Live cells or cells at early stage of apoptosis are 
impermeable to PI staining which are contrary dying cells or cells at the late stage of 
apoptosis. Cells at late stage of apoptosis loose membrane integrity and are permeable to 
PI thereby producing yellow or orange stained cell morphology when counter stained 
with AO/PI. Interestingly, massive staining of U87MG cells by PI and the orange colour 
stained cells observed in merged images of AO and PI further suggest late stage of 
apoptosis. Similar features were also observed in cells treated with vinblastine (Fig. 4.4). 
Similar massive multi nucleated bodies and nuclear fragmentation were observed in 
U87MG cells treated with combined low-dose gamma tocotrienol with IC20 dose of 
jerantinine A and combined low-dose delta tocotrienol with IC20 dose of jerantinine B 
(Fig. 4.4). The orange coloured stained cells in merged images of AO and PI indicating 
the late stage of apoptosis.  In contrast, only minor nuclear chromatin condensation and 
fragmentation were observed in U87MG cells treated with single IC50 doses of delta or 
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gamma tocotrienol (Fig. 4.4) thus further supporting the proposition that apoptosis was 
still at its early stage. Furthermore, this indicates better and more potent effect of 
combined low-dose treatments as well as improved potency of tocotrienols compared to 
single IC50 doses of tocotrienols.  
 
On the other hand, apoptotic features including nuclear chromatin condensation and 
membrane blebbing were evident in A549 cells treated with IC50 doses of jerantinines A 
and B (Fig. 4.5). While, only nuclear chromatin condensation was observed in cells 
treated with IC50 doses of control drug, vinblastine, delta tocotrienol and combined low-
dose delta tocotrienol with IC20 dose of jerantinine A (Fig. 4.5). Interestingly, unlike 
U87MG cells, minimal staining with PI was observed in A549 cells where cells were 
stained green in merged images of AO and PI. In addition to the indication of early 
apoptotic stage, this also demonstrates that apoptosis occurred at an earlier stage in 
U87MG cells compared to A549 cells treated with jerantinines A and B or the combined 
low-dose treatments with delta and gamma tocotrienols.  
 
Furthermore, massive membrane blebs with condensed nuclear chromatin were observed 
in circular and oval shaped HT-29 cells treated with IC50 doses of jerantinines A and B 
and control drug vinblastine for 24 h (Fig. 4.6). HT-29 cells treated with jerantinine B 
appeared to be at the later stage of apoptosis and thus the yellow colour was seen in 
merged images of AO and PI compared to HT-29 cells receiving jerantinine A.  In 
contrast, only minimal nuclear fragmentation was evident in HT-29 cells treated with 
IC50 dose of delta tocotrienol (Fig. 4.6). Nevertheless, on a more positive note, nuclear 
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chromatin condensation and nuclear fragmentation were evident in HT-29 cells treated 
with combined low-dose delta tocotrienol with IC20 doses of jerantinines A or B (Fig. 
4.6) indicating much improved potency compared to single high-dose delta tocotrienol. 
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Fig 4.4: Representative AO/PI images of U87MG cells treated for 24 h with individual and 
combined low-dose tocotrienols (delta and gamma) with IC20 dose of jerantinines (A and B). 
U87MG cells treated with vinblastine and plain media containing DMSO served as positive and 
negative controls, respectively. Morphological features of apoptosis including nuclear chromatin 
condensation (red arrows) and nuclear chromatin fragmentation (yellow arrows) were evident. 
Images were captured at 40X magnification and merged using the NIS-Elements software under 
Nikon Ti eclipse confocal microscope observation.   
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Fig 4.5: Representative AO/PI images of A549 cells treated for 24 h with individual and 
combined low-dose delta tocotrienol with IC20 dose of jerantinine A. A549 cells treated with 
vinblastine and plain media containing DMSO served as positive and negative controls, 
respectively. Morphological features of apoptosis including nuclear chromatin condensation (red 
arrows) and membrane blebbing (blue arrows) were evident. Images were captured at 40X 
magnification and merged using the NIS-Elements software under Nikon Ti eclipse confocal 
microscope observation.   
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Fig 4.6: Representative AO/PI images of HT-29 cells treated for 24 h with individual and 
combined low-dose delta tocotrienol with IC20 doses of jerantinines (A and B). HT-29 cells 
treated with vinblastine and plain media containing DMSO served as positive and negative 
controls, respectively. Morphological features of apoptosis including nuclear chromatin 
condensation (red arrows), nuclear chromatin fragmentation (yellow arrows) and membrane 
blebbing (blue arrows) were evident. Images were captured at 40X magnification and merged 
using the NIS-Elements software under Nikon Ti eclipse confocal microscope observation.   
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4.3.4. DNA damage patterns of U87MG, A549 and HT-29 cells treated with 
individual and combined treatments  
As shown in Fig. 4.7, a considerable double stranded DNA break (DSBs) was induced in 
U87MG cells treated with single IC50 dose of jerantinine A, jerantinine B, delta and 
gamma tocotrienols and control drug, vinblastine (Fig. 4.7a). Interestingly combined low-
doses of jerantinine B with delta tocotrienol gave similar effects to single IC50 dose delta 
tocotrienol (Fig. 4.7a, c). Similarly, combined treatment of low-dose gamma tocotrienol 
with jerantinines A and B induced a slightly higher DSBs compared to single IC50 dose 
treatment with gamma tocotrienol. In contrast, minimal or no SSBs was evident on 
U87MG cells receiving individual and combined treatments of low-dose tocotrienols 
(delta and gamma) with IC20 doses of jerantinines (A and B) (Fig. 4.7b, d). Similarly, 
control drug vinblastine did not induce SSBs in U87MG cells (Fig 4.7b, d). 
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Fig 4.7: Induction of DNA damage by individual IC50 doses and combined low-dose treatments of 
tocotrienols (delta and gamma) with IC20 dose of jerantinines (A and B) on U87MG cells after 72 
h. U87MG cells treated with plain media containing DMSO and IC50 dose of vinblastine served as 
negative and positive controls, respectively. Fold change in DNA damage over untreated controls 
under neutral (a) and alkaline conditions (b) represent DSBs and SSBs, respectively measured 
using OpenComet software from a population of 200 cells. Representative images of treated 
U87MG cells under (c) neutral and (d) alkaline conditions show migrating comets which indicate 
DNA damage. P*<0.05. 
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For A549 cells, individual treatments of IC50 doses of jerantinines A and B, and control 
drug vinblastine induced significant DSBs in A549 cells as confirmed by neutral COMET 
assay with over 50% tail DNA (Fig. 4.8a, c). A similar trend was also observed in A549 
cells treated with delta tocotrienol and combined treatment of low-dose delta tocotrienol 
with IC20 dose of jerantinine A (Fig. 4.8a). In contrast, similar treatments could not 
induce SSBs as confirmed by alkaline electrophoresis, although a slight but non-
significant increase in tail DNA percentage was observed in A549 cells treated with 
jerantinines A and B and delta tocotrienol compared to untreated control cells (Fig. 4.8b, 
d). Likewise, DSBs was also observed in HT-29 cells treated with jerantinine A, delta 
tocotrienol and combined low-dose treatment of delta tocotrienol with jerantinine A (Fig. 
4.9a, c). As shown in Fig. 4.9a, jerantinine B and its combined low-dose treatment with 
delta tocotrienol also induced DSBs. In contrast, alkaline COMET revealed that 
jerantinines A and B and combined low-dose treatments but not delta tocotrienol and 
control drug vinblastine induced slight but non-significant increase of SSBs in treated 
HT-29 cells compared to untreated controls (Fig 4.9b, d).  
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Fig 4.8: Induction of DNA damage by individual IC50 doses and combined low-dose treatments of 
δ-tocotrienol with IC20 dose of jerantinine A on A549 cells after 72 h. A549 cells treated with 
plain media containing DMSO and IC50 dose of vinblastine served as negative and positive 
controls, respectively. Fold change in DNA damage over untreated controls under neutral (a) and 
alkaline conditions (b) represent DSBs and SSBs, respectively measured using OpenComet 
software from a population of 200 cells. Representative images of treated U87MG cells under (c) 
neutral and (d) alkaline conditions show migrating comets which indicate DNA damage.  
P*<0.05. 
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Fig 4.9: Induction of DNA damage by individual IC50 doses and combined low-dose treatments of 
δ-tocotrienol with IC20 dose of jerantinines (A and B) on HT-29 cells after 72 h. HT-29 cells 
treated with plain media containing DMSO and IC50 dose of vinblastine served as negative and 
positive controls, respectively. Fold change in DNA damage over untreated controls under neutral 
(a) and alkaline conditions (b) represent DSBs and SSBs, respectively measured using 
OpenComet software from a population of 200 cells. Representative images of treated U87MG 
cells under (c) neutral and (d) alkaline conditions show migrating comets which indicate DNA 
damage. P*<0.05.   
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4.4 Discussion 
Apoptotic cell death has distinctively defined morphological features under the electron 
microscope which include an onset of cell and nucleus shrinkage, membrane blebbing, 
nuclear chromatin condensation and fragmentation into masses and its subsequent 
margination against nuclear membranes (Saraste and Pulkki, 2000). This results in 
disassembly of cells into smaller apoptotic bodies which either undergo secondary 
necrosis or in most cases occurrence of phagocytosis by neighbouring cells to avoid 
releasing its cellular content into other tissues and induce inflammation. In addition, 
DNA fragmentation and caspase activation are also used as biochemical hallmark for 
apoptosis. 
 
Individual and combined low-dose treatments of tocotrienols (delta and gamma) with 
IC20 doses of jerantinines (A and B) induced synergistic growth inhibition as reported in 
Chapter Three. To date there are no detailed studies on the effect of jerantinines (A and 
B) on morphology of cancer cells. This necessitated the present study to further 
investigate and determine the type of cell death induced by individual and combined low-
dose treatments. Apoptosis cells undergoing cell shrinkage have low levels of Na
+
 and K
+
 
that causes loss of contact with neighbouring cells and detachment from the extracellular 
matrix (ECM). This causes the cells to acquire rounded shaped morphology. This is 
followed by formation of blebs as a result of separation of the plasma membrane from 
cytoskeletons. Previous studies have demonstrated that in addition to previously 
perceived inhibition of cell to cell contact factors by caspases, cell membrane blebbing 
also requires phosphorylation of myosin light chain into an active form as well as 
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rearrangement of the actin cytoskeleton. Furthermore, condensation and subsequent 
formation of apoptotic bodies have been shown to correlate with dissolution of 
polymerized actin and degradation/disassembling of microtubules (Howard and Hyman, 
2003; Stricker et al., 2010). In relation to the present study, treatment with jerantinines A 
and B and combined treatments with gamma or delta tocotrienol resulted in cell 
shrinkage, consistent membrane blebbing and formation of apoptotic bodies against all 
screened cell lines. This is consistent with the recent findings that showed disruption of 
microtubules by jerantinines A and B was accompanied by membrane blebbing (Qazzaz 
et al., 2016; Raja et al., 2014). Based on the similarities in apoptotic morphology with the 
present study, it is possible that the combined low-dose treatments may also evoke 
disruption of microtubule networks.  
 
Unlike jerantinines A and B, there was no evidence of membrane blebbing although, 
other apoptotic features including nuclear chromatin condensation and fragmentation and 
cell shrinkage were evident in A549, U87MG and HT-29 cells treated with delta or 
gamma tocotrienol. This further corroborates previous studies illustrating the 
morphological features of apoptosis induced by tocotrienols. For instance, alpha, delta 
and gamma tocotrienols induced apoptosis in human lung and brain cancer cells by 
evoking changes in cell morphology including nuclear chromatin condensation and 
nuclear margination (Lim et al., 2014a). Similarly, nuclear chromatin condensation, cell 
blebbing and apoptotic bodies formation were also evident in breast cancer cells treated 
with gamma tocotrienol (Takahashi and Loo, 2004; Yu et al., 1999). Recent studies have 
also demonstrated that tocotrienols induce other forms of cell death. For instance, gamma 
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tocotrienol induced apoptosis and autophagy in prostate cancer cells (Jiang et al., 2012a). 
Similarly, gamma tocotrienol induced paraptosis cell death evoking changes in cellular 
morphology including swelling of mitochondria, endoplasmic reticulum and formation of 
intracellular vacuoles in SW620 human colon cancer cells (Zhang et al., 2013). In fact, 
tocotrienols have been shown to induce both apoptosis and other forms of cell death 
which may be dependent on dosage and microcellular environment. For instance,  a high 
dose of delta tocotrienol (10µg/ml) isolated from Kielmeryera coriacea induced apoptotic 
features including chromatin condensation and fragmentation and features such as 
formation of pyknotic nuclei  that is consistent with necrosis (De Mesquita et al., 2011). 
Similarly, combined treatment of gamma tocotrienol with 6-gingerol induced 
morphological features of cell death that included cell shrinkage and pyknosis (Yusof et 
al., 2015). However, in comparison to this study, features such as pyknotic nuclei that can 
be detected by H&E staining technique were not observed for individual and combined 
low-dose treatments of tocotrienols (delta and gamma) with IC20 doses of jerantinines (A 
and B) as only features consistent with apoptosis were evident. These studies nonetheless 
further illustrate the dynamic potential of tocotrienols which may be dependent on the 
type of cell and concentration of tocotrienol administered.  Histologically, apoptotic cells 
are single or cluster of cells that appear as circular or oval mass with dark cytoplasm and 
dense purple nuclear chromatin fragments upon staining with haematoxylin and eosin 
stains (Elmore, 2007). This is consistent with the features observed herein thereby 
implicating apoptosis as a mode of cell death induced by individual and combined 
treatments of low-dose tocotrienols (delta and gamma) with IC20 doses of jerantinines (A 
and B). 
128 
 
 
On the other hand, internucleosomal DNA fragmentation is used as a biochemical 
hallmark of apoptosis. Whilst the DNA laddering technique provides evidence for DNA 
damage illustrating the characteristic fragmentation, the DNA COMET assay allows for 
more detailed determination of SSBs or DSBs. Indeed, the present study showed that IC50 
dose of jerantinine A, jerantinine B and vinblastine induced predominantly DSBs on 
A549, HT-29 and U87MG cells. Similarly, A549, HT-29 and U87MG cells treated with 
IC50 dose of delta or gamma tocotrienol showed evidence of DSBs breaks. Similar 
multitude of dominant DSBs were observed in combined low-dose treatments (Fig. 4.7, 
4.8, 4.9) indicating a strong synergy as well as improved potency of tocotrienols. In 
addition, there was minimal or no evidence of induction SSBs on U87MG, A549 and HT-
29 cells receiving individual and combined low-dose treatments (Fig 4.7b, 4.8b, 4.9b). 
Previous studies had shown that tocotrienol and vinblastine activate DSBs in cancer cells 
(Lim et al., 2014a, 2014b) which is consistent with the present study. Although in the 
present study slight but non-significant SSBs were also evident for A549 cells treated 
with delta tocotrienol. This could be attributed to the difference in automated scoring 
method adopted in this study compared to manual method in the previous study. In fact, 
SSBs and base damage account for 98% of overall DNA damage. However, the effect is 
insignificant in relation to cytotoxicity (Ismail et al., 2005). In relation to the present 
study, undoubtedly the apoptotic effects of tocotrienols, combined low-dose treatments 
with jerantinines (A and B) and vinblastine are as a result of DSBs. This is further 
supported by the observed high levels of DSBs compared to minimal or no evidence 
SSBs. To date, there are no reported studies on DNA damage patterns induced by 
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jerantinines and as such the results from the present study might be the first. Previous 
studies have shown that chemotherapeutic agents can induce both SSBs and DSBs. For 
instance, etoposide induces SSBs and DSBs by interacting with topoisomerase IIα 
(Fortoul et al., 2006). This results in p53 dependent and independent late S and G2 cell 
growth arrests (Clifford et al., 2003; Lee and Xiao, 2012). Although a study demonstrated 
that jerantinine A induced G2/M growth arrest, the potential of jerantinine derivatives 
inhibiting topoisomerase II is unlikely considering that recent studies have confirmed 
inhibition and disruption of microtubule networks as mode of action for jerantinine 
derivatives (Frei et al., 2013; Raja et al., 2014). This is supported by the fact that 
etoposide that inhibits topoisomerase II has no effect on microtubules although its parent 
derivative podophyllotoxin disrupt microtubules to induce mitotic arrest (Lee and Xiao, 
2012). Therefore, the apoptotic effects of jerantinines (A and B), tocotrienols and the 
combined low-dose treatments in this study are as a result of DSBs and the SSBs are 
insignificant effects at the onset of apoptosis that precedes the DSBs.  
 
DSBs and DNA lesion prevent replication and transcription of DNA thus representing the 
lethal form of DNA damage that triggers a cascade of sensors consequently resulting in 
inhibition of cell cycle progression, DNA repair or induction of apoptosis. Phosphatidyl 
inositol 3-kinase related kinases ATM (ataxia-telangiectasia mutated) and ATR (ATM 
and Rad3-related) are key cellular sensors of DNA lesions that are activated directly or 
indirectly upon induction of DNA DSBs by cisplatin, irradiation (IR) or methylation 
agents (Norbury and Zhivotovsky, 2004). Although both pathways are different but are 
related at the downstream. ATR is primarily activated by SSBs that block and cause the 
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collapse of the DNA replication fork. Eventually though, these DNA lesions blocking 
replication fork may be converted to DSBs (Roos and Kaina, 2013). As demonstrated by 
the present study, jerantinine A, jerantinine B and the combined low-dose treatments with 
delta or gamma tocotrienol induced a dominant DSBs with minimal or no evidence of 
SSBs as such it is possible that both ATM and ATR are activated. Furthermore, the 
minimal SSBs observed in some treatments herein may be the resultant delayed 
conversion to DSBs.  
 
In addition, p53 plays a vital role in DNA damage induced apoptosis via activation of 
ATM or ATR. ATM and ATR phosphorylate Ser15 of p53 causing direct activation. p53 
is also indirectly phosphorylated via phosphorylation of upstream ChK2 (checkpoint 
kinase-2) and ChK1 (checkpoint kinase-1) by ATM and ATR upon induction of DSB and 
collapsed replication fork respectively (Guo and Kumagai, 2000; Shieh et al., 2000). 
Regardless of the type of DNA damage and kinases activated by both individual and 
combined treatments of jerantinines (A and B) with delta or gamma tocotrienol, it is 
highly possible that DNA damage induced apoptosis may be mediated via up-regulation 
of p53. Indeed, studies have shown the up-regulation of p53 by gamma tocotrienol and 
jerantinine A (Kannappan et al., 2010; Raja et al., 2014) further supporting the 
aforementioned proposition.  
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4.5 Conclusion  
Treatments for U87MG, A549 and HT-29 cells with individual and combined low-dose  
tocotrienols (delta and gamma) with IC20 dose of  jerantinines (A and B) caused changes 
in cellular morphological features including nuclear chromatin condensation and 
fragmentation, cell shrinkage and apoptotic bodies implicate apoptosis phenomenon 
without doubt. The apoptotic potential was further confirmed as jerantinines (A and B) 
and the combined low-dose treatments induced dominant DSBs on A549, HT-29 and 
U87MG. The similarities in DNA damage patterns and morphological features 
characterised by massive membrane blebbing induced by jerantinines (A and B) and 
control drug vinblastine indicate the possibility of these compounds having similar 
mechanism of action. Undoubtedly, the manifestations of minimal or no evidence of 
SSBs suggest that the apoptotic effects are as a result of DSBs which may be mediated 
via dependent or independent of p53.  
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5.0 CHAPTER FIVE 
Induction of cell cycle arrest and disruption of microtubule mediated via caspase 
dependent and independent apoptosis by individual and combined treatments of 
tocotrienols (delta and gamma) and jerantinines (A and B) 
 
5.1 Introduction  
Results from Chapter Four revealed that single and combined treatments induced changes 
in cellular morphology that included membrane blebbing, cell shrinkage, nuclear 
chromatin fragmentation and condensation and formation of apoptotic bodies. In 
addition, there was an induction of DSBs pattern of DNA damage on U87MG, A549 and 
HT-29 cells that indicating an occurrence of apoptotic cell death. As in most cases, 
apoptosis is characterized by growth arrest at different points of the cell cycle. Activation 
of caspase enzymes is one of the key biochemical hallmarks for apoptosis although there 
is also evidence of caspase independent apoptotic cell death. In addition, the 
manifestation of morphological features such as membrane blebbing and DSBs type of 
DNA damage as shown in Chapter Four are similar to those of microtubule inhibiting 
control drug, vinblastine. Considering that disruption of microtubules has been suggested 
as a possible mechanism of apoptosis induction for jerantinine derivatives, it is 
imperative to determine the type of cell cycle arrest involved as it relates to 
antimicrotubule effects of jerantinines. Besides, the combined low-dose treatments would 
represent a shift in cell cycle arrest considering that both tocotrienols and jerantinines 
may induce different growth arrest patterns. Microtubule targeting agents mediate 
apoptosis via the mitochondria pathway although the death receptor pathway is also 
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activated. Hence, the potential roles of caspase enzymes as well as cell death dependent 
and independent of caspase enzymes were investigated.  
 
Flow cytometry was used to evaluate the various checkpoints of cell cycle arrest. This is 
based on the univariate analysis of cellular DNA content stained with propidium iodide 
(PI) that allows for determination of cell distribution across the various phases (G1, S and 
G2/M) of the cell cycle presented as DNA histogram of a singlet cells (Nunez, 2001).  
 
On the other hand, immunofluorescence microscopic technique was employed for 
morphological investigations on microtubule structures caused by the effects of 
individual and combined low-dose treatments. The technique is based on the use of 
antibody raised against tubulins. Tubulins (alpha and beta) are the monomers that make 
up the microtubules. Polymerization dynamics can be detected via morphological 
observation. Colorimetric techniques were conducted for quantitative evaluation of 
caspase enzymes activities. The technique is based on the spectrophotometric 
determination p-nitroanilide (pNA) after cleavage from the respective substrates of 
caspase 8 (IETD-pNA), caspase 9 (LEHD-pNA) and caspase 3 (DEVD-pNA). The 
cysteinyl aspartic acid-protease (caspase) enzymes play the key roles in mediating both 
death receptor and mitochondria pathway of apoptosis. Initiator caspase 8 and 9 trigger 
death receptor and mitochondria pathway, respectively that are executed via activation of 
executioner caspase 3. The mitochondria pathway is initiated upon loss of mitochondrial 
membrane potential and subsequently executed through activation of APAF-1 and 
caspase 9 by cytochrome c thereby forming an apoptosome (Fulda et al., 2010). 
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Therefore, caspase involvement in apoptotic pathway should be elucidated. Besides, cell 
viability studies were conducted in the presence of caspase specific inhibitors to 
determine the role of caspase in the cell death phenomenon induced by individual and 
combined low-dose treatments. The caspase 8, 9 and 3 specific inhibitors are synthetic 
peptides that irreversibly inhibit FLICE (FADD-like ICE), caspase 9 and caspase 3 
related activities to block apoptosis.   
The specific objectives of the present chapter are: 
i) To determine the checkpoints of cell cycle arrest on cancer cells treated with 
single and combined treatments by using flow cytometry.  
ii) To determine the potential antimicrotubule effects of individual and combined 
low-dose treatments. 
iii)  To determine the role of caspase enzymes in mediation of apoptosis and cell 
death phenomenon induced by single and combined treatments. 
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5.1. Materials and Methods 
5.1.1 Chemical reagent/kits and cell cultureware 
The following reagents and kits listed in Table 5.1 were used to conduct the experiments. 
Table 5.1: List of chemical reagents, kits and glassware used and the respective 
manufacturers. 
s/no Chemical reagents/kits Manufacturer  
1 Monoclonal antitubulin antibody and goat anti 
mouse IgG (FITC) 
Santa Cruz Biotechnology, 
Santa Cruz, CA 
2 Prolong gold antifade Molecular Probes, Eugene, 
OR 
3 4’,6-diamidino-2-phenylindole (DAPI), triton X-
100, sodium citrate, ribonuclease A solution, 
propidium iodide and bovine serum albumin 
(BSA) 
Nacalai Tesque, Japan 
4 Colorimetric caspase 8: (GTX 85543), caspase 9: 
(GTX 85538) and caspase 3: (GTX 85558) Kits 
GeneTex, USA 
5 Caspase specific inhibitors for caspase 8: Z-IE-
(OME)-TD- (OME)-FMK (GTX47946), caspase 
9: Z-LE-(OME)-HD-(OME)-FMK (GTX 47945) 
and caspase 3: ZD-(OME)-E-(OME)-VD-(OME)-
FMK (GTX 47950) 
GeneTex, USA 
6 4-well chamber slides SPL life sciences, Korea 
 
5.1.1 Cell cycle analysis by flow cytometry  
U87MG, A549 and HT-29 cells were seeded in 6-well plates and incubated for 24 h to 
facilitate attachment. Thereafter, the medium was replaced with treatment medium for 
single and combined low-dose treatments on the respective cell lines as indicated in 
Table 4.2. Following 24 h and 48 h incubation periods, a total of 1 x 10
6
 cells were 
collected for cell cycle analysis according to the previously described protocol (Raja et 
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al., 2014).  The treated and untreated cells were detached and washed twice with pre-
chilled PBS with centrifugation at 2200rpm for 5min at 4
o
C. The cells were subsequently 
re-suspended in 500 µl flourochrome solution (0.1% Triton X-100, 0.1% sodium citrate, 
and 0.1mg ribonuclease and 50 µg propidium iodide) and stored overnight in the dark at 
4
o
C. The cell cycle data was captured using the BD accuri c6 flow cytometer (BD 
biosciences, USA) and data from three repeats were analyzed using FCS express 5 
(Denovo software, USA). The cell cycle checkpoint with the highest percentage increase 
in cell population compared to untreated controls was considered to be the point of cell 
cycle arrest.  
 
5.1.2 Immunofluorescence staining for microtubules  
U87MG, A549 and HT-29 cells were seeded at a density of 5 x 10
3
 cells in 4-well 
chamber slides and incubated for 24 h at cell condition to facilitate attachment. 
Thereafter, the medium was replaced with treatment medium for single and combined 
treatments on the respective cell lines as indicated in Table 4.2. Whereas, cells containing 
plain medium with equivalent amount of DMSO or IC50 dose of vinblastine were used as 
negative and positive controls, respectively. After 72 h incubation, the cells were fixed 
and permeabilised with -20
0
C methanol and 0.5% triton X-100 for 10 min. The cells were 
blocked with 10% BSA for 20 min and incubated with monoclonal antitubulin antibody 
at the dilution (1:200) in 1.5% BSA blocking buffer for 60min at 37
o
C. The slides were 
washed with three changes of PBS for 5min followed by incubation with goat anti mouse 
IgG (FITC) diluted at 1:200 in 1.5% BSA blocking buffer for 45 min at 37
o
C. Finally, the 
slides were stained with 10 µg/ml DAPI for 15 min and mounted with prolong gold 
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antifade. The slides were visualized and captured at 40X magnification under Nikon 
eclipse Ti confocal microscope (Nikon, Japan).  
 
5.1.3 Caspase assay  
U87MG, A549 and HT-29 cells were seeded at a density of 1 x 10
6
 in 6-well plates (SPL 
Life Sciences, Korea) and incubated for 24 h to facilitate attachment. Subsequently, the 
medium was replaced with treatment medium for individual IC50 doses and combined 
low-dose treatments of tocotrienols (delta and gamma) with IC20 doses of jerantinines (A 
and B) on the respective cell lines as shown in Table 4.2. Whereas, cells treated with 
plain medium containing equivalent amount of DMSO served as untreated control. 
Following incubation at different time points in between 1 h – 48 h, cells were detached 
and centrifuged at 2200 rpm for 5 min to pellet cells. The cell pellets were re-suspended 
in pre-chilled PBS and centrifuged at 2200 rpm for 5 min to remove all traces of trypsin 
and media.  The pellets were suspended in 50 µl of respective cell lysis buffer, incubated 
on ice for 10 min and centrifuged at 10,000 rpm for 1 min to collect the supernatant 
which was stored at -80
o
C until analysis. Gene Tex caspase 8, 9 and 3 kits were used for 
evaluating the activity of caspase enzymes. Fifty microliter of the supernatant was mixed 
with 50 µl 2X reaction buffer containing 10mM dithiothreitol (DTT). Thereafter, 5µl of 
conjugated chromophore p-nitroanilide (pNA) substrate (4mM) for respective caspases 8, 
9 and 3 was added and the mixture was incubated for 4-6 h. The absorbance for treated 
and untreated samples was read at 405nm using the Epoch multiplate spectrophotometer 
(Biotek, USA) and the fold increase in caspase activities was determined by comparing 
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the results to untreated controls. Results were presented as mean ± standard deviation 
(SD) from triplicate experiments. 
 
5.1.4 Caspase inhibition assay 
U87MG, A549 and HT-29 cells were seeded at a density of 5 x 10
3
 in 96-well plates 
(SPL life Sciences, Korea). Following an overnight incubation, the cells were treated 
with individual IC50 doses or combined low-dose tocotrienols with IC20 dose of 
jerantinines (A and B) as shown in Table 4.2 with or without 1µM individual caspase 8, 
caspase 9: Z-LE-(OME)-HD-(OME)-FMK) and caspase 3: ZD-(OME)-E-(OME)-VD-
(OME)-FMK specific inhibitors for 72 h. U87MG, A549 and HT-29 cells treated with 
plain media containing DMSO with or without individual caspase 8, 9 and 3 specific 
inhibitors were served as control. Following 72 h incubation, the percentage of cell 
viability was determined using the neutral red uptake assay as previously described 
(Repetto et al., 2008). Results were presented as mean ± SEM of triplicates conducted 
from three independent experiments.  
 
5.1.5 Statistical analysis  
Statistical analysis was conducted using one way ANOVA (Dunnets t-test) to compare 
between treated and untreated groups for cell cycle analysis, caspase assay and caspase 
inhibition assay. P values <0.001 (***), P <0.01 (**) and P <0.5 (*) were considered 
statistically significant.  
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5.2 Results 
 
5.2.1. Determination of cell cycle arrest induced by single and combined treatments  
Following 24 h and 48 h treatments, the effects of both individual and combined low-
dose treatments on cell cycle were analyzed based on three independent experiments. In 
comparison to untreated control, the individual IC50 dose of delta tocotrienol induced an 
increase of G0/G1 cell population with 81.4% and 87.5% arrests in U87MG cells after 24 
h and 48 h, respectively (Fig. 5.1). Similar patterns of growth arrest of 67.7% and 79.9% 
at G0/G1 were evident in U87MG cells receiving IC50 dose of gamma tocotrienol after 24 
h and 48 h, respectively. As shown in Table 5.2, this represented up to 26.3% and 18.7% 
increase of G0/G1 cell population (P <0.001) for U87MG cells receiving IC50 dose of 
delta and gamma tocotrienols, respectively.  In contrast, significant G2/M growth arrest 
was evident in U87MG cells treated with IC50 of jerantinine A (66.9% and 83.5%) and 
jerantinine B (67.9% and 57.3%) after 24 h and 48 h which represented a significant (P 
<0.001) increase of up to 67.6% and 52%, respectively (Fig. 5.1). Unlike single IC50 
doses of tocotrienols (delta and gamma) and jerantinines (A and B), the combined 
treatment of low-dose gamma tocotrienol with IC20 dose of jerantinine A demonstrated a 
change in pattern of cell cycle arrest from 7.5% (P <0.001) increase in G2/M arrest to 
23.6 % (P <0.001) increase in G0/G1 populations of U87MG cells after 24h and 48h, 
respectively. In contrast, the combined treatment of low-dose gamma tocotrienol with 
IC20 dose of jerantinine B induced slight increase of 3.6% in S population and significant 
increase of 13.4% (P <0.001) in G0/G1 population of U87MG cells after 24 h and 48 h, 
respectively. Similar trend was also evident for combined treatment of low-dose delta 
tocotrienol with IC20 dose of jerantinine B, although, there was significant (P <0.001) 
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increase in S (11.1%) populations after 24 h (Table 5.1). On the other hand, single IC50 
dose of delta tocotrienol induced slight increase (6.2%) in G2/M and a significant 
increase of G0/G1 (17.8%) populations of A549 cells after 24 h and 48 h, respectively 
(Table 5.3). In contrast, as shown in Fig 5.2, jerantinines (A and B) and the combined 
treatment of low-dose delta tocotrienol with  IC20 dose of jerantinine A induced 
significant increase (P <0.001) in G2/M populations of A549 cells after 24 h and 48 h 
(Table 5.3). As shown in Fig 5.3, single IC50 dose of delta tocotrienol induced slight 
increase in G0/G1 population (24 h) with a more significant increase (P <0.05) evident 
after 48h. In contrast IC50 doses of jerantinines (A and B) induced significant increase of 
up to 70% in G2/M populations of HT-29 cells after 24 h and 48 h treatments. On the 
other hand, an increase in G0/G1 populations was evident on HT-29 cells treated with 
combined treatment of low-dose delta tocotrienol with IC20 dose of jerantinine B for 24 h 
and 48 h. Whereas, an increase in G0/G1 and S populations were evident in HT-29 cells 
receiving combined treatment of low-dose delta tocotrienol with IC20 dose of jerantinine 
A for 24 h and 48 h, respectively (Table 5.4).     
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 Fig 5.1:  a) Representative flow cytometric profiles of U87MG cells treated with individual and combined low-dose treatments for 24 h 
and 48 h. Histogram profiles of flow cytometric data for 24 h (b) and 48 h (c) based on three independent experiments. Significant 
difference for higher cell populations in treated compared to untreated groups was calculated at p < 0.5 (*), p < 0.01 (**) and p < 0.001 
(***). 
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Table 5.2: Induction of cell cycle arrest on U87MG cells by single and combined treatments. 
Samples Changes over untreated control (%) Designated cell cycle arrest 
 G0/G1 G2/M S Stage p-value Stage P-value 
 24h 48h 24h 48h 24h 48h 24h 48h 
           
δ-T3 +20.2 +26.3 -10.1 -11.1 -10.0 -15.2 G0/G1 *** G0/G1 *** 
γ-T3 +6.5 +18.7 -5.4 -8.8 -1.0 -10.0 G0/G1 *** G0/G1 *** 
JA -46.0 -44.7 +51.0 +67.6 -5.0 -22.9 G2/M *** G2/M *** 
JB -42.0 -43.4 +52.0 +41.4 -10.0 +2.0 G2/M *** G2/M *** 
δ-T3+ JB -4.5 +11.1 -3.1 -0.4 +7.6 -10.7 S *** G0/G1 ** 
γ-T3 + JA -9.5 +23.6 +7.5 -13.7 +2.0 -10.0 G2/M *** G0/G1 *** 
γ-T3 + JB -2.4 +13.4 -1.2 -4.3 +3.6 -2.1 S - G0/G1 *** 
The points of cell cycle arrest tested at 24h and 48h are shaded, statistically significant percentage of populations higher in treated comparing to 
untreated groups are set at P < 0.001 (***), P < 0.01(**), P < 0.05(*). 
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Fig 5.2:  a) Representative flow cytometric profiles of A549 cells treated with individual and combined low-dose treatments for 24 h and 
48h. Histogram profiles of flow cytometric data for 24 h (b) and 48 h (c) based on three independent experiments. Significant difference 
for higher cell populations in treated compared to untreated groups was calculated at p < 0.5 (*), p < 0.01 (**) and p < 0.001 (***). 
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Table 5.3: Induction of cell cycle arrest on A549 cells by single and combined treatments. 
Samples Changes over untreated control (%) Designated cell cycle arrest 
 G0/G1 G2/M S Stage p-value Stage P-value 
 24h 48h 24h 48h 24h 48h 24h 48h 
           
δ-T3 +0.8 +17.8 +6.2 -2.2 -6.9 -15.5 G2/M - G0/G1 *** 
JA -48.8 -37.4 +54.9 +49.4 -5.8 -12.0 G2/M *** G2/M *** 
JB -47 -60.7 +55.4 +75.9 -8.6 -15.4 G2/M *** G2/M *** 
δ-T3+ JA -33.6 -28.0 +41.4 +41.2 -7.8 -13.2 G2/M *** G2/M *** 
The points of cell cycle arrest tested at 24h and 48h are shaded, statistically significant percentage of populations higher in treated comparing to 
untreated groups are set at P < 0.001 (***), P < 0.01(**), P < 0.05(*). 
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Fig 5.3:  a) Representative flow cytometric profiles of HT-29 cells treated with individual and combined low-dose treatments for 24 h and 
48 h. Histogram profiles of flow cytometric data for 24 h (b) and 48 h (c) based on three independent experiments. Significant difference 
for higher cell populations in treated compared to untreated groups was calculated at p < 0.5 (*), p < 0.01 (**) and p < 0.001 (***).  
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Table 5.4: Induction of cell cycle arrest on HT-29 cells by single and combined treatments. 
Samples Changes over untreated control (%) Designated cell cycle arrest 
 G0/G1 G2/M S Stage p-value Stage P-value 
 24h 48h 24h 48h 24h 48h 24h 48h 
           
δ-T3 +3.0 +5.3 -3.0 -1.0 +0.7 -4.3 G0/G1 - G0/G1 * 
JA -60.9 -40.2 +44.7 +70 -9.1 -4.5 G2/M *** G2/M *** 
JB -48.3 -55.7 +55.4 +66.6 -7.0 -10.9 G2/M *** G2/M *** 
δ-T3+ JA +1.7 -0.9 -3.3 -4.5 +1.6 +5.5 G0/G1 - S - 
δ-T3+ JB +1.0 +4.0 -0.02 -3.9 -0.8 0.0 G0/G1 - G0/G1 - 
The points of cell cycle arrest tested at 24 h and 48 h are shaded, statistically significant percentage of populations higher in treated comparing to 
untreated groups are set at P < 0.001 (***), P < 0.01(**), P < 0.05(*). 
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5.2.2. Observation of microtubules following single and combined treatments  
Following 72 h incubation, immunoflourescense staining showed disruption of alpha 
tubulin by IC50 doses of jerantinines (A and B) on U87MG cells (Fig. 5.4). Similar 
effects were also observed in U87MG cells treated with IC50 dose of control drug, 
vinblastine (Fig. 5.4). In contrast, treatment of U87MG cells with IC50 dose of delta or 
gamma tocotrienol did not cause disruption of microtubules as confirmed by the intact 
alpha tubulin structures with extended cytoplasm in Fig. 5.4. Furthermore, A549 and 
HT-29 cancer cells receiving treatment for 72 h with IC50 doses of jerantinines (A and 
B) and vinblastine caused considerable disruption of microtubules as confirmed by 
alpha tubulin structures in Fig. 5.5 and 5.6, respectively. In a similar trend to that 
observed in U87MG cells, IC50 doses of delta tocotrienol did not induce disruption of 
microtubules in A549 (Fig. 5.5) and HT-29 cells (Fig. 5.6) thereby exhibiting similar 
pattern of intact alpha tubulin compared to untreated controls.  
 
Interestingly, unlike single IC50 doses of delta or gamma tocotrienol, combined 
treatment of low- dose tocotrienols (delta and gamma) with IC20 doses of jerantinines 
(A and B) caused considerable disruption of microtubules in U87MG cells (Fig. 5.4). 
Similar trend was also evident in A549 and HT-29 cells receiving combined treatment 
of low-dose tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and B). 
This strongly indicates an improve potency of delta and gamma tocotrienols that 
results from its synergy with jerantinine A and B derivatives.  
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Fig 5.4: Immunofluorescence stained microtubules of U87MG cells reacted with monoclonal 
tubulin antibody. U87MG cells were treated with plain media containing DMSO (untreated 
control), IC50 dose of vinblastine (positive control) and single IC50 dose or combined 
treatment of low-dose tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and 
B) for 72 h. Vinblastine, jerantinines (A and B) and combined treatment of low-dose 
tocotrienols with IC20 doses of jerantinines (A and B) but not tocotrienols alone caused 
disruption of microtubules. Images were captured at 40X magnification under Nikon Ti 
eclipse confocal microscope (Nikon Japan).  
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Fig 5.5 Immunofluorescence stained microtubules of A549 cells reacted with monoclonal 
tubulin antibody. A549 cells were treated with plain media containing DMSO (untreated 
control), IC50 dose of vinblastine (positive control) and single IC50 dose or combined 
treatment of low-doses delta tocotrienol with IC20 doses of jerantinines (A and B) for 72 h. 
Vinblastine, jerantinines (A and B) and combined treatment of low-dose delta tocotrienol with 
jerantinines (A and B) but not delta tocotrienol alone caused disruption of microtubules. 
Images were captured at 40X magnification under Nikon Ti eclipse confocal microscope 
(Nikon, Japan). 
 
 
 
 
 
 
 
 
 
 
 
158 
 
 
159 
 
Fig 5.6 Immunofluorescence stained microtubules of HT-29 cells reacted with monoclonal 
tubulin antibody. HT-29 cells were treated with plain media containing DMSO (untreated 
control), IC50 dose of vinblastine (positive control) and single IC50 dose or combined 
treatment of low-dose delta tocotrienol with IC20 doses of jerantinines (A and B) for 72 h. 
Vinblastine, jerantinines (A and B) and combined treatment of low-dose delta tocotrienol with 
IC20 doses of jerantinines (A and B) but not delta tocotrienol alone caused disruption of 
microtubules. Images were captured at 40X magnification under Nikon Ti eclipse confocal 
microscope (Nikon, Japan).  
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5.2.3. Evaluation of the effects of individual and combined treatments on caspase 
enzyme activity and caspase independent cell death   
Following a kinetic study, the respective time points for peak activity of caspase 8, 9 
and 3 upon treatment of cells were determined (see appendix 2). Similarly, 1 µM of 
caspase specific inhibitors suppressed the basal level of caspase enzymes (see 
appendix 3a,b). Following 1 h individual treatment with IC50 dose of delta and gamma 
tocotrienols an increase in caspase 8 activities was evident on A549 (36.6%, P <0.05), 
U87MG (21.4% and 11.3%) and HT-29 (18.7%) cells (Fig. 5.7 a, d, g). Similar 
increased caspase 8 activities compared to untreated controls were also observed after 
9 h treatment with IC50 dose of jerantinine A (23.3%, 28.7% and 9.3%), jerantinine B 
(16.7%, 31.9% and 14.5%) and the respective combined low-dose treatments with 
delta or gamma tocotrienol on U87MG, A549 and HT-29 cells, respectively (Fig. 5.7 
b, e, h). In contrast, an upregulation of caspase 9 levels was only evident on A549 
cells after 24 h treatment with IC50 dose of delta tocotrienol (13.7%) but not on both 
HT-29 and U87MG cells treated with delta or gamma tocotrienol. Whereas, with the 
exception of HT-29 cells treated with jerantinine B, an increased caspase 9 activity 
was evident on U87MG (7.8%), A549 (12.1%) and HT-29 (5.2%) cells treated with 
single IC50 dose of jerantinine A and U87MG (1.6%) and A549 (12.0%) treated with 
single IC50 dose of jerantinine B (Fig. 5.7 b, e, h). Combined low-dose treatments of 
delta tocotrienol with IC20 dose of jerantinine B (14.5%), delta tocotrienol with IC20 
dose of jerantinine A (24.3%) and delta tocotrienol with IC20 dose of jerantinine A 
(5.5%) induced the highest increase of caspase 9 levels on U87MG, A549 and HT-29 
cells, respectively. Although such increased activity was at much lower level 
compared to caspase 8, nonetheless, this also demonstrates potential involvement of 
both initiator caspases in apoptosis. On the other hand, U87MG, A549 and HT-29 
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cancer cells receiving IC50 doses of delta or gamma tocotrienol, jerantinine A, 
jerantinine B and the combined low-dose treatments for 48 h induced an appreciable 
increase in caspase 3 activity (Fig. 5.7 g, h, i). In fact, significant increase compared 
to untreated controls was evident on U87MG (31.8%, P < 0.05) and HT-29 (20.4%, P 
<0.01) receiving combined treatment of low-dose delta tocotrienol with IC20 dose of 
jerantinine B. Similar significant increase of caspase 3 enzyme activity was also 
evident only on HT-29 cells receiving IC50 doses of delta tocotrienol (26.1%, P < 
0.001), jerantinine A (19.9%, P <0.01) and jerantinine B (19.8%, P < 0.01). 
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Fig 5.7: Induction of caspase 8, 9 and 3 enzymatic activities by individual IC50 dose and 
combined low-dose treatments of tocotrienols (delta and gamma) with IC20 doses of 
jerantinines (A and B) on U87MG (a, b, c), A549 (d, e, f) and HT-29 cells (g, h, i). A total of 
1 x 10
6 
cells were treated with respective treatments followed by protein extraction and 
subsequent determination of caspase activity. Results are presented as percentage increase of 
respective enzymatic activity over untreated control cells. P <0.001 (***), P <0.01 (**), P 
<0.05 (*) indicate significant increase of caspase enzyme activity for treated groups compared 
to untreated controls.  
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Fig 5.8: Cell viability profiles of U87MG (a, b, c), A549 (d, e, f) and HT-29 (g, h, i) cells 
treated with or without caspase specific inhibitors. A total of 5 x 10
3
cells were treated with 
respective treatments of individual IC50 dose or combined low-dose tocotrienols ( delta and 
gamma) with IC20 doses of jerantinines (A and B) with or without 1 µM of caspase 8 (Z-
IETD-FMK), caspase 9 (Z-LEHD-FMK) and caspase 3 (Z-DEVD-FMK) inhibitors for 72h and 
the cell viability was determined by neutral red uptake assay. Results are presented as mean ± 
SEM percentage of cell viability comparing to untreated controls conducted in triplicates 
from three independent experiments. Both individual IC50 doses and combined low-dose 
treatments of tocotrienols (delta and gamma) with IC20 doses of jerantinine (A and B) induce 
cell death independent of caspase activation in U87MG, A549 and HT-29 cells. Statistical 
significance between groups with or without inhibitors was calculated at P <0.001 (***), P 
<0.01 (**), P <0.05 (*).  
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The percentage viability of treated cells with or without 1 µM of individual caspase 8, 
9, 3 specific inhibitors for 72 h was determined using the neutral uptake assay. 
Caspase specific inhibitors at concentration of up to 10 µM induce cell death as 
instructed by kit manufacturer whereas, concentration of 1 µM was found to inhibit 
caspase activity without causing profound damage to murine mammary cancer cells 
(Shah et al., 2009). In light of this evidence, 1 µM of caspase inhibitors was used in 
study. In fact, a separate study demonstrated that it did not cause any profound 
damage to all cells with 80% and more cell viability (see appendix 3a). As shown in 
Fig. 5.8 (a, b, c), treatments of A549, U87MG and HT-29 cells with individual IC50 
doses of tocotrienols (delta and gamma), jerantinines (A and B) and the combined 
low-dose treatments of tocotrienols with IC20 doses of jerantinines (A and B) in the 
presence of 1 µM of caspase 8 inhibitor could not block cell death after 72 h 
incubation. Similar trend was also evident in all treated cell lines which were given 
with 1 µM of caspase 9 specific inhibitor (Fig 5.8 d, e, and f) and caspase 3 specific 
inhibitor (Fig. 5.8 g, h and i). In fact, the cell viability below 50% was evident on 
U87MG, A549 and HT-29 cells receiving individual and combined treatment of low-
dose tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and B) with or 
without caspase specific inhibitors. Nevertheless, statistical analysis revealed there 
was no significant difference between cell viability of treated groups without 
inhibitors and treated groups containing 1 µM of caspase 8, 9 and 3 specific 
inhibitors. 
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 5.3. Discussion  
Cell proliferation is essential for growth and development of organisms. However, 
uncontrolled cell growth due to defect in cell cycle checkpoints causes cancer. 
Considering its significant role in cancer, drugs targeting cell cycle progression have 
consonantly been developed. In fact, some of these drugs are administered to patients 
in combination for the purpose of maximizing potent effects on cancer cells as well as 
minimizing undesirable effect to normal cells (Diaz-Moralli et al., 2013). The results 
from Chapter Four revealed that both individual and combined low-dose treatments of 
tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and B) induced 
morphological changes and DSBs indicative of apoptosis. DSBs are triggers of cell 
cycle arrest that eventually stops the uncontrolled proliferation of cancer cells  thereby 
committing cells to apoptosis (Collins et al., 1997). It is therefore imperative to 
investigate the effects of both individual and combined low-dose treatments on cell 
growth. Evidently, IC50 doses of delta and gamma tocotrienols consistently triggered 
G0/G1 cell cycle arrest after 24 h and 48 h treatments on U87MG, A549 and HT-29 
cells. This is consistent with previous studies that reported the induction of G0/G1 
growth arrest by tocotrienols (Fernandes et al., 2010; Hodul et al., 2013; Lim et al., 
2014a, 2014b). Although a slight increase in G2/M population was observed in A549 
cells receiving IC50 dose of delta tocotrienol after 24 h, nonetheless this eventually 
resulted in significant (P <0.001) G0/G1 cell cycle arrest after 48 h treatment. In 
contrast, a more profound G2/M arrest (P <0.001) was consistently evident on 
U87MG, A549 and HT-29 cells treated for 24 h and 48 h with IC50 doses of 
jerantinines A and B conforming to the recently published studies (Qazzaz et al., 
2016; Raja et al., 2014). Antimicrotubule agents such as taxanes, paclitaxel etc have 
been shown to induce G2/M arrest (Bhalla, 2003; Perez, 2009), thus suggesting that 
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jerantinines A and B herein may target microtubule as a mechanism of apoptosis 
induction. Interestingly, only combined treatment of low-dose delta tocotrienol with 
IC20 dose of jerantinine A induced G2/M arrest (P<0.001) on A549 cells after 24 h 
and 48 h. Whereas, there was a time dependent shift in pattern of cell cycle arrest for 
the remainder of the combined low-dose treatments on U87MG and HT-29 cells. This 
includes a shift in increasing S population (24 h) to G0/G1 population (48 h) for 
combined treatment of low-dose tocotrienols (delta and gamma) with IC20 dose of 
jerantinine B on U87MG cells.  Similarly, there was a shift from G2/M to G0/G1 and 
G0/G1 to S after 24 h and 48 h for combined treatment of low-dose gamma 
tocotrienol with IC20 dose of jerantinine A on U87MG cells and combined treatments 
of low-dose delta tocotrienol with IC20 dose of jerantinine A on HT-29 cells, 
respectively. This is not surprising considering that these are sub-effective doses 
which may take longer time to induce a potent cell cycle arrest. Furthermore, this may 
be attributed to the different pattern of cell cycle arrests induced by individual doses 
of tocotrienols (delta and gamma) and jerantinines (A and B) which are 
predominantly arrested at G0/G1 and G2/M, respectively. On the other hand, based on 
the pattern of cell cycle arrests, the results herein suggest that combined low-dose 
treatments may not induce microtubule inhibition. Although, this may not be 
exclusive as considering that there was evidence of G2/M arrest on U87MG cells 
receiving combined treatment of low-dose gamma tocotrienol with IC20 dose of 
jerantinine A after 24 h. 
 
 Microtubules compose primarily of beta (β) and alpha (α) tubulin dimers which are 
the integral part of cytoskeleton. The vast roles of microtubules in cells include 
maintaining cell structure, cellular mobility, mitosis and cell signaling (Hawkins et 
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al., 2010). The important role of microtubules in cellular division has made them 
desirable targets for chemotherapeutic agents especially in rapidly growing cells. 
Subsequent research over the years has led to discovery and clinical use of 
microtubule inhibitors that are primarily classified into microtubule stabilizing and 
destabilizing agents. A few prominent examples of the stabilizing agents include the 
taxanes, paclitaxel whereas vinca alkaloids are exemplified of the destabilizing agents 
(Perez, 2009). Despite the limiting problems that include toxicity and multi drug 
resistance, microtubule interacting drugs have recorded a certain degree of success in 
cancer chemotherapy. This necessitates the development of more improved and robust 
alternatives. 
 
Previous preliminary study on synthetic derivative of jerantinine E revealed a 
disruption of microtubule network and inhibition of tubulin polymerization in A549 
cells as a possible mechanism of apoptotic induction  (Frei et al., 2013). Further 
mechanistic studies revealed that jerantinines A and B evoked G2/M growth arrest 
consistent with that of tubulin interacting drugs. Further evaluation revealed that 
disruption of tubulin dynamics would result in multipolar spindle and irregular 
chromosome segregation (Qazzaz et al., 2016; Raja et al., 2014). On the other hand, 
although tocotrienols evoked G0/G1 cell growth arrest, Lim et al.,(2014a) has 
suggested that inhibition of microtubules may be the possible mode of action based on 
the observed similarities with control drug, vinblastine on the pattern of DNA damage 
induced in A549 and U87MG cells. Considering that the data from this study is 
consistent with the evidence from the aforementioned studies, it was interesting to 
investigate the tubulin inhibitory effects of individual and combined low-dose 
treatment of tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and B). 
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As such, in this study, immunofluorescence technique was employed to achieve this 
objective.  
 
Indeed, results from immunofluorescence assay herein demonstrated disruption of 
microtubules by IC50 doses of jerantinines (A and B). In contrast, U87MG, A549 and 
HT-29 cells receiving IC50 dose of delta or gamma tocotrienol displayed intact alpha 
tubulin structures similar to that of untreated controls. Interestingly, owing to the 
original antimicrotubule effects of jerantinines A and B, the addition of IC20 dose of 
jerantinine A or B to either delta or gamma tocotrienol has caused considerable 
disruption of microtubules. This was also accompanied by cell shrinkage and 
decreased intensity of stained alpha tubulin compared to untreated controls which can 
be attributed to the loss of microtubule networks. On the other hand, although 
tocotrienols (delta and gamma) induced dissimilar effects, the results herein do not 
conclusively rule out the potential effects of tocotrienols towards microtubules. 
Nevertheless, this would represent an improved potency and efficacy of tocotrienols 
resulting from its synergy with jerantinines A and B thus adding a multidimensional 
approach that would include inhibition of microtubules in addition to the pre-
established mechanism of apoptotic induction by tocotrienols. This is surprising for 
combined low-dose treatments on U87MG and HT-29 cells that induced 
predominantly G0/G1 arrest. This observation was not consistent with G2/M arrest 
that is often attributed to most antimicrotubule agents. Therefore, it is possible that the 
low doses of tocotrienols (delta and gamma) are potent enough to induce profound 
G0/G1 arrest without significant number of U87MG and HT-29 cells to proceed to the 
G2/M phase. This potentially explains the antimicrotubule effects of the combined 
low-dose treatments despite the induction of G0/G1 growth arrest which indicates co-
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integrative synergistic interaction between combined treatments. On the other hand, 
the antimicrotubule effect of combined low-dose treatment of delta tocotrienol with 
IC20 dose of jerantinine A on A549 cells was accompanied by G2/M arrest. This 
suggests that in contrast to combined treatments on U87MG and HT-29 cells, the low-
dose tocotrienol was not potent enough to induce a profound G0/G1 arrest on A549 
cells.   
 
Furthermore, these results are contrary to the aforementioned proposition by Lim et 
al.,(2014b) that tocotrienols may also inhibit microtubules. This is not a surprise 
considering that tocotrienols inhibit cyclin D1 thereby inducing G0/G1 growth arrest 
in lung carcinoma (A549 and H1650) cells and glioblastoma (U87MG) cancer cells 
(Ji et al., 2012; Lim et al., 2014a, 2014b). Cyclin D1 is a regulator protein expressed 
in the G1/S phase transition  (Ji et al., 2012).  However,  this is not exclusive to only 
cyclin D1 as a few studies have also demonstrated that delta tocotrienol and its peroxy 
dimer from Kielmeyera coriacea induced G2/M growth arrest in HL-60 (leukaemia) 
cancer cells (de Mesquita et al., 2011). Similarly, delta tocotrienol down regulated 
retinoblastoma, cyclin D1, cyclin B1, cyclin dependent kinase 4 and 1 (CDK4 and 
CDK1) in MDA-MB-231 breast cancer cells. Although G2/M regulatory proteins 
were down regulated, inhibition of proliferation was marked by loss of cyclin D1 and 
G0/G1 growth arrest (Elangovan et al., 2008).  On the other hand, jerantinine A down 
regulated cyclin B1, the protein regulating the G2/M transition phase of the cell cycle 
(Raja et al., 2014). These aforementioned studies have shown that tocotrienols could 
potentially evoke G2/M arrest (depending on cellular microenvironment) consistent 
with microtubule interacting drugs, however to date, there are no reports suggesting 
tocotrienols as antimicrotubule agents. Undeniably, the low doses of delta and gamma 
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tocotrienols herein have potentiated the antimicrotubule effects of IC20 doses of 
jerantinines A and B. However, such potentiating effects of low-dose tocotrienols 
towards the antimictotubule effects of IC20 doses of jerantinines A and B are not 
reflected by the pattern of G0/G1 growth arrest. Alternatively, the effect could be 
potentiated via up regulation of p53. 
 
The presence of lower level of p53 protein present in healthy cells increases with 
phosphorylation upon induction of different types of cellular damage such as DNA 
damage and inhibition of microtubules. According to a previous study, jerantinine A 
caused an increased p53 level (Raja et al., 2014), thus, it is speculated that the 
antimicrotubule effect of jerantinine A, jerantinine B and the respective combined 
low-dose treatments with delta or gamma tocotrienol are mediated via up-regulation 
of p53. In contrast, although studies have illustrated the upregulation of p53 by 
gamma tocotrienol (Kannappan et al., 2010b), there are no reports on disruption of 
microtubule as the possible mechanism of action. The pattern of p53 phosphorylation 
in cells with disrupted microtubules is distinctively different from cells undergoing 
only cellular DNA damage. In fact, the pattern of p53 phosphorylation in cells treated 
with microtubule inhibiting compounds is varied by the types of cells and microtubule 
inhibitors (Perez, 2009). For instance, there was an increased phosphorylation of p53 
on serine-15 only in epithelial tumor cells but not fibroblasts cells treated with 
microtubule inhibitors (Stewart et al., 2001). Hence, p53 upregulation by tocotrienols 
may be in response to cellular DNA damage. Nonetheless, this study demonstrated the 
antimocrotubule effects of jerantinine A and jerantinine B that may involve 
upregulation of p53 which is further amplified when combined in lower dose with 
delta or gamma tocotrienol. 
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The disruption of microtubules as well as DNA damage and manifestation of 
morphological hallmarks of apoptosis indicate an induction of apoptotic cell death by 
both individual and combined low-dose treatments. Considering that microtubule 
targeting agents execute apoptosis predominantly via the mitochondria and also death 
receptors, it is therefore necessary to investigate the potential role of caspase 
enzymes. Apoptotic cell death is mediated through extrinsic and intrinsic pathways 
which may be dependent on activity of initiator and executioner caspases. In addition 
to evidence of caspase independent apoptosis, researches have illustrated the cross 
linkage of both pathways through the activities of executioner caspase. The extrinsic 
pathway is mediated by the tumor necrosis factor (TNF) receptor super family such as 
CD95 and TNF-related apoptosis inducing ligand (TRAIL). Upon induction by 
chemotherapeutic agents, activated receptors recruit adaptor molecules such as Fas-
associated death domain (FADD) which activates caspase 8 and subsequently caspase 
3 (Fulda and Debatin, 2006a). Alternatively, caspase 8 can also trigger the 
mitochondria pathway via truncation and subsequent activation of BH3 interacting 
domain agonist (BID) (Elmore, 2007). On the other hand, the mitochondria pathway 
is triggered upon disruption and permeabilization of the mitochondrial membrane by 
the proapoptotic B-cell lymphoma protein (Bcl) family proteins thereby releasing 
proteins including cytochrome C, second mitochondrial activator of caspase/direct 
inhibitor of apoptosis binding protein with low PI (Smac/Diablo), apoptosis inducing 
factor (AIF), High temperature requirement (HtrA2/Omi) and endonuclease G in the 
cytosol. These proteins activate caspase 9 to induce apoptosis or alternatively activate 
caspase independent cell death (Fulda et al., 2010). 
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Herein, increased caspase 8 and 3 activities were evident in U87MG, A549 and HT-
29 cells after 1h treatment with IC50 dose of delta or gamma tocotrienol (A549, 
U87MG, and HT-29). Indeed, previous studies on tocotrienols revealed the role of 
caspase enzymes for the induction of apoptosis. These studies showed that induction 
of apoptosis by alpha, beta, delta and gamma tocotrienols in human brain and lung 
cancer cells was mediated through upregulation of caspase 8 activities (Lim et al., 
2014a, 2014b). Similarly, gamma tocotrienol and tocotrienol rich fraction (TRF) 
increased intracellular activities of caspase 8 and 3 but not caspase 9 in murine 
mammary cancer cells (Shah et al., 2003). This is in agreement with the present study 
for caspase 8 and 3 activities. Dissimilarity on increased caspase 9 activity was 
evident in A549 cells treated with delta tocotrienol. Such contrasting evidence on 
caspase activation could be attributed to the response of different isomers to different 
cellular microenvironment. For example, gamma tocotrienol induced upregulation of 
caspase 8, 9 and 3 activities in human hepatoma Hep3B cells (Sakai et al., 2006). On 
the other hand, jerantinines A and B induced slight increase in caspase 9 activities in 
three cell lines (U87MG, A549, HT-29) and two cell lines (U87MG and A549), 
respectively. Owing to the ability of jerantinines (A and B) to induce caspase 9 
activity, the respective combined low-dose treatment of tocotrienols with IC20 doses 
of jerantinines (A and B) caused slight upregulation of caspase 9 (Fig. 4.1). This 
demonstrates an improved multidimensional mechanism of apoptosis induction for 
combined low-dose treatments as compared to individual IC50 doses of delta and 
gamma tocotrienols.  
 
Although caspase 8 has been linked to death receptor pathway, the mechanisms of 
action of tocotrienols elucidated from previous studies demonstrated the ambiguity for 
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both pathways that may be dependent on cellular microenvironment. For instance, 
gamma tocotrienol induced apoptosis via caspase 8 activation independent of the 
death receptor signaling pathway in +SA mammary tumor cells which are known to 
be resistant to death receptor induced apoptosis (Shah and Sylvester, 2004). Similarly, 
beta tocotrienol was reported to induce caspase 8 dependent apoptosis via 
mitochondria and death receptor pathways in lung and brain cancers (Lim et al., 
2014b). In contrast, gamma tocotrienol induced TRAIL receptor death receptor 
mediated apoptosis in human colon cancers. This was dependent on ROS, 
extracellular signal regulated kinase 1 (ERK-1), p53 and Bax as deletion of the genes 
or sequestering of ROS abolished the upregulation of death receptors (Kannappan et 
al., 2010b).  In light of the aforementioned evidence, it is possible that activation of 
caspase 8 and subsequently caspase 3 herein by delta and gamma tocotrienols is not 
exclusively mediated through the death receptor or mitochondria pathway. On the 
other hand, combined treatments of jerantinine A or B with delta or gamma 
tocotrienol on A549, U87MG or HT-29 cells demonstrated a similar trend of 
dominant caspase 8 and 3 activities. This is an addition to the increased caspase 9 
activities although at a much lower level compared to the former caspase enzymes. 
Undoubtedly, this demonstrates an improved activity compared to single high-dose 
tocotrienols that would involve both death receptor and mitochondria pathways. 
However, unlike tocotrienol, reports on the potential role of caspase enzymes in 
jerantinine derivatives induced apoptosis are limited. In fact, thus far, there are no 
studies on jerantinine B. The only recent mechanistic study showed that jerantinine A 
induced an increased intracellular activity of caspase 3 (Raja et al., 2014) by which 
the present study showed similar finding. The activation of caspase 8, 9 and 3 by 
jerantinines A and B as demonstrated in this study provides new information which 
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strongly indicates potential of both death receptor and mitochondria mediated 
pathways. The activation caspase 8 enzyme after 1h and 9h by tocotrienols (delta and 
gamma) and jerantinines (A and B), respectively was indicative of the fact that 
caspase mediated apoptosis occurred at an earlier stage in the former compared to the 
latter. Interestingly, unlike single IC50 doses of tocotrienols, the combined low-dose 
treatments with IC20 doses of jerantinines (A and B), activation of caspase 8 after 9h 
treatment represented a change in time required for the manifestation of apoptosis. 
This is not surprising and could be attributed to the fact that the lower dose of 
tocotrienols would take longer time to induce apoptosis compared to IC50 doses.   
 
Induction of both caspase dependent and independent cell death has been reported as 
a potential alternative to circumventing drug resistance and limitations of tocotrienol 
potency (Constantinou et al., 2008). Available literatures on the potential induction of 
caspase independent cell death by tocotrienols have been contradictory. For instance, 
treatment with 1µM of caspase 8 and 3 inhibitors blocked the induction of apoptosis 
by gamma-tocotrienol and tocotrienol rich fraction (TRF) in murine mammary cancer 
cells (Shah et al., 2009). Similarly, Takahashi and Loo, (2004) reported that gamma 
tocotrienol induced apoptosis in MDA-MB-231 breast cancer cells via disruption of 
mitochondria membrane, followed by cytochrome C release and subsequent 
manifestation of chromatin condensation and fragmentation. However, further 
mechanistic studies did not detect poly (ADP-ribose)-polymerase (PARP) cleavage or 
changes in expression Bax and BCL-2 proteins indicating that apoptosis was 
independent of caspase enzyme and also cytochrome C release was not crucial to the 
induction of apoptosis (Takahashi and Loo, 2004). In addition, gamma tocotrienol 
induced paraptosis like cell death in SW620 human colon cancer cells via suppression 
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of Wnt signalling pathway (Zhang et al., 2013). In some studies, the induction of both 
apoptotic and non-apoptotic cell death by tocotrienols were also observed. For 
instance, gamma tocotrienol induced apoptosis, necrosis and autophagy in human PC-
3 and LNCaP prostate cancer cells via intracellular upregulation of 
dihydrosphingosine and dihydroceramide (Jiang et al., 2012b). Similarly, both natural 
and synthetic homolog’s of vitamin E induced caspase dependent and independent 
DNA damage and dominant caspase independent programmed cell death in prostate 
cancer cells (Constantinou et al., 2012, 2009). Evidently, data from the present study 
showed a trend of induction of cell growth inhibition independent of caspase 8, 9 or 3 
activation by both individual and combined treatments of low-dose tocotrienols (delta 
and gamma) with IC20 doses of jerantinines (A and B) on A549, HT-29 and U87MG 
cells as there was no significant difference between cells treated with or without 
caspase specific inhibitors. This further corroborates the aforementioned literatures. 
These studies undoubtedly suggest the potential role of cellular environment in 
determining the induction and possibly control of apoptotic pathways. This suggestion 
is further supported by studies that gamma tocopherol induced caspase 9 activation in 
LNCaP prostate cancer cells (Jiang et al., 2004) but not colon cancer cells (HT-29, 
HCT-15, HCT-116 and, SW480) (Campbell et al., 2006). Alternatively, caspase 
independent cell death could be regulated by lysosomes as a study has demonstrated 
that cells deficient of lysomal cathepsin D were resistant to alpha tocopheryl succinate 
(Constantinou et al., 2008; Neuzil et al., 2002). 
 
Previous studies reported that microtubule targeting drugs such as paclitaxel and 
epothilone B induced caspase independent cell death in NSCLC cells via upregulation 
of cathepsin B (Bröker et al., 2004). Similarly, paclitaxel triggered AIF induced 
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caspase independent cell death in human ovrian carcinoma cells (Ahn et al., 2004). 
On the other hand, there are no available literatures on possible induction of caspase 
independent cell death by jerantinine A or B. The present study has demonstrated an 
induction of cell growth inhibition independent of caspase 8, 9 and 3 activation by 
jerantinine A or B and its combined low-dose treatment with delta and gamma 
tocotrienol on A549, U87MG and HT-29 cells. In addition, it further demonstrates 
that this mechanism of action is not cell specific thus providing new information on 
the mechanistic action of jerantinine derivatives.  
 
Mechanism of caspase independent apoptosis recruits an intricate action of genes that 
are dependent or independent of mitochondria. Pro-apoptotic proteins including AIF 
and endonuclease G released by mitochondria translocate to the nucleus causing 
nuclear chromatin condensation and DNA fragmentation as a latter event of apoptosis 
(Joza et al., 2001; Li et al., 2001). In addition, AIF and Endonuclease G have dual 
roles including the induction of caspase independent cell death (Elmore, 2007). As 
illustrated by previous studies, lysosomal cathepsin D also triggers caspase 
independent release of AIF in caspase 3
-/-
 and Apaf 1
-/-
 cells that are characterized by 
cell shrinkage and chromatin condensation. This was mediated through cathepsin D 
activation of Bax through conformational change. Subsequently Bax is relocated to 
outer mitochondria membrane in a Bid independent manner where it induces 
mitochondrial release of AIF for apoptosis induction (Bidère et al., 2003; Susin et al., 
2000). Furthermore, addition of broad caspase inhibitor z-VAD-FMK could neither 
block translocation of AIF from the mitochondria nor its subsequent apoptotic effect 
(Bröke et al., 2005). Although there are studies indicating induction of caspase 
independent cell death by tocotrienols, elucidation on the possible mechanism of 
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action is still lacking. It is noteworthy to say that the aforementioned action could be 
mediated via cathepsin D upregulation of Bax and subsequent release of AIF as 
demonstrated in T-lymphocytes (Bidère et al., 2003). 
 
5.4 Conclusion 
This study demonstrated the apoptotic potential of tocotrienols (delta and gamma) and 
jerantinines (A and B) on U87MG, A549 and HT-29 cells. Analysis of cell cycle data 
confirmed induction of G0/G1 arrests by individual IC50 doses of delta and gamma 
tocotrienols and combined low-dose treatments on U87MG and HT-29 cells. 
Whereas, jerantinines A and B induced G2/M cell cycle arrest on U87MG, A549 and 
HT-29 cells. This demonstrated that the pattern of cell cycle arrest (G2/M) induced by 
jerantinines A and B was related to the respective antimicrotubules effects in contrast 
to that of combined low-dose treatments even though induction of antimicrotubule 
effects by IC20 dose of jerantinines A and B was evident. The study demonstrated an 
improved potent effect of combined low-dose treatments via multi targeted approach 
that involves disruption of microtubules compared to individual doses of tocotrienols 
(delta and gamma) that could be mediated potentially via death receptor and 
mitochondria pathways. Further studies on death receptors and markers of 
mitochondria pathways would be conducted to further elucidate the mechanism of 
action. 
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6.0 CHAPTER SIX 
Alteration of apoptosis related genes expression in U87MG cells by individual 
and combined treatments of tocotrienols (delta and gamma) and jerantinines (A 
and B) 
 
6.1 Introduction 
Previous findings from Chapters Three and Four demonstrated an improved potency 
for combined treatments via synergistic interaction compared to individual tocotrienol 
treatments thus justifying the need to further elucidate the mechanism of action. 
Investigations from Chapter Five revealed that mechanism mediating the individual 
and combined low-dose treatments of tocotrienols (delta and gamma) and jerantinines 
(A and B) involved caspase dependent and independent apoptotic cell death. The 
activation of caspase enzymes suggested the possible involvement of mitochondria 
pathway and/or death receptor pathways. Furthermore,  disruption of microtubules 
was evidenced in cells treated with jerantinines (A and B) and the combined low-dose 
treatments with tocotrienols but not individual treatment of tocotrienols (delta and 
gamma) suggests an additional mechanism that involves possible recruitment of the 
p53 tumor suppressor gene which is attributed by DNA damage or inhibition of 
microtubules. The major pathways (extrinsic and intrinsic) of apoptosis are mediated 
through complex mechanisms that involve death receptors, caspase enzymes and pro- 
and anti- apoptosis related proteins (Norberg et al., 2010). Therefore, it is imperative 
to investigate the potential role of these proteins towards the execution of apoptosis 
by individual and combined low-dose treatments.  
 
Apoptosis antibody array is a rapid and accurate technique that allows detection and 
characterization of expression profiles of several apoptosis related proteins (Mai et al., 
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2014)  and therefore was employed herein to determine the potential of pro-apoptotic 
and anti-apoptotic proteins. The Human Apoptosis Antibody Array G-series (Ray 
Biotech, USA) used in this study utilizes the sandwich enzyme linked immunosorbent 
assay (ELISA) principle. This is based on the ability of sample proteins to bind to 
antibodies imprinted on histology slide after which, signals are developed with 
biotinylated detection antibodies and streptavidin-conjugated flour. Further Western 
blotting studies and ELISA were conducted to validate and confirm proteins (Bid, p53 
and cytochrome C) of interest. BID plays a key role in apoptosis induction by 
transferring apoptotic stimuli form death receptors into mitochondria. This activates 
the mitochondria pathway via disruption of mitochondrial membrane potential and 
subsequent release of apoptosis related proteins including cytochrome C. On the other 
hand, p53 activation is triggered in response to DNA damage, microtubule disruption 
and also plays key roles in cell cycle arrest and mediating mitochondria pathway for 
apoptosis (Vazquez et al., 2008). The Western blotting technique is based on the 
principle of antigen-antibody reaction that is detected though chromogenic substrates 
or chemiluminiscence. Whereas, Human cytochrome C ELISA kit (R&D Systems, 
USA) was used to investigate the cytochrome C release as a marker for the 
confirmation of mitochondria pathway for mediation of apoptosis. This technique is 
based on the solid phase sandwich ELISA that allows for quantification of cellular 
cytochrome C levels.    
 
U87MG brain cancer cells thus far are the least studied in terms of cytotoxic activity 
of tocotrienols in comparison to A549 and HT-29 cells. In fact, there are no reported 
studies on the cytotoxic effect of jerantinine derivatives on U87MG cells. In addition, 
unlike A549 and HT-29 cells, three different combinations of tocotrienols (delta and 
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gamma) with jerantinines (A and B) herein induced synergistic effects with only mild 
toxicity towards MRC5 cells. Furthermore, reports have shown that tocotrienols can 
penetrate the blood brain barrier. Therefore, U87MG cells were selected for further 
mechanistic studies considering the aforementioned reasons in addition to the fact that 
brain cancer has poor prognosis and high incidence rate in children.  
The specific objectives of the study are: 
a) To determine the roles of both pro- and anti-apoptotic proteins found in 
U87MG cells receiving individual and combined treatments  
b) To determine the role of cytochrome C as a marker for mitochondria mediated 
apoptotic pathway 
c) To propose the potential apoptotic mechanisms of action for individual and 
combined low-dose treatments 
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6.2 Materials and Methods 
6.2.1 Chemical reagent/kits and cell cultureware 
The following reagents and kits listed in Table 6.1 were used to conducts the 
experiments.  
Table 6.1: List of chemical reagents, kits and glassware and the respective 
manufacturers. 
s/no Chemical reagents/kits Manufacturer  
1 Human Apoptosis Antibody Array G-series 
(AAH- APO-G1-8) 
Ray Biotech, USA 
2 BCA protein assay Kit Fisher Scientific, USA 
3 Quantikine Human cytochrome C ELISA kit R&D Systems, USA 
4 Bovine serum albumin (BSA) Sigma, USA 
5 p53 (DO-1: SC-126) mouse monoclonal 
antibody, BID (B-3: SC-373-939) mouse 
monoclonal antibody 
Santa Cruz Biotechnology 
INC, USA 
6 Pierce rabbit anti mouse (PB 186444) secondary 
horse radish peroxidise (HRP) linked antibody, 
Spectra multicolour protein ladder 
Thermo Scientific, USA 
7 Tris-base Promega, USA 
8 Glycine, 30% acrylamide,  Ammonium 
perisulphate, Tris-CL 
Biorad USA 
9 Methanol Merck, Germany 
10 3,3’,5,5’-Tetramethylbenzidine (TMB) 
peroxidase substrate 
KPL, USA 
11 Tetramethylethylenediamine (Nacalai Tesque, 
Japan), Sodium dodecyl sulphate 
Sigma, USA 
12 0.45 micron nitrocellulose membrane Thermo Scientific, USA 
13 90mm cell culture petri dish SPL Life sciences, Korea 
14 Tween 20 Nacalai Tesque, Japan 
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6.2.2 Apoptosis array 
U87MG cells were seeded at a density of 1 x 10
6
 and treated with individual or 
combined treatments of tocotrienols (delta and gamma) and jerantinines (A and B) as 
previously described in Table 4.2. Cells treated with plain media containing DMSO to 
serve as untreated control. Following 72 h treatment, the cells were detached using 
trypsin and centrifuged at 2200 rpm for 5 min. The cell pellets were suspended in pre-
chilled PBS and centrifuged for 5min at 2200 rpm to remove any trace of trypsin. 
Thereafter, the cell pellets were re-suspended in 1x lysis buffer supplemented with 1x 
protease cocktail inhibitor supplied by Raybiotech, USA and incubated on ice for 10 
min. The cell suspension was centrifuged at 10,000 rpm for 1 min and the supernatant 
protein lysate was collected. The protein concentration was determined using the 
Graphpad Prism 6 from a standard curve prepared using the BCA protein assay kit 
(see appendix 4). The protein lysate was stored at -80
o
C until analysis.  
For apoptosis array, the glass chip chamber was assembled and allowed to air dry for 
60 min followed by 30 min incubation with 100 µl of 1x blocking buffer. Thereafter, 
600 µg of protein lysate was loaded in each well followed by overnight incubation at 
4
o
C. The sample was decanted and the chambers were then washed with gentle 
shaking for5 times, each for 2 min and then 2 times for 2 min each with 150 µl of 1x 
wash buffer I and II, respectively. Seventy microliter of biotin conjugated antibodies 
was added to each well and incubated for 2 h at room temperature. Seventy microliter 
of 1500 fold diluted Hilyte plus conjugated streptavidin was added to each subarray 
followed by 2 h incubation in the dark. Each subarray was washed twice for 2 min 
with 1x wash buffer I at room temperature. The slide was disassembled, immersed 
into 50 ml tube filled with wash buffer I (twice) and II (once) and rinsed with gentle 
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shaking for 10 min. Finally, the slide was completely air dried and signals were 
scanned using compatible laser scanner at Raybiotec Inc, USA. 
 
6.2.3 Western blotting analysis  
U87MG cells were seeded in 90 mm dish and incubated in cell culture conditions. 
Upon confluency, the cells were treated with individual IC50 doses or combined low-
dose treatments of tocotrienols (delta and gamma) with IC20 doses of jerantinines (A 
and B) as shown in Table 4.2 for 24 h. After treatments, cells were detached and a 
total of 4 x 10
6
 U87MG cells were suspended in pre-chilled PBS and centrifuged at 
2200 rpm for 5 min (twice) to pellet cells and remove traces of media and trypsin. The 
pellets were then suspended in 200 µL of 1x laemmli sample buffer followed by 
gentle vortexing and sonication. Following the lysis step, the cell samples were 
incubated on ice for 20 min. The mixture was centrifuged 10000 rpm for 1min and the 
supernatant was collected and stored at -80
o
C until analysis. For Sodium dodecyl-
sulphate poly acrylamide gel electrophoresis, 12% gradient gel (for recipe, see 
Appendix 6) was prepared. The samples were heated at 99
o
C for 5 min and 20 µL was 
then loaded into each well. The gel was run at 150V for 60 min in 1x 
Tris/glycine/SDS running buffer (for recipe see, Appendix 6). Thereafter, the protein 
bands were transferred in wet condition to 0.45 µM nitrocellulose membrane using 
the X-Cell II blot module (Invitrogen, USA). The transfer was run for 80 min at 25V 
using 1x Towbin transfer buffer (for recipe, see Appendix 3). After completion of 
transfer, the membrane was blocked in 3% BSA in 1x Tris-buffered saline with tween 
20 (TBST) (for recipe, see Appendix 6) for 60 min followed by separate overnight 
incubation with diluted primary antibodies (anti- glyceraldehyde -3-phosphate 
dehydrogenase (GAPDH) at 1:3000), (anti-BID at 1:1000), (anti-p53 at 1:1000). The 
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antibody was discarded and the membrane was washed with three changes of TBST 
for 5 min each. The membrane was then incubated for 2 h with rabbit anti-mouse 
HRP linked secondary antibody diluted to ratio 1:5000 in TBST. Finally, the 
membrane was washed with four changes of TBST for 5 min each followed by TMB 
substrate wash until bands were visible. The membrane was washed with distilled 
water, air dried and images were subsequently captured using GS-800 calibrated 
densitometer (Bio-Rad, USA).  
 
6.2.4 Enzyme-linked immuno sorbent assay (ELISA) for cytochrome C detection  
U87MG cells were seeded into different treatment groups in 90 mm cell culture dish 
and incubated for 24 h to facilitate attachment. Thereafter, the cells were treated with 
single IC50 doses or combined low-dose treatment of tocotrienols (delta and gamma) 
with IC20 doses of jerantinines (A and B) as stated in Table 4.2. U87MG cells that 
received plain media containing DMSO served as an untreated control. A total of 1.5 
x 10
6
 cells were pelleted after 24 h treatment and washed three times with cold PBS. 
The cells, were suspended in 1ml of cell lysis buffer 2 provided by manufacturer 
(R&D Systems, USA) and incubated at room temperature for 1 h with gentle shaking. 
The cells were centrifuged at 1000 x g for 15 min and a 10-fold dilution of the 
supernatant in 200 µL of calibrator diluent was prepared and stored in -80
o
C until use. 
Prior to analysis, all reagents and working standards were prepared according to 
manufacturer’s instruction. Calibrator diluents (100 µl) (R&D Systems, USA) diluted 
at 1: 10 in distilled water was added into each well. For generation of calibration 
curves to quantify cytochrome C, 100 µL of human cytochrome C standards prepared 
at a serial dilution (0, 0.625, 1.25, 2.5, 5, 10 and 20 ng/ml) were added to each well of 
the 96-well plate pre-coated with monoclonal antibody raised against cytochrome C. 
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For treated U87MG cells, a standard curve was prepared using Pierce BCA protein 
assay kit (Thermo Fisher Scientific, USA) and the protein content of samples was 
quantified by interpolation using the Graphpad Prism 6. Then, 100 µL of treated and 
untreated control samples were added to pre-coated wells containing 100 µL of 
calibrator diluent followed by 2 h incubation at room temperature. Each well was then 
aspirated and washed four times with 400 µL of wash buffer and the plate was 
inverted and blotted against a paper towel to completely remove any liquid. Two 
hundred microliter of human cytochrome C conjugate was added to each well and 
incubated for 2 h at room temperature. The wells were aspirated and washed four 
times with wash buffer and 200 µL substrate solution was added in to each well and 
incubated for 30 min at room temperature protected from light. Finally, 50 µL of stop 
solution was added and the optical density was determined using Epoch microplate 
spectrophotometer (Biotek, USA) at wavelength of 450 nm. 
 
6.2.5: Statistical analysis 
One way analysis of variance using the Dunnet’s t-test was used to compare the 
differences in expression levels between the treated and untreated controls for all 
three assays. P <0.001 (***), P <0.01 (**), P <0.05 (*) were indicated as significant 
difference.   
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6.3 Results  
 
6.3.1 Assessment of apoptosis related gene expression levels altered by individual 
and combined treatments on U87MG cells via apoptosis array 
Following the scanning of signals, the data obtained was analysed using the Ray 
biotech analysis tool and results were presented as mean ± SD fold change over 
untreated U87MG cells from two replicates. Following 72 h treatment with IC50 dose 
of delta tocotrienol, there was a slight upregulation of pro-apoptotic proteins, Bax, 
Bid, Bim, p27 and death receptors, TRAIL-R (1 and 2). This is contrary to the evident 
downregulation of bad, p53 and in fact over 2-folds downregulation of FAS death 
receptor. This indicates that delta tocotrienol induced apoptosis was not mediated 
through FAS death receptor. As shown in Fig 6.1, there was a general downregulation 
of anti-apoptotic proteins including Bcl-2, XIAP, cIAP-2. Surprisingly, there was an 
upregulation of the anti-apoptotic protein, survivin and in fact over 2-folds 
upregulation of livin. On the other hand, as shown in Fig. 6.2, U87MG cells treated 
with IC50 dose of gamma tocotrienol showed an upregulation of pro-apoptotic 
including Bad, Bax, Bid and death receptors, TRAILR-1 and TRAILR-2. The 
upregulation was however below 2 folds comparing to untreated controls. In a similar 
trend to that of U87MG cells treated with delta tocotrienol, there was below 2 folds 
downregulation of some pro-apoptotic proteins including FAS, p53, Bim and 
cytochrome C. In contrast to delta tocotrienol U87MG cells, there was evidence of a 
slight upregulation of most anti-apoptotic including Bcl-2, Bcl-2 and cIAP-2. Similar 
up regulations were also evident on livin and survivin in contrast to over 2-folds 
downregulation of XIAP. The results demonstrated similar expression profiles of pro-
apoptotic and anti-apoptotic proteins on U87MG cells treated with IC50 doses of delta 
and gamma tocotrienols after 72 h. 
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Fig 6.1: Protein expression profiles of U87MG cells receiving individual IC50 dose of delta 
tocotrienol for 72 h. Protein was extracted from 1 x 10
6
 U87MG cells and the expression 
levels of pro- and anti-apoptotic proteins were determined using apoptosis array analysis. 
Results are reflected by the fold change of treated over the untreated control cells from two 
repeats. P <0.001 (***), P <0.01 (**) and P <0.05 (*) indicate significant difference between 
treated and untreated groups.  
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Fig 6.2: Protein expression profiles of U87MG cells receiving individual IC50 dose of gamma 
tocotrienol for 72 h. Protein was extracted from 1 x 10
6
 U87MG cells and the expression 
levels of pro- and anti-apoptotic proteins were determined using apoptosis array analysis. 
Results are reflected by the fold change of treated over the untreated control cells from two 
repeats. P <0.001 (***), P <0.01 (**) and P <0.05 (*) indicate significant difference between 
treated and untreated groups.  
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U87MG cells treated with IC50 dose of jerantinine A showed marked increase on the 
pro- apoptotic proteins including Bid, p27, Bad and cytochrome C. In fact, unlike 
U87MG cells treated with IC50 doses of tocotrienols (delta and gamma), there was 
over 1.5-fold and 2 folds upregulation of Bim and p53, respectively as shown in Fig. 
6.3. Similarly, there was also over 1.4-fold upregulation level of FAS death receptor. 
But, unlike tocotrienols (delta and gamma), jerantinine A induced an upregulation of 
only TRAILR-1 death receptor. However, similar upregulation that was below 2 folds 
change of anti-apoptotic proteins including Bcl-2, Bcl-w, cIAP-2 were evident. In 
fact, there was over 2-fold upregulation level of survivin.  
 
U87MG cells receiving IC50 dose of jerantinine B demonstrated an upregulation of 
over 1.1-fold change for pro-apoptotic proteins including Bad, Bax, Bid, Bim, and 
p53 amongst others. There was also an upregulation of death receptors, FAS and 
TRAILR-1 although TRAILR-2 was down regulated. This is similar to the expression 
profiles of death receptors of U87MG cells receiving IC50 dose of jerantinine A (Table 
6.2). In comparison to jerantinine A, U87MG cells receiving IC50 dose of jerantinine 
B also demonstrated greater expression profiles of Bad and Bax proteins with up to 
1.1-fold increase compared to the 0.12-fold evident in the former. Except for XIAP, 
there was a general upregulation of anti-apoptotic proteins including Bcl-2, Bcl-w, 
cIAP-2 and livin. In fact, there was over 2-folds upregulation level of survivin.  
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Fig 6.3: Protein expression profiles of U87MG cells receiving individual IC50 dose of 
jerantinine A for 72 h. Protein was extracted from 1 x 10
6
 U87MG cells and the expression 
levels of pro- and anti-apoptotic proteins were determined using apoptosis array analysis. 
Results are reflected by the fold change of treated over the untreated control cells from two 
repeats. P <0.001 (***), P <0.01 (**) and P <0.05 (*) indicate significant difference between 
treated and untreated groups.  
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Fig 6.4: Protein expression profiles of U87MG cells receiving individual IC50 dose of 
jerantinine B for 72 h. Protein was extracted from 1 x 10
6
 U87MG cells and the expression 
levels of pro- and anti-apoptotic proteins were determined using apoptosis array analysis. 
Results are reflected by the fold change of treated over the untreated control cells from two 
repeats. P <0.001 (***), P <0.01 (**) and P <0.05 (*) indicate significant difference between 
treated and untreated groups.  
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Combined treatment of low doses demonstrated an improved potency by causing 
upregulation of pro-apoptotic protein of both death receptor and mitochondria 
pathway. The combined treatment of low-dose delta tocotrienol with IC20 dose 
jerantinine B induced upregulation of BH3 proteins (Bax, Bid, Bim and Bad), FAS, 
p27, p53 and TRAIL-R (1 and 2) (Fig 6.5). This is similar to the expression profiles 
on U87MG cells receiving combined low–dose treatment of gamma tocotrienol with 
jerantinine B. This is contrary to the observation of downregulation of p53, FAS, Bad 
in U87MG cells treated with individual dose of delta tocotrienol. In addition, there 
was an overall increase in expression of pro-apoptotic proteins for up to 1.9-fold 
compared to 1.1-fold observed for U87MG cells treated with individual dose of delta 
tocotrienol. As shown in Table 6.3 there was an upregulation (< 2-fold) of anti-
apoptotic proteins except for XIAP which had been down regulated (1.2-fold) on 
U87MG cells treated with combined low-dose delta tocotrienol with IC20 dose of 
jerantinine B. This is similar to the expression profile observed in U87MG cells 
treated with IC50 dose of jerantinine B although the expression of survivin was below 
2-fold change.  As shown in Fig. 6.6, combined low-dose treatment of gamma 
tocotrienol with IC20 dose of jerantinine A caused a general up regulation of pro-
apoptotic proteins including cytochrome C, p27, Bad, Bax. In fact, there was over 3-
fold upregulation of p53. Similar upregulation of death receptors, FAS and TRAIL-
R1 was also evident. However, there was a downregulation of Bid (0.01-fold) and 
TRAIL-R2 (0.3-fold) (Fig. 6.6). On the other hand, there was a general upregulation 
of anti-apoptotic proteins including XIAP and with over 2 fold increase evident for 
survivin. In comparison to individual IC50 dose of gamma tocotrienol, the combined 
low-dose treatment caused improved expression of pro-apoptotic proteins especially 
p53 (3.7-fold), FAS (1.4-fold), cytochrome C (1.9-fold) and p27 (1.5-fold). Similarly, 
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the combined low-dose treatment also caused improved p53 expression (3.7-fold) as 
compared to the p53 (2-fold) level observed in U87MG cells treated with individual 
IC50 dose of jerantinine A (Fig 6.3). However, in contrast to individual doses of 
gamma tocotrienol and jerantinine A, the combined low-dose treatment did not cause 
the downregulation of XIAP. 
 
Similarly, combined low-dose treatment of gamma tocotrienol with IC20 dose of 
jerantinine B caused upregulation of p53 although this was below 2-fold increase in 
comparison to combined treatments with jerantinine A (Fig. 6.7). Nonetheless, there 
was an improved upregulation of Bad, Bim, Bax, Bid, FAS, TRAIL R-1, and TRAIL 
R-2. In fact, this also demonstrated improved expression of proteins particularly p53 
(1.6-fold), FAS (0.4-fold), p27 (1.3-fold) and BIM (1.2-fold) comparing to individual 
dose of gamma tocotrienol (Table 6.2). There was a similar upregulation profile of 
anti-apoptotic proteins except for XIAP in comparison to individual dose of gamma 
tocotrienol. Whereas, unlike the individual dose of jerantinine B, the upregulation of 
survivin induced by the combined treatment of low-dose gamma tocotrienol with 
jerantinine B was below 2-fold change.   
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Fig 6.5: Protein expression profiles of U87MG cells receiving combined low-dose treatment 
of delta tocotrienol with IC20 dose of jerantinine B for 72 h. Protein was extracted from 1 x 
10
6
 U87MG cells and the expression levels of pro- and anti-apoptotic proteins were 
determined using apoptosis array analysis. Results are reflected by the fold change of treated 
over the untreated control cells from two repeats. P <0.001 (***), P <0.01 (**) and P <0.05 
(*) indicate significant difference between treated and untreated groups.  
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Fig 6.6: Protein expression profiles of U87MG cells receiving combined low-dose treatment 
of gamma tocotrienol with IC20 dose of jerantinine A for 72 h. Protein was extracted from 1 x 
10
6
 U87MG cells and the expression levels of pro- and anti-apoptotic proteins were 
determined using apoptosis array analysis. Results are reflected by the fold change of treated 
over the untreated control cells from two repeats. P <0.001 (***), P <0.01 (**) and P <0.05 
(*) indicate significant difference between treated and untreated groups.  
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Fig 6.7: Protein expression profiles of U87MG cells receiving combined low-dose treatment 
of gamma tocotrienol with IC20 dose of jerantinine B for 72 h. Protein was extracted from 1 x 
10
6
 U87MG cells and the expression levels of pro- and anti-apoptotic proteins were 
determined using apoptosis array analysis. Results are reflected by the fold change of treated 
over the untreated control cells from two repeats. P <0.001 (***), P <0.01 (**) and P <0.05 
(*) indicate significant difference between treated and untreated groups.  
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Table 6.2: Summary of fold change in expression profiles of pro-apoptotic proteins in 
U87MG cells  
Treatments Fold change over untreated control 
 Bad Bax Bid Bim Cyto 
C 
Fas p27 p53 TRAIL-
R1 
TRAIL-
R2 
δ-T3 -1.1 +0.02 +1.1 +0.01 +0.04 -2.3 +1.1 -1.8 +0.17 +1.1 
γ-T3 +0.1 +1.1 +1.1 -1.1 -0.1 -1.9 0.00 -1.9 +0.03 +1.3 
JA +0.01 +0.1 +1.4 +1.6 +0.3 +1.4 +1.2 +2.0 +0.2 -1.3 
JB +1.1 +1.1 +1.0 +0.1 -0.06 +1.2 +1.3 +1.3 +0.1 -1.0 
δ-T3+JB +1.3 +1.4 +1.9 +1.8 +1.3 +1.1 +1.4 +1.3 +0.1 +1.0 
γ-T3+JA +0.01 +1.1 -0.01 +1.1 +1.9 +1.4 +1.5 +3.7 +1.3 -0.3 
γ-T3+JB +1.1 +1.2 +1.1 +1.2 -1.1 +0.4 +1.3 +1.6 +0.1 +1.2 
(-) and (+) indicate down and upregulations of proteins compared to untreated controls. Proteins with 
2-fold and above changes in expression are bolded and shaded. 
 
 
Table 6.3: Summary of fold change in expression profiles of anti-apoptotic proteins in 
U87MG cells 
Treatments Fold change over untreated control 
 Bcl-2 Bcl-w cIAP-2 Livin Survivin XIAP 
δ-T3 -0.5 -1.3 -1.3 +4.2 +1.9 -1.2 
γ-T3 +1.1 0.0 +1.0 +0.15 +1.1 -2.2 
JA +1.3 +1.2 +1.2 +1.2 +2.5 -1.5 
JB +1.1 +1.1 +0.02 +0.2 +2.4 -1.3 
δ-T3+JB +1.4 +1.5 +1.1 +1.5 +1.4 -1.2 
γ-T3+JA +0.01 +0.04 +1.9 +1.4 +2.2 +1.3 
γ-T3+JB +1.2 +1.1 +0.01 +1.2 +1.9 -1.1 
(-) and (+) indicate down and upregulations of proteins compared to untreated controls. Proteins with 
2-fold and above changes in expression are bolded and shaded. 
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6.3.2 Western detection of Bid and p53 levels altered by individual and combined 
treatment on U87MG cells  
 
Western blotting analysis of U87MG cells following 24 h treatment with individual or 
combined low-dose treatments corroborated data  obtained from apoptosis array on 
the activation of BID by individual IC50 doses and combined low-dose tocotrienols 
(delta and gamma) with IC20 doses of jerantinines (A and B) (Fig 6.8, 6.9). Similarly, 
an upregulation of p53 was only evident in jerantinines (A and B) and combined low-
dose treatments with tocotrienols (delta and gamma) but not individual IC50 doses of 
tocotrienols (Fig. 6.8, 6.9). 
 
 
Fig 6.8: Western blotting profiles of Bid and p53 expression detected in protein lysate of 
U87MG cells treated with individual IC50 doses or combined low-dose treatments of 
tocotrienols (delta and gamma) with IC20 doses of jerantinine (A and B) for 24 h. Bid and p53 
proteins with molecular sizes of 22kDA and 53kDA, respectively are detected. GAPDH is 
served as a loading control for the assay. 
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Fig. 6.9: Relative density profiles quantitated from the western protein bands (Fig. 6.8) of a) 
Bid and b) p53 obtained from U87MG cells receiving individual and combined treatments. 
Results are represented as mean ± SD from two repeats. Statistical analysis was conducted 
using one way ANOVA (Dunnet’s t-test) and statistical significance between treated and 
untreated was set at P <0.05. 
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6.3.3 Evaluation of cytochrome C level altered by individual and combined 
treatments on U87MG cells via ELISA       
Following 24 h treatments with individual IC50 doses of tocotrienols (delta and 
gamma), jerantinines (A and B) and the respective combined low-dose treatments of 
tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and B), the 
cytochrome C levels were determined as a marker for apoptosis via ELISA. Results 
showed that individual IC50 doses of tocotrienols (delta and gamma) and jerantinines 
(A and B) augmented cytochrome C levels compared to untreated controls (Fig. 6.10). 
Similarly, combined low-dose treatments of gamma tocotrienol with IC20 doses of 
jerantinines (A and B) and delta tocotrienol with IC20 dose of jerantinine B also 
induced increased cytochrome C levels at the same multitude to that of individual 
doses as compared to untreated controls (Fig. 6.10) 
 
Fig. 6.10: Cytochrome C levels of U87MG cells receiving individual and combined 
treatments. A total of 1.5 x 10
6
 cells were treated with individual IC50 doses and combined 
treatments of low-dose tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and 
B). Cells receiving plain media with DMSO served as untreated control. The cytochrome C 
levels were quantified and results are presented as mean ± SD from three repeats. Statistical 
analysis was conducted using one way ANOVA (Dunnet’s t-test) and statistical significance 
between treated and untreated was set at P <0.05 
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6.3. Discussion  
Apoptosis is a programmed cell death characterized by striking balance of activities 
between pro- and anti-apoptotic proteins which can be dependent and independent of 
caspase enzyme activity. The timely activation of apoptotic proteins that results in 
regulation of signaling pathways is mediated via best understood pathways of death 
receptor (extrinsic) and mitochondria (intrinsic). Tocotrienols have been shown to 
induce apoptosis in cancer cells via death receptor or mitochondria pathway 
depending on the nature of cellular microenvironment (Ling et al., 2012; Sun et al., 
2009). In fact, recent studies demonstrated that tocotrienols caused upregulation of 
caspase 8, Bid and cytochrome C suggesting potential activation of both death 
receptor and mitochondria mediated pathways (Lim et al., 2014a, 2014b). Indeed, 
results from Chapter Five in the present study have demonstrated the activation of 
predominantly caspase 8 and 3 enzymes by delta and gamma tocotrienols. 
Furthermore, it demonstrated the potential of cell death independent of activation of 
caspase enzymes. As such, it was therefore necessary to elucidate the mechanism of 
action for delta and gamma tocotrienols herein to confirm the potential involvement 
of death receptor or mitochondria pathway.  
 
Apoptosis induced via the death receptor pathway involves interaction between death 
domain and respective ligands for death receptors of the tumor necrosis factor (TNF) 
family resulting in recruitment of adaptor proteins and subsequent transmitting of 
death signals from cell surface to intracellular signaling pathways. The adaptor 
proteins (TRADD and FADD) activate caspase 8 to mediate apoptosis via subsequent 
activation of caspase 3 or alternative release of mitochondria related proteins via 
truncation of Bid to tBid (Elmore, 2007). Herein, there were upregulations of 
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TRAILR-1 and TRAILR-2 thus indicating that activation of caspase 8 by delta 
tocotrienol was mediated via death receptor. On a similar note, gamma tocotrienol 
induced upregulation of TRAILR-2 indicating that caspase 8 is activated via death 
receptor and subsequent recruitment of adapter proteins such as TRADD. 
Tocotrienols induction of caspase 8 mediated apoptosis can be dependent or 
independent of death receptors depending on the type of isomer as well as cell lines 
studied. For instance, previous study had shown that gamma tocotrienol promoted 
TRAIL induced apoptosis in prostate cancer cells (Kannappan et al., 2010a) in 
contrast to gamma  tocotrienol induced upregulation of caspase 8 independent of 
death receptors in neoplastic mammary epithelial cells (Shah and Sylvester, 2004). 
The balance between pro- and anti-apoptotic Bcl2 family proteins determines the fate 
of cells undergoing apoptosis. As shown in Fig 6.1 and 6.2, there were general 
downregulation of anti-apoptotic proteins in U87MG cells receiving delta tocotrienol, 
whereas, slight but non-significant upregulation of anti-apoptotic proteins were 
evident in cells receiving gamma tocotrienol. Nonetheless, the balances between the 
pro- and anti-apoptotic proteins committed the U87MG cells to death. Results from 
the apoptosis array showed down regulation of cytochrome C in cells treated with 
gamma tocotrienol after 72 h, whereas, there was slight increase in cells treated with 
delta tocotrienol. However, this did not rule out the involvement of cytochrome C 
towards apoptosis execution by both delta and gamma tocotrienols as ELISA study 
showed cytochrome C levels peak after 24h (Fig 6.10). Similar trend was also evident 
in study for Bid activity as demonstrated by Western blotting data shown in Fig. 6.8. 
Undoubtedly, the induction of caspase 8 enzyme activity by both delta and gamma 
tocotrienols triggered Bid subsequently activating the mitochondria pathway and 
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cytochrome C release. These results confirmed that both delta and gamma tocotrienols 
triggered the death receptor and mitochondria pathways in U87MG cells.  
 
On the other hand, there was a marked increase in expression levels of death receptor 
protein FAS in U87MG cells after 72 h treatment with IC50 dose of jerantinine A or 
jerantinine B. Although in contrast to delta tocotrienol there was a slight upregulation 
of TRAILR-1 only for both jerantinines A and B. The activation of caspase enzymes 
by jerantinines A and B as shown in Chapter Five suggested the potential role of both 
death receptor and mitochondria pathways. Undoubtedly the activation of FAS and 
TRAILR-1 death receptors herein by both jerantinines A and B which subsequently 
resulted in activation of BID and cytochrome C release confirmed the activation of 
both pathways in mediation of apoptosis (Ozören and El-Deiry, 2003). Although there 
are a few mechanistic studies on the mechanism of action of jerantinines A and B  
(Qazzaz et al., 2016; Raja et al., 2014), to date, there are no reports on the potential 
role of death receptors. Nonetheless, the reported activation of caspase 3 by 
jerantinine A on lung and colon cancer cells (Raja et al., 2014) is in agreement with 
data generated from this study. In fact, activation of caspase 3 can be triggered by 
both death receptor and mitochondria pathways (Saraste and Pulkki, 2000).  
 
The combined treatment of low-dose tocotrienols (delta and gamma) with IC20 doses 
of jerantinines A and B have demonstrated an improved potency as compared to 
single high-dose tocotrienols as reported in previous chapters. Similarly, as shown in 
Fig. 6.1, 6.2, 6.5, 6.6 and 6.7 herein, unlike single IC50 dose of gamma or delta 
tocotrienol, the combined treatment of low-dose tocotrienols (delta and gamma) with 
IC20 doses of jerantinines (A and B) triggered the death receptor pathway via 
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upregulation of TRAIL and FAS death receptors. The subsequent activation of BID 
and eventual release of cytochrome C as evidenced in ELISA and Western blotting 
studies confirmed the role of mitochondria pathway in the execution of apoptosis. 
More importantly, this demonstrated an improved multi-targeted mechanism via 
recruitment of both TRADD and FADD death domain as compared to the potential 
recruitment of only TRADD by individual IC50 dose of delta and gamma tocotrienols. 
The individual IC50 doses of jerantinine A and B and combined treatments of low-
dose tocotrienols (delta and gamma) with IC20 doses of jerantinine A and B in this 
study induced upregulation of p53 and p27 in U87MG cells after 72 h treatment 
suggesting potential roles of these proteins towards G2/M and G0/G1 cell cycle 
arrests as evidenced in Chapter Five. In addition to potential induction of cell cycle 
arrest, p53 protein can engage the mitochondria pathway indirectly by transcriptional 
activation of proapaptotic proteins such as Bid, Noxa or Puma (Fulda and Debatin, 
2006; Oda et al., 2000; Sax et al., 2002; Yu et al., 2001). Alternatively, p53 can 
directly trigger the mitochondria pathway via activation of Bax or Bak or through 
deactivation of anti-apoptotic Bcl-2 proteins (Chipuk, 2004; Fulda and Debatin, 2006; 
Mihara et al., 2003; Moll et al., 2005). Undoubtedly, the upregulation of p53 as well 
as Bcl-2 pro-apoptotic proteins including Bax and Bid by individual IC50 doses of 
jerantinines (A and B) and the combined low-dose treatment with tocotrienols (delta 
and gamma) on U87MG cells confirmed the recruitment of mitochondria pathway in 
mediation of apoptosis. 
 
Survivin is a bifunctional that regulates cell division and also suppresses apoptosis. 
Survivin inhibits apoptosis by blocking SMAC and subsequently binding to XIAP 
(Johnson and Howerth, 2004; Mita et al., 2008) . In this study, there was a general 
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upregulation of survivin with over 2-fold increase as evidenced in U87MG cells 
receiving IC50 doses of jerantinines (A and B) and combined treatment of low-dose 
gamma tocotrienol with IC20 dose of jerantinine A. Interestingly though, there was an 
upregulation of cytochrome C as shown in Fig 6.6 suggesting that survivin did not 
suppress the mitochondria pathway. XIAP was generally downregulated and thus not 
available for binding to survivin and probably accounting for the increased levels 
observed and its inability to suppress the mitochondria pathway. SMAC/DIABLO in 
addition to AIF, endonuclease G and cathepsin have been reported to be positive 
modulators of caspase independent cell death (Bröker et al., 2005, 2004; Candé et al., 
2002; Lockshin and Zakeri, 2004; Lorenzo and Susin, 2004). Considering that both 
individual and combined treatments induced caspase independent cell death (Chapter 
Five) suggest potential activation of SMAC/DIABLO which competes with survivin 
for binding of XIAP (Pavlyukov et al., 2011). In addition, previous studies have also 
shown that constitutive activation of STAT3 may lead to upregulation of survivin and 
thus inhibitors of oncogenic signal such as  STAT3, phosphatidylinositol 3-kinase 
(PI3-K), Akt , EFGR and  MEK1 can suppress survivin (Johnson and Howerth, 2004). 
Previous studies have indeed shown that tocotrienols can suppress these oncogenic 
signals as well (Ling et al., 2012; Samant and Sylvester, 2006; Weng et al., 2009). In 
fact, another study showed that delta tocotrienol suppression of antitumor activity of 
survivin in non–small cell lung cancer cells was associated with downregulation of 
Notch-1 and VEGF (Ji et al., 2011). Similarly, cytoprotection offered by survivin has 
been shown to be ineffective in FAS induced apoptosis (Johnson and Howerth, 2004). 
Hence, although survivin is upregulated, the potential inhibition of the mitochondria 
pathway is probably mitigated by suppression of oncogenic signal by delta and 
gamma tocotrienols as well as Fas induced apoptosis by jerantinines A and B.  
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6.4 Conclusion  
Data gathered from apoptosis array, ELISA and Western blotting analysis herein 
showed that delta and gamma tocotrienols triggered both death receptor and 
mitochondria pathways mediated via TRAIL activation thereby triggering caspase 
enzyme activity, BID activation and cytochrome C release in U87MG cancer cells. 
On the other hand, jerantinines A and B induced apoptosis in U87MG cells via death 
receptors (FAS and TRAIL) and mitochondria pathways as confirmed by activation of 
Bid and cytochrome C release. Similarly, combined low-dose treatments of 
jerantinines (A and B) with tocotrienols (delta and gamma) mediated apoptosis via 
FAS, TRAIL death receptor and mitochondria pathway associated with BID 
activation and cytochrome C release. In addition, unlike single delta and gamma 
tocotrienols, individual doses of jerantinines A and B and the respective combine low-
dose treatments activated p53 pathway with peak activation evidenced in combined 
treatment of jerantinine A with gamma tocotrienol. Overall, an improved multi-
targeted mechanism of apoptosis induction on U87MG cells by combined low-dose 
treatments compared to individual dose of tocotrienols (delta and gamma) is 
potentiated via this study. 
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7.0 CHAPTER SEVEN 
General Discussion and Conclusions 
7.1 Background  
Anticancer agents sourced from nature have continuously been explored for 
development of more efficient and potent cytotoxic drugs. These natural products in 
fact still constitute the vast majority of recent anticancer drugs. However, toxicity and 
drug resistance have limited potential clinical application of some of these drugs and 
most prominently, the vitamin E isomers (tocotrienols) are amongst these therapeutic 
candidates. Whilst tocotrienols have shown great pharmacological values especially in 
vitro, the potential clinical application has been limited due to high-dose led toxicity 
such as hemorrhage, stroke and others which are often the consequences of the need 
to deliver higher dosage for potent effects (Lonn et al., 2005). Furthermore, delivery 
of high dosage in particular orally overloads the transport protein resulting in 
metabolic degradation of tocotrienols thus causing low levels of therapeutic doses 
(Shirode and Sylvester, 2010). Recent literatures have suggested combinatorial 
treatment that would reduce the doses of tocotrienols as a possible alternative to 
circumvent such aforementioned limitations. Indeed, drug combinations can result in 
sequential, concurrent or concerted pharmacological interactions between two or more 
chemotherapeutic agents which may successively minimize toxicity, improve 
therapeutic potency of candidates and overcome drug resistance (Boik, 2001; Lim et 
al., 2013). In light of this, the present combination study as sequentially reported in 
Chapter Three to Chapter Six was undertaken with the aims of procuring the 
minimized potent dosage of the individual drug candidates and investigating towards 
the elucidation of mechanisms of action for potent treatment combinations.  
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Ficus species was chosen for combinatorial treatment with tocotrienols based on its 
history of traditional medicinal use as anticancer agents (Lansky et al., 2008; Singh et 
al., 2011) and recent pharmacological studies that suggested the application of Ficus 
species as adjunct cytotoxic agents (Nugroho et al., 2013, 2012). On the other hand, 
jerantinines A and B, the pure compounds isolated from Tabernaemontana 
corymbosa, have demonstrated an interesting anticancer activity, most notably on 
reversal of drug resistance. However, as demonstrated by limited preliminary and 
mechanistic studies, jerantinine derivatives induce similar toxic effects to non-
cancerous cells (Qazzaz et al., 2016; Raja et al., 2014). Therefore, jerantinines A and 
B were selected in this study as combined treatment candidates with hopes to 
minimize such non-selective toxicity and exert more importantly different 
mechanisms of action in comparison to tocotrienols to potentiate improvement in 
potency via multi-targeted approach. The study started with initial antiproliferative 
screening to determine the growth inhibitory potency and the pharmacological 
interaction of combined treatments. Upon confirmation of synergism, further studies 
were conducted to investigate the morphological changes, DNA damage patterns and 
cell cycle arrest pattern. Based on the results of DNA damage and cell cycle arrest, 
investigations on possible antimicrotubule effects and potential role of caspase 
enzymes towards the mediation of apoptosis were conducted. Finally, molecular and 
cell-based assays were conducted to establish the potential roles of pro- and anti- 
apoptosis related proteins.     
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7.2 Combined low-dose treatments exert synergistic anticancer effects on cancer 
cells and minimize toxicity towards non-cancerous cells  
As reported in Chapter Three, three different Ficus species (Ficus hispida, Ficus 
fistulosa and Ficus schwarzii) were collected from different locations in Malaysia for 
antiproliferative screening. Ficus hispida and Ficus fistulosa were selected for this 
study based on pharmacological and ethno-medicinal uses as potential anticancer 
treatments (Lansky et al., 2008; Peraza-Sánchez et al., 2002; Pratumvinit et al., 2009; 
Subramaniam et al., 2009; Tuyen et al., 1998; Zhang et al., 2002). Whereas, Ficus 
schwarzii was selected to provide new valuable information on its bioactivity 
considering that to date there is no published study on the bioactivity of this plant. 
Ethanol and alkaloid crude extracts were prepared for bark and leaf parts of each plant 
to allow for determination if antiproliferative potency of Ficus spcies was due to 
alkaloids that present in the crude extracts. The antiproliferative study revealed that 
crude alkaloid extracts from leaves and bark of Ficus species generally exerted more 
potent antiproliferative effects compared to ethanol extracts. Furthermore, based on 
NCI standard for crude extracts, the antiprofilerative potency was ranked as F. 
fistulosa > F. schwarzii > F. hispida in a decreasing order of potency. This is in 
agreement to a recent study that demonstrated the antiproliferative potency (IC50 = 2-7 
µM) of F. fistulosa alkaloids, e.g. fistulopsines (A and B) on HCT 116 and MCF7 
cells lines (Yap et al., 2016). Whereas, the lower potency of F. hisipida extracts 
observed in current study is contrary to the published potent effects of F. hisipida 
alkaloids including O-Methyltylophorindine and hispiloscine (Peraza-Sánchez et al., 
2002; Yap et al., 2015). This is attributed to the fact that crude extracts contain other 
non-cytotoxic compounds that may have antagonistic effects. Furthermore, the type of 
210 
 
cell lines screened, location and time of plant collection may also account for the 
observed difference in potency.  
 
On the other hand, jerantinines (A and B), the pure compounds isolated from T. 
corymbosa induced potent antiproliferative effects on U87MG, A549 and HT-29 cells 
with IC50 values fall below 4 µg/ml. However, similar potent effect was also evident 
on non-cancerous MRC5 cells thereby corroborating recent studies on the cytotoxic 
potency of jerantinines (Frei et al., 2013; Qazzaz et al., 2016; Raja et al., 2014). This 
is contrasted to the mild toxicity induced by tocotrienols (delta and gamma) towards 
non-cancerous MRC5 cells as shown in current study. However, the potency of 
tocotrienols (delta and gamma) tested on U87MG, A549, and HT-29 cancer cells, was 
lower as compared to jerantinines (A and B).     
 
The combined treatment at lower dosage was adopted in this study to reduce the 
required potent doses thereby eliminating the need for single high tocotrienol dosage. 
This would circumvent the limitations of high dosage and minimize toxicity towards 
non-cancerous cells. In addition, the combined treatment would improve potency via 
multi-targeted mechanism compared to individual tocotrienol doses. The combined 
treatment of F. fistulosa with tocotrienols (delta and gamma) induced the most potent 
synergistic effect on cancer cells compared to the additive or antagonistic effects 
observed for combined treatment of F. schwarzii with tocotrienols (delta and gamma). 
This is in agreement with recent studies that demonstrated the application of Ficus 
species as adjunct treatments (Nugroho et al., 2013, 2012). However, the type of 
pharmacological interaction between adjunct treatments was not determined (Nugroho 
et al., 2013). In fact, the potential toxicity to non-cancerous cells was not determined 
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(Nugroho et al., 2012). In contrast, the present study demonstrated the synergistic 
potencies of Ficus species. In addition, the combined treatment approach adopted in 
this study showed that the use of low-dose Ficus species causes a considerable 
reduction of potent doses of adjunct treatments thereby minimizing toxicity towards 
non-cancerous cells. However, further mechanistic studies on F. fistulosa and F. 
schwarzii was discontinued despite the display of remarkable synergistic potency. 
This was justified by the fact that crude extracts contain numerous compounds that 
would make it difficult to properly elucidate for the underlying mechanisms of action 
and hence generating less interest and value compared to pure compounds of the 
study. Whereas, purified alkaloids jerantinines (A and B) have shown promising 
anticancer activity. However, the underlying mechanism of action is not fully 
understood. Therefore, the present study was focused on establishing the mechanism 
of action for apoptosis induction by jerantinines A and B and tocotrienols.   
Nevertheless, the potentials of these plant species as an adjunct anticancer treatment 
cannot be underestimated if pure bioactive compounds should have been isolated. 
 
The combined treatments of low-dose tocotrienols (delta and gamma) with IC20 doses 
of jerantinines (A and B) have promisingly shown reductions of required potent doses 
and toxicity levels of jerantinines (A and B) towards non-cancerous MRC5 cells. The 
combined treatments that induced synergistic effects (IC50 values fall below 4 µg/ml) 
and showed good selectivity window of at least 2-fold between cancer and non-
cancerous cells were selected for further mechanistic studies.     
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7.3 Tocotrienols induce apoptosis via death receptor and mitochondria pathway 
Tocotrienols have been reported to possess potent anticancer effects against a broad 
spectrum of cancer cell lines (Nesaretnam and Yew, 2007; Sen et al., 2007; Sylvester 
et al., 2010). However, the potency has been limited due to metabolic degradation and 
combined treatment that is capable of improving potency has been suggested as an 
alternative. Hence, in this study, in addition to the development of combined 
treatments, the individual doses of delta and gamma tocotrienols were also studied. 
This was to allow for comparison between individual doses of tocotrienols and 
combined low-dose treatments to determine if the combined treatments have resulted 
in an improved potency possibly via a multi-targeted pathway. The data herein 
confirmed that the potent antiproliferative effects of tocotrienols (delta and gamma) 
occurred on cancer cells especially U87MG and HT-29 cells selectively with only 
trivial toxicity exerted on non-cancerous MRC5 cells. This effect was characterized 
by manifestation of the morphological and biochemical features of apoptosis that 
included cell shrinkage, nuclear chromatin condensation and fragmentation, G0/G1 
cell cycle arrest and double stranded DNA breaks.  Further investigations revealed the 
recruitment of initiator caspase enzymes 8 and 9 and executioner caspase 3 as well as 
potential induction of apoptosis independent of caspase activation. This is in 
agreement with recent studies that confirmed activation of caspase 8 and 3 enzymes 
preceded the double stranded DNA breaks by tocotrienols on U87MG and A549 cells 
(Lim et al., 2014a, 2014b). In fact, these studies suggested the potential recruitment of 
both death receptor and mitochondria pathways by tocotrienols. 
 
Tocotrienols (delta and gamma) herein induced the most potent antiproliferative 
effects on U87MG cells. In addition, to date, very few studies have been conducted on 
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the cytotoxic potency of tocotrienols on U87MG cancer cells. Therefore, taking into 
consideration on the aforementioned, U87MG cells was selected for further 
mechanistic studies using molecular and cell-based assays for the mechanism of 
action elucidation. These tocotrienol studies have generally confirmed the recruitment 
of TRAIL death receptors, Bid activation and mitochondria pathway through 
cytochrome C release. A proposed mechanism of action is shown in Fig 7.1 and 
suggests that TRAIL activation of caspase 8 triggered an activation of Bid. 
Eventually, the truncated tBid activated the mitochondria pathway via Bax activation 
and leading to subsequent release of cytochrome C. This is in agreement with the 
suggestion by Lim et al. (2014b) on the potential recruitment of death receptor and 
mitochondria pathways. The study also conforms to a previous report stating the 
TRAIL activation by gamma tocotrienol (Kannappan et al., 2010). However, this is 
contrary to a previous report that tocotrienol induced caspase 8 activation on +SA 
mammary cells was unrelated to death receptors (Shah and Sylvester, 2004). It is 
noteworthy to mention that +SA mammary cells have been proven resistant to death 
receptor induced apoptosis (Shah and Sylvester, 2004). 
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Fig 7.1: Schematic representation on the proposed mechanism of action for tocotrienols (delta 
and gamma). Apoptosis was induced via death receptor (TRAIL-R1 and R2) and 
mitochondria pathways. The activation of caspase 8 by TRAIL caused BID activation and 
subsequent release of cytochrome C from mitochondria to induce apoptosis. 
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7.4 Jerantinines target Fas and p53 linked apoptosis with anti-microtubule 
effects 
As reported in Chapters Four and Five, both jerantinines (A and B) induced similar 
mode of apoptotic cell death. This was characterized by morphological features that 
included membrane blebbing and apoptotic body formation as well as induction of 
double stranded breaks as a biochemical hallmark of apoptosis. The similarities of 
morphological features and DNA damage patterns between jerantinines (A and B) and 
vinblastine (control) prompted the investigations on the potential antimicrotubule 
effects of jerantinines (A and B). Jerantinines (A and B) induced G2/M cell cycle 
arrest and caused disruption of microtubule networks. The disruption of microtubules 
was accompanied by cell shrinkage and lower alpha tubulin signals as compared to 
untreated control. The pattern of cell cycle arrest of Jerantinines (A and B)  is 
consistent with that of microtubule targeting agents (Perez, 2009). Furthermore, this 
finding corroborated previous studies that confirmed jerantinines (A and B) are 
antimicrotubule agents indeed (Frei et al., 2013; Qazzaz et al., 2016; Raja et al., 
2014). However, similar to microtubule targeting agents, jerantinines (A and B) 
showed non-selective toxicity to have induced similar toxic effects to both cancer and 
non-cancerous MRC5 cells. Investigation on the possible mechanism revealed that 
jerantinines (A and B) involved caspase 8 activation which was triggered by Fas death 
receptor.  Fas death receptor induced apoptosis is mediated through Fas associated 
death domain (FADD). The activation of Bid, Bax and cytochrome C by jerantinines 
(A and B) also confirmed the involvement of the mitochondria pathway of apoptosis 
(Fig 7.2). This is in agreement with previous reports that death receptors can directly 
trigger apoptosis via caspase 8 and 3 or alternatively activate the mitochondria 
pathway through Bid activation (Elmore, 2007; Fulda and Debatin, 2006a; Ozören 
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and El-Deiry, 2003; Saraste and Pulkki, 2000). On the other hand, it is strongly 
suggested that jerantinines (A and B) triggered p53 activity may be linked to their 
antimicrotubule effects. This is attributed to the phosphorylation and stability of p53 
that have been shown to increase after microtubule disruption. In fact, the p53 residue 
responsible for microtubule disruption induced phosphorylation varies depending on 
the type of microtubule inhibitor and cell types (Stewart et al., 2001). This is further 
supported by the fact that p53 activates mitochondria pathway via upregulation of 
Noxa and Puma and blocking of Bcl2 anti-apoptotic proteins. Therefore, the 
predominant activation of mitochondria by microtubule targeting agents including 
jerantinines (A and B) herein may be also mediated via increased p53 activity. 
However, this is not conclusive based on this study considering that p53 can be 
activated in response to DNA damage as well.  
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Fig 7.2: Schematic representation on the proposed mechanism of action for jerantinines (A 
and B). Apoptosis was induced via death receptor (TRAIL and FAS) and mitochondria 
pathways. The activation of caspase 8 by TRAIL and FAS caused BID activation and 
subsequent release of cytochrome C from mitochondria to induce apoptosis. Microtubule 
inhibition also promoted mitochondria mediated pathway of apoptosis via p53 activation.  
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7.5 Combined treatment confers multi-targeted mechanisms for enhanced 
therapeutic application 
The combined treatment approach at lower dosage adopted in this study was aimed at 
limiting the need for high-dose tocotrienols and also to reduce the toxicity of 
jerantinines (A and B) towards non-cancerous MRC5 cells. As stated above and in 
Chapter Three, the combined treatment caused a reduction in required potent doses 
and reduced toxicity towards non-cancerous cells. Combined treatments that induced 
synergistic antiproliferative effects with at least 2-fold selective toxicity between 
cancer cells (U87MG, A549 and HT-29) and non-cancerous MRC5 cells were 
selected for further studies. Based on these criteria, the combined treatments were 
most effective on U87MG cells with three different combinations comparing to the 
combined treatments for HT-29 (two combinations) and A549 (one combination) 
cells. Induction of similar multitude of morphological changes, double stranded DNA 
breaks, caspase enzyme activity and caspase independent apoptosis by individual 
doses of tocotrienols (delta and gamma) and combined low-dose treatments with 
jerantinines (A and B) were observed in general. Besides these similarities, the 
combined low-dose treatment conferred multi-targeted mechanisms that enhanced 
therapeutic potency compared to individual doses of tocotrienols. Unlike the 
individual doses of tocotrienols, the combined low-dose treatments caused disruption 
of microtubule networks on U87MG, HT-29 and A549 cells which might be the 
surplus effects of jerantinines (A and B). Further mechanistic studies conducted on 
U87MG cells revealed the activation of both Fas and TRAIL death receptors 
compared to only TRAIL activation by tocotrienols (delta and gamma). Furthermore, 
as shown in the proposed mechanism of action (Fig 7.3), combined low-dose 
treatments activated p53 which may be attributed to microtubule disruption and 
219 
 
mitochondria pathway of apoptosis. The initial hypothesis was that the 
antimicrotubule effect of jerantinines (A and B) even at lower dosage may be 
mediated via p53 activation which has been further potentiated by tocotrienols. 
However, considering the fact that tocotrienols do not activate p53 suggests that the 
antimicrotubule effects could be attributed solely to IC20 doses of jerantinines (A and 
B). p53 protein in response to chemotherapeutic agents also mediate cell cycle arrest 
at stages preceding cell replication (G1/S), pre-mitotic (G2), chromosome 
condensation and chromosome partition (Schwartz and Rotter, 1998). p53 trans-
activate kinase inhibitor proteins including p21 and p27 to induce cell cycle arrest. 
Herein, both IC50 doses of delta and gamma tocotrienols caused an upregulation of 
p27 indicative of cell cycle arrest in U87MG cells. p27 is however not limited to 
regulation of the early G1 phase only (Slingerland and Pagano, 2000). Contrary to 
individual dose of jerantinines (A and B), the combined low-dose treatments induced 
predominantly G0/G1 cell cycle arrest. This is consistent with individual doses of 
tocotrienols (delta and gamma) in this study and previously published studies 
(Fernandes et al., 2010; S.-W. Lim et al., 2014a; Xu et al., 2009). Therefore, this 
implies that although antimicrotubule effect is attributable to IC20 doses of 
jerantinines (A and B), the multi-targeted mechanism demonstrated by combined low-
dose treatments is undoubtedly potentiated by low-dose tocotrienols. The combined 
low-dose treatments would be valuable for future anticancer chemotherapeutic 
regimen.  
 
It is noteworthy to mention that the schematic diagram of the proposed mechanisms 
of action for individual and combined treatments as shown in Fig. 7.1, 7.2 and 7.3 are 
representation of only caspase dependent apoptosis. Caspase independent apoptosis is 
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mediated via lysosomal cathepsin and mitochondrial proteins such as AIF, 
endonuclease G and SMAC/DIABLO (Bröker et al., 2005; Elmore, 2007; Lockshin 
and Zakeri, 2004). Indeed all individual and combined treatments demonstrated an 
induction of caspase independent cell growth inhibition on U87MG, A549 and HT-29 
cells (Chapter Five). However, the present was focused on caspase dependent 
apoptosis and as such did not establish the mechanism mediating the caspase 
independent apoptosis.   
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Fig 7.3: Schematic representation on the proposed mechanism of action for combined 
treatments of low-dose tocotrienols (delta and gamma) with IC20 doses of jerantinines (A and 
B). Apoptosis was induced via death receptor (TRAIL and FAS) and mitochondria pathways. 
The activation of caspase 8 by TRAIL and FAS caused BID activation and subsequent release 
of cytochrome C from mitochondria to induce apoptosis. Microtubule inhibition also 
promoted mitochondria mediated pathway of apoptosis via p53 activation.  
 
    
 
 
 
222 
 
7.6 Conclusions 
Findings from this study confirmed the cytotoxic potency of Ficus species against 
cancer cells thereby corroborating the ethno-medicinal use of Ficus species for 
treatment of cancer. Furthermore, the study demonstrated that F. fistulosa and F. 
schwarzii would be most suitable to treat brain and colon cancers and the potent 
effects observed against these cancer cells are due to the presence of alkaloids in the 
crude extracts. On the other hand, the findings revealed that the cytotoxic potencies of 
tocotrienols (delta and gamma) and jerantinines (A and B) on U87MG, A549 and HT-
29 cells are in line with recent published studies. 
 
The combined treatments of tocotrienols (delta and gamma) with IC20 doses of 
jerantinines (A and B) and alkaloid extracts of F. fistulosa and F. schwarzii induced 
synergistic cytotoxic effects on U87MG, A549 and HT-29 cells. In addition, the 
combined treatments have caused reduction in required potent doses thereby 
minimizing toxicity to non-cancerous cells. This undoubtedly accomplished the 
ultimate aims of this study to reduce potent doses and minimize toxicity towards non-
cancerous cells. Furthermore, the study revealed that tocotrienols (delta and gamma) 
induced apoptosis characterized by manifestation of morphological changes, double 
stranded DNA breaks, G0/G1 cell cycle arrest and caspase enzyme activity which 
were mediated via TRAIL death receptor and mitochondria pathway. Whereas, in 
addition to TRAIL death receptor and mitochondria pathway, individual doses of 
jerantinines (A and B) and the combined low-dose treatment with tocotrienols (delta 
and gamma) also induced FAS and p53 activation characterized by the disruption of 
microtubule networks. These results demonstrated that multi-targeted and improved 
mechanism of action including microtubule disruption and p53 activation to the 
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existing mechanism of tocotrienols induced apoptosis. Furthermore, the confirmation 
of induction of double stranded DNA breaks, caspase 8 enzyme activity and potential 
induction of apoptosis independent of caspase enzymes by jerantinines (A and B) 
might be the first. Therefore, this study provides a new insight into the mechanistic 
action of jerantinines (A and B).  It also accomplishes one of the specific objectives of 
this study to investigate the mechanism mediating the apoptotic effects of individual 
and combined low-dose treatments. Undoubtedly, the combined low-dose treatments 
of tocotrienols (delta and gamma) and jerantinines (A and B) would be a valuable 
chemotherapeutic regimen against cancers in future. 
 
7.7 Limitations of current study and recommendations for future investigations 
The combined  low-dose treatments of tocotrienols with jerantinines (A and B) and 
Ficus extracts induced synergistic effects with improved potency on U87MG, A549 
and HT-29 cells as shown in Chapter Three. Stronger antiproliferative potency has 
been exhibited by the alkaloids that are present in the crude extracts of F. fistulosa 
and F. schwarzii compared to ethanol extracts. However, unlike jerantinines (A and 
B), these are not purified alkaloids which highlight one of the limitations of this study. 
Nonetheless, this opens a new avenue for further research as such, future bioassay 
guided phytochemical studies should be conducted to isolate the pure bioactive 
alkaloidal compounds to allow for proper elucidation of mechanism of action which is 
responsible for the induction of apoptosis.  
 
Most MTAs are known to be toxic to non-cancerous cells by which the phenomenon 
was also demonstrated by the individual doses of jerantinines (A and B) in the present 
study. Undoubtedly, combined low-dose treatments demonstrated an improved 
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selective toxicity towards cancer cells with negligible harm on non-cancerous cells. 
However, only one type of normal cells (human lung fibroblast in this case) was 
tested and future studies should be planned to cover a broader range of non-cancerous 
cells. Furthermore, in vivo toxicological studies should also be conducted on 
jerantinines considering that MTAs have been shown to be neurotoxic. In addition, 
future studies focusing on targeted delivery might also minimize the toxicity of 
jerantinines (A and B). 
 
The individual IC50 doses of tocotrienols (delta and gamma), jerantinines (A and B) 
and combined treatments of  low-dose tocotrienols (delta and gamma) with IC20 doses 
of jerantinines (A and B) induced caspase dependent apoptosis and apoptosis 
independent of caspase activation. However, the present study has been more focused 
on the mechanisms associating with the caspase dependent apoptosis. Considering the 
induction of caspase dependent and independent apoptosis have been suggested as 
potential alternative to improve potency, it is important that future studies enlist the 
elucidation of the mechanism mediating caspase independent cell death and establish 
the potential roles of protein such as SMAC/DIABLO, AIF, cathepsins and 
Endonuclease G amongst others that have been shown to promote caspase 
independent cell death. 
 
Furthermore, the present study confirmed the activation of p53 by individual doses of 
jerantinines (A and B) and combined low-dose treatments but not individual IC50 
doses of tocotrienols (delta and gamma). Although this demonstrates that tocotrienol 
induced DNA damage was independent of p53, however, future study should also 
determine the mechanism of p53 activation herein which could be as a result of 
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microtubule disruption and its potential role in promoting mitochondria mediated 
apoptosis. 
 
Oral delivery of high-dose tocotrienol causes overload of the transport protein and 
subsequent metabolic degradation thus resulting in less available therapeutic dose. 
Indeed, the combination of tocotrienol with jerantinine or extracts from Ficus species 
caused reduction in the required potent dose for tocotrienols thus eliminating the need 
for single high doses. However, only in vitro study had been carried out. A 
translational in vivo study should be conducted to determine if the combined 
treatments herein can improve the therapeutic potency and reduce toxicity towards 
normal cells as evidenced in the current in vitro study. 
 
Jerantinines A and B have demonstrated the potential of reversing p-glycoprotein 
induced drug resistance associated with commercially available microtubule targeting 
agents such as vinblastine and vincristine. Therefore, understanding the mechanism 
mediating the reversal of drug resistance as well as harnessing the structure-
bioactivity relationship would be invaluable. Indeed, this would champion the 
development of jerantinine derivatives and mimics for combined treatments with 
tocotrienols as future potent Microtubule targeting agents against brain, colon and 
lung cancers.  
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APPENDIX 
 
Appendix 1a: Histograms profiles of the growth inhibitory effect of single treatments on MRC5 normal lung fibroblast cell 
lines a) Delta tocotrienol, b) gamma tocotrienol, c) vinblastine, d) Jerantinine A, e) Jerantinine B, f) Ficus fistulosa bark, g) 
Ficus fistulosa leaf, h) Ficus Schwarzii bark, i) Ficus schwarzii leaf, j) Ficus hispida leaf, k) Ficus hispida bark after 72-hr 
treatment. Results are mean ±SEM. N=9 *P<0.001 
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Appendix 1b: Histograms profiles of the growth inhibitory effect for combined low-dose treatments on MRC5 cells 
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Appendix 2: Kinetic study for caspase enzyme activity  
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Appendix 3a: Screening of toxicity for caspase specific inhibitors following treatments 
for 72h with 1µM against a) A549 b) U87MG c) HT-29 cancer cells  
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Appendix 3b: Screening on the effect of caspase specific inhibitors (1µM) on basal 
caspase level
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Appendix 4: a) Protein calibration curve b) Interpolation of data from calibration curve 
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Appendix 5: a) Cytochrome c standards calibration curve b) Interpolation of sample 
concentration  
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Appendix 6 
a) Recipe for Gill’s (1) hematoxylin solution  
s/no Reagents Volume (ml)/weight (g)  
1 Ethylene glycol 250ml 
2 Distilled water 750ml 
3 Hematoxylin 2g 
4 Sodium iodate  0.2g 
5 Ammonium aluminium sulfate  20g 
6 Glacial acetic acid  20ml 
Ethyelene glycol was dissolved in distilled water and subsequently, hematoxylin, sodium 
iodate, ammonium aluminium sulfate and glacial acetic acid were added respectively 
with continuous stirring for one hour at room temperature. Thereafter, the solution was 
filtered and stored at room temperature away from light. 
b) Eosin Stock preparation 
1% eosin Y stock solution was prepared by dissolving 10g of eosin Y in 800ml of 95% 
ethanol and 200ml of distilled water. The solution was mixed vigorously to dissolve and 
stored at room temperature. Subsequently a 0.25% working solution of (1L) was prepared 
by diluting 250ml of stock in 750ml of 80% ethanol. Finally 5ml of concentrated glacial 
acetic acid was added to improve the reddish colour of the solution. 
c) Towbin Transfer buffer 
10x towbin buffer was prepared without SDS based on the following composition  
s/no Reagents Volume (ml)/weight (g)  
1 TrisBase 3.03g (25mM) 
2 Glycine 14.4g (192mM) 
3 dH20 700ml 
After mixture, the solution was made up to 1L with dH20. 1x was subsequently 
with the addition of 20% methanol. 
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d) Tris-buffered saline with Tween-20 (1L) 
s/no Reagents Concentration   
1 Tris 20mM 
2 NACL 150mM 
3 Tween 20 0.1% 
 
e) Running buffer (Tris/Glycine/SDS) (1L) 
s/no Reagents Concentration   
1 TrisBase  25mM 
2 Glycine  192mM 
3 SDS 0.1% 
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